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Folate receptor overexpression is a confirmed cancer biomarker which has been relatively 
underutilised within the literature in the application of targeted cellular delivery of therapeutics 
and diagnostics to date.  
 
A folate receptor targeting theranostic nanoparticle system has been developed and its ability 
to track nanoparticle uptake and deliver a novel Pt(IV) pro drug to human cancer cell lines 
measured. This system comprises folate capped gold nanoparticles for the targeted delivery of 
a fluourescent ruthenium based polypyridyl probe and a novel Pt(IV) pro drug to folate receptor 
positive cell lines. The ability of the system to display selective uptake in folate receptor 
positive cell lines was probed through comparative uptake of a citrate capped gold nanoparticle 
system, comprising the same theranostic agents as that of the folate capped system. This 
difference in uptake was investigated through the use of folate receptor blocking and simulating 
flow of particles within a cellular suspension, comparing uptake of respective particles with 
confocal microscopy, flow cytometry and ICPMS.  
 
The novel Pt(IV) agent has been fully characterised and its anti-cancer efficacy investigated, 
presenting with improved toxicity over cisplatin in cisplatin resistant A549 cells. Cisplatin-
DNA adducts have been identified through employment of a commercially available antibody, 
where the Pt(IV) agent displayed increased adducts over cisplatin alone. This adduct formation 
and imparted toxicity was investigated by confocal microscopy, flow cytometry, ICPMS and 
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ADC – Acetonedicarboxylate 
A549 – Human lung cancer cell line 
CRISPR - Clustered Regularly Interspaced Short Palindromic Repeats 
cDNA – Complementary DeoxyriboNucleic Acid 
DLS – Dynamic Light Scattering 
DMEM – Dulbecco’s Modified Eagle Media  
DNA – DeoxyriboNucleic Acid 
dNTP - DeoxyriboNucleotide TriPhosphate 
EDTA – EthyleneDiamineTetraaceticAcid 
FACS – Fluorescence Activated Cell Sorting 
FOLR1 – Folate receptor gene responsible for folate receptor α 
FOLR2 - Folate receptor gene responsible for folate receptor β 
FOLR3 - Folate receptor gene responsible for folate receptor γ 
GPI – Glycosylphosphatidylinositol 
GNP-Cit – Citrate capped gold nanoparticles 
GNP-Fol – Folate capped gold nanoparticles 
GNP-GSH-Fol – Citrate capped gold nanoparticles with folate tethered via glutathione 
GNP-Cit-Theranos - Citrate capped gold nanoparticles loaded with RuPhen and YoungPt(IV) 
GNP-Fol-Theranos - Folate capped gold nanoparticles loaded with RuPhen and YoungPt(IV) 
HeLa – Cancerous human cervical cell line 
MLCT – Metal Ligand Charge Transfer 
MSC – Mesenchymal Stem Cells 
PDI – PolyDispersity Index 
PBS – Phosphate Buffered Saline 
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PCR – Polymerase Chain Reaction 
RPMI – Gibco cell culture media 
RNA – RiboNucleic Acid 
StDev – Standard Deviation 
SPR – Surface Plasmon Reference 
TEM - Transition Electron Microscopy 
λmax – Wavelength with maximum absorbance 
λmin – Wavelength with minimum absorbance 
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Chapter 1: Introduction 
1.1. Folate Receptors 
It has been a consistent objective of cancer research to develop targeted, patient specific 
therapeutic agents so as to maximise anti-tumour efficacy whilst minimising non-target cell 
damage and inherent toxicity to the patient. In this regard, there is an omnipresent demand for 
research to identify and explore potential means of targeting specific cancer sub-types with 
chemotherapeutic agents. Combining such targeted therapeutics with innovative and accurate 
diagnostic measures should therefore pave the way to truly personalised anti-cancer treatments, 
significantly improving the prospects for the prospective patients. One such form of potential 
cancer cell targeting vector is that of folate receptors.  
 
Since the early 1990’s, research has found that folate receptors are significantly over expressed 
on the surface of a variety of cancer cell lines and tissues whilst maintaining a comparably low 
expression in healthy cell lines1. These receptors have a high binding affinity and specificity 
for folic acid and its structural derivatives and have since been established as a scientifically 
acknowledged cancer biomarker2, 3, 4. The structure of folic acid is represented below in Figure 
101.  
 
Figure 101: Structure of folic acid. 
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This overexpression and confirmation as a cancer biomarker establishes folate receptors as an 
exciting prospect within anticancer research and may present with serious potential within the 
field.  
 
1.1.1. Receptor Type and Function 
Folate receptors are present in a wide variety of healthy cell lines throughout the human 
body and are believed to offer a key role in the maintenance of these cells through enabling 
influx and efflux of folic acid and folate based derivatives 5. In this regard, it is believed that 
these folate based entities assist with a number of cellular processes, including assisting in the 
recycling of ADP back to ATP for cellular processes and mitosis, through a number of different 
pathways and metabolites6, 7. Why folate receptors are not expressed in all healthy cell tissues 
is a contentious area of the literature and one that is not fully understood on account of the 
positive role they may play and the potential benefits to the cells. However, it appears that the 
general consensus is that folic acid and folates are still able to be taken up into cells that are 
folate receptor negative through other active uptake proteins as well as passive uptake 
mechanisms. In particular, there are three proposed folate active uptake methods8, 9: 
1. Reduced Folate Carrier SLC19A1 – an organic anion exchanger; 
2. Proton Coupled Folate Transporter SLC46A1 - a unidirectional folate transporter 
which primarily operates at acidic pH; and 
3. Folate Receptors α and β – folate receptor influx proteins via receptor-mediated 
endocytosis.  
Whilst there are three confirmed active uptake means for cellular uptake of folates, folate 
receptors α and β display the highest binding affinity and selectivity for folates and so are 
considered to be the primary means of uptake, where more than one system is presented.  
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1.1.2. Folate Receptor Expression 
Whilst folate receptors α and β are cited above as the primary folate receptors 
responsible for folate uptake into cells, there are a total of four types of folate receptor (α, β, γ 
and δ)7, 11. Folate receptors α and β are both surface localised cellular proteins, however, α is 
typically expressed on the surface of the epithelial cells of the lungs and kidneys, and β is 
typically expressed on the surface of activated myeloid cells11-14. Folate receptors γ and δ are 
far less prominent than α and β, where folate receptor γ is primarily an excretory protein and is 
found in the blood, whilst folate receptor δ is expressed on regulatory T-Cells and its function 
is yet to be ascertained11, 15, 16. It is therefore evident in the literature that these receptors operate 
somewhat independently from one another within healthy tissues, however, in some tissues 
there is a degree of co-localisation. Levels of expression of these receptors within healthy cells 
and tissues that are receptor positive do vary, however, they are not typically expressed in large 
quantities.  
 
In contrast, folate receptor expression varies significantly in different cancer cell lines, with 
some cell lines being receptor negative (zero expression) and some displaying large levels of 
expression for a multitude of these receptors. Most interestingly, and opportunistically, there 
are certain cancer cell types which not only express folate receptors α and / or β (the primary 
influx proteins), but they overexpress said receptors with levels significantly beyond those of 
healthy cells. In particular, as reported in Elnakat et al.7 and Shen et al.11, folate receptor α is 
known to be overexpressed in cancers of the ovary, breast, head & neck, endometrium, lung, 
bladder, pancreas, colon and kidney17-25. As further reported by Shen et al.11, folate receptor β 
is known to typically be overexpressed in cancers of the lung, breast, liver, brain, uterus, 
thyroid, stomach, ovary, head & neck, skin, kidney, pancreas, bladder, cervix, oesophagus, 
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prostate, testis, and colon26, 27. Accordingly, it is evident that there are cancerous tissues which 
display a high level of overexpression of both of these folate receptors. 
 
It is hypothesised that this overexpression of folate receptors α and β in cancer cell lines is as 
a result of their increased metabolic needs, stemming from their rapid multiplication. 
Accordingly, it is assumed within the literature that the bulk of folic acid transportation is via 
receptor mediated endocytosis as it offers the most selective and efficient means for folate 
uptake28. At present, the exact mechanics of folate receptor mediated binding and uptake of 
folic acid conjugates is not completely understood, however, as above, there is little debate 
surrounding the proposed mechanism of receptor mediated endocytosis.  
 
1.1.3. Utilisation within Research 
The above research all in effect stem from the pioneering research of Leamon and Low, 
who identified folic acid’s ability to transfer large proteins into plant cells as a result of the 
folic acid – folate receptor interaction, forming the first establishment of folate receptor 
mediated endocytosis of agents into cells29. Shortly after, research conducted by Coney et al.2 
and Weitman et al.30 reported that several monoclonal antibodies which were typically used to 
identify cancer cells in tissue biopsies were also able to selectively bind to folate receptors28. 
Subsequently, folate receptor targeted delivery of chemotherapeutics and imaging agents was 
a developing field of research.  
 
An early research contribution in this regard is that of Leamon et al., whose subsequent 
research into folate based cytotoxics employed the use of folate-tethered protein toxins for 
tumour targeting28, 31. These protein based studies included the use of folate-momordin and 
folate-pseudomonas exotoxin, the latter possessing an IC50 of ~10
-11 M. significantly, this 
5 
 
research also demonstrated that the nature of the bond linking the folate to the protein directly 
affects the toxicity of the system. Specifically, when linked by a reducible disulfide bond, an 
IC50 of ~10
-11 M was achieved. In contrast, when linked via a thioether bond, potency was 
reduced by four orders of magnitude31. These results therefore displayed an early indication of 
increased cellular uptake of anticancer agents when folate receptors were targeted and the 
importance of designing folate targeting anticancer treatments with a cleavable linker for 
improved drug delivery32.  
 
Figure 102 below is a diagrammatical representation produced by Leamon et al.28 that gives an 
overview of the proposed folate receptor mediated uptake of folic acid drug conjugates (whilst 
the specifics for this overview are targeted to their conjugates, the overview of the mechanism 
of uptake is identical to that proposed for all folic acid conjugates). 
 
 
Figure 102: Image and text directly sourced from Leamon et al.28 
“Folate Receptor (FR) mediated endocytosis of a folic acid drug conjugate.  
Folate conjugates bind to FR’s with high affinity and are subsequently internalized into 
endosomes that can reduce disulfide bonds. Within the endosome, a folate–disulfide–drug 
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conjugate is released from the FR and the prodrug is reduced to liberate the parent drug cargo. 
Because the pH of FR-containing endosomes is only mildly acidic, acid-labile linkers do not 
release the attached drug as efficiently”. 
 
Folate Targeted Therapeutics  
A number of folate targeted chemotherapeutics have been investigated in the literature, some 
of which have subsequently entered into clinical trials11. One such example is that of Naumann 
et al, who developed the folate receptor targeting anticancer agent Vintafolide (EC145)33. 
Vintafolide is a folic acid–desacetylvinblastine conjugate that Naumann et al. have progressed 
through phases one to three of clinical trials to ascertain its potential as a targeted 
chemotherapeutic when utilised in combination therapy with Pegylated Liposomal 
Doxorubicin (PLD)33-135. The structure of Vintafolide is provided in Figure 103.  
 
Figure 103: Chemical structure of Vintafolide36. 
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As can be seen in Figure 103, Vintafolide comprises a folic acid unit (circled in blue) that is 
connected to a desacetylvinblastine monohydrazide (DAVLBH, circled in red) conjugate by 
way of a disulphide linker37. DAVLBH is an agent which prevents microtubule formation 
within the cells during mitosis, thus preventing cellular replication and leading to apoptosis.  
 
These studies looked at the survival rates of women who presented with recurring platinum 
agent resistant ovarian cancer and looked to compare the progression-free survival of the 
patients. Where a combination of Vintafolide and PLD were used, the median survival rate was 
5 months, whereas PLD alone was 2.7 months. Additionally, the patients subjected to the 
combination therapy presented with no additional symptoms or side-effects over those 
experienced by the PLD group only, further supporting that Vintafolide was indeed highly 
targeting33.  
 
Folate Targeted Diagnostics 
In addition to the utilisation of folate as a means for targeted therapeutics, there are also 
examples in the literature of folate targeted imaging agents. A more recent example of such 
research includes that of Okusanya et al, who developed a fluorescently labelled folate receptor 
α targeting molecular contrast agent38. This folate receptor targeting contrast agent comprised 
a folate-fluorescein-isothiocyanate (FITC) conjugated folic acid unit, displaying fluorescence 
within the green region of the visible spectrum (λex 465-490nm, λem 520-530nm). This contrast 
agent was utilised intra-operatively to identify folate receptor α positive lung adenocarcinoma 
cells via real-time optical imaging. Sample images collected and reported by Okusanya et al 




Figure 104: Image and text were sourced as per Okusanya et al38. 
 
“Lung adenocarcinomas can be detected using intraoperative molecular imaging. Three 
representative patients diagnosed with lung adenocarcinoma by preoperative CT, PET, and 
optical molecular imaging”. 
This research reported that 92% of the lung adenocarcinomas studied presented with FITC 
fluorescence, with no false positives or non-selective binding of the contrast agent. Of the 8% 
that were not fluorescent, postoperative immunohistochemistry confirmed that there were no α 
folate receptors expressed. Patient bisection was required for the majority of cases in order to 








It is evident from the literature that folate receptor expression appears to be a viable 
mechanism for targeted delivery of chemotherapeutics and diagnostic agents. There are a 
number of established and promising agents within the field directed toward either a folate 
receptor targeting therapeutic or diagnostic system. However, there does not yet appear to be a 
folate receptor targeting agent which displays the potential to act as both a therapeutic and 
diagnostic (theranostic) system. Accordingly, utilisation of theranostic agents which exhibit 
folate receptor targeting might present with notable research outcomes, given that cellular 
delivery of such agents by way of folate receptor mediated endocytosis appears to have not yet 
been established in the literature.  
 
1.2. Gold Nanoparticles 
1.2.1. Nanoparticles and their Properties 
Nanoparticles of varying forms have been utilised within research in a broad spectrum 
of applications, from the use of Multi-Walled Carbon Nanotubes (MWCNTs) and Single-
Walled Carbon Nanotubes (SWCNTs) as nano-carriers of chemotherapeutic agents39-42, to the 
use of colloidal quantum dots for solar cells43 (examples of such SWCNT and MWCNT 




Figure 105: Diagrammatic representation of Single-Walled Carbon Nanotube (SWCNTs) and 
Multi-Walled Carbon Nanotube (MWCNTs) delivery systems for platinum(IV) prodrugs. 
Figure sourced and amended from Chart 18 of Johnstone, Suntharalingam and Lippard44. 
 
Polymer based nanoparticles are also commonly employed within the literature. An example 
of which is that of Zhe Wang et al., who demonstrated RGD peptide targeted delivery of anti-
angiogenesis (combretastatin A4) and anticancer (Paclitaxel) agents to Human Umbilical Vein 
Endothelial Cells (HUVECs) through utilisation of Poly-Lactic-co-Glycolic Acid (PLGA) 
nanoparticular system45.  
Of the various nanoparticular systems of the literature, one particular form which has been used 
extensively in research is that of gold nanoparticles. Gold nanoparticles can be readily 
synthesised as spherical particles (which are more commonly utilised within therapeutic and 
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diagnostic applications), or as nano-rods, for varying uses such as contrast agents, bacterial 
separation agents and therapeutics46-49. These spherical gold nanoparticles have been used 
extensively within the literature in the delivery of large payloads of therapeutic compounds and 
/ or imaging agents to cancerous tissues. Gold nanoparticles have been utilised to this end as a 
result of a number of favourable properties, which include: 
• a passive tumour targeting effect; 
• ability to be surface functionalised with a wide variety of compounds;  
• a large loading capacity; and 
• limited cellular toxicity. 
As above, nanoparticles have been proven to exhibit a passive tumour targeting effect as a 
result of their extended circulation time in the bloodstream and accumulation within tumour 
regions and micro-environments50. This inherently useful quality of nanoparticles is depicted 
in Figure 106 as produced by Loureiro et al51. In brief, the tumour vasculature presents with 
large pores which facilitate extravasation of nanoparticles from the blood stream into the 
tumour micro-environment. The nanoparticles then typically accumulate within these tissues 
as they are not readily flushed out. This retention is largely as a result of poor lymphatic 
drainage of the tissue. This is known as the “Enhanced Permeability and Retention “(EPR) 
effect51. Accordingly, gold nanoparticles that are in the 10-200nm range and surface 
functionalised with anti-cancer compounds may significantly increase the effectively delivered 




Figure 106: Diagrammatical representation of passive tumour targeting of nanoparticles as 
produced by Loureiro et al51.  
 
The loading capacity, cellular toxicity and surface functionalisation of these gold nanoparticles 
are largely dependent on the size of the particles and their surface properties. The size and 
surface properties of these nanoparticles are in turn largely dictated by the method employed 
in their synthesis and the reagents employed in their composition.  
 
1.2.2. Citrate Capped Gold Nanoparticles 
All spherical nanoparticles may be synthesised by way of either a “top-down” or 
“bottom-up” methodology, through laser ablation of bulk materials or reduction of a gold salt 
respectively52-54. The “bottom-up” gold salt reduction method is most commonly utilised 
within the literature and also forms the most commonly utilised gold nanoparticle system in 




This bottom-up method was first reported by Turkevich et al. who developed a consistent batch 
method for formation of citrate capped / stabilised gold nanoparticles54. This fundamental 
protocol was then further developed within the field by Vossmeyer et al, whose adaptation of 
the Turkevich method allows for batch production of consistently sized and monodisperse 
GNP-Cit55. This research demonstrates the highly tuneable characteristics of the GNP-Cit 
through variation of the gold salt to citrate ion ratio, reaction temperature and orders of 
addition. Moreover, the article offers an in depth analysis of the physical principles of gold salt 
reduction and particle formation, as depicted in Figure 107 (adapted from the literature)55. 
 
Figure 107: Representation of gold salt reduction and particle nucleation and growth as set 
forth by Vossmeyer et al. Figure and text are sourced and adapted from the literature55. 
(a) Redox reaction of citrate and Au(III) to form Au(I) ions and acetonedicarboxylate (ADC). 
(b) ADC organizes Au(I) to form areas of high Au(I) concentration, facilitating (c) 
disproportionation of Au(I) to Au(0) and Au(III), leading to (d) nucleation and growth of Au(0) 
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to form GNP-Cit. Fast nucleation and good stabilization give a narrow size distribution of the 
particles. Conversely, slow nucleation and low stabilization give a broad size distribution of 
the particles55. 
 
This research further demonstrates that batches of 13nm GNP-Cit may be utilised for consistent 
production of 25nm GNP-Cit as a starting block which is compounded on. These 25nm 
particles may then be carried forward in the same manner for consistent production of 50nm 
and 100nm particles. Thus, the production and characteristics of GNP-Cit are well explored 
and understood within the literature.  
 
1.2.3. Folate Capped Gold Nanoparticles 
Another example of a gold nanoparticular system is that of folate capped gold 
nanoparticles (GNP-Fol). In contrast to the well understood citrate capped gold nanoparticular 
preparation as above, folate capped gold nanoparticles have been comparatively under-utilised 
within the literature and hence, protocols for their preparation are equally unexplored. In this 
regard, one prominent example of the direct bottom-up synthesis of GNP-Fol is that of Wang 
et al56. By comparison to the Vossmeyer GNP-Cit protocol, this GNP-Fol protocol utilises folic 
acid and sodium folate in coordination with gold salt, employing the use of less conventional 
microwave reactor heating. Whilst this is one of the more prominent examples of direct 
synthesis of GNP-Fol within the literature, the quality of the particles are comparatively poor 
with respect to Vossmeyer GNP-Cit. More particularly, it appears that there has not been 
development of a GNP-Fol protocol which produces particles of a consistent size, which are 
monodisperse and are largely spherical. For comparison, and to emphasis the difference in 
particle quality of the literature, TEM images of the Vossmeyer GNP-Cit and Wang GNP-Fol 
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systems are represented in Figure 108 (as  drawn from the respective articles of the authors55 & 
56).  
 
Figure 108: TEM images drawn from the literature for comparison of particle qualities of the: 
a) Vossmeyer et al. GNP-Cit system55; and b) Wang et al. GNP-Fol system56 
 
Whilst these particles therefore seemingly present with poorer physical properties than the 
GNP-Cit system, they have still been used within the literature for a broad range of studies on 
account of their intrinsic potential as a folate receptor targeting nanoparticular system. More 
particularly, given that their surface is capped / stabilised by folate moieties, it has been shown 
in the literature that these particles may be readily taken up by folate receptor positive cell 
lines.  
 
1.2.4. Utilisation within Research 
As discussed above, there are broad ranges of utilisation of gold nanoparticular systems 
within the literature. However, of primary concern in the present research is the utilisation of 
citrate and folate capped gold nanoparticles for delivery of diagnostic and therapeutic agents 
to cancer cells. In this regard, and as noted, a significant advantage of using nanoparticles as a 




of large payloads of the agents to the target cancer cells44. This benefit can be further enhanced 
through surface functionalisation of nanoparticles with a ligand that may selectively bind to 
receptors that are explicitly expressed on the surface of specific cancer cells, thus facilitating 
receptor mediated endocytosis44, 57.  
 
Applications of GNP-Cit 
An example of a GNP-Cit system which exhibits targeted delivery of chemotherapeutic agents 
is that of Yang et al58. In this research Yang et al synthesised GNP-Cit via utilisation of the 
Vossmeyer protocol and subsequently functionalised the surface of the particles with an RGD 
peptide (cancer tissue targeting agent) and the anticancer agent Bleomycin (the structure of 
Bleomycin is shown in Figure 109). Yang et al demonstrated the increased uptake and 
anticancer efficacy of this targeted anticancer GNP-Cit system within human breast cancer 
cells (MDA-MB-231) in comparison to a non-RGD labelled (non-targeting) GNP-Cit system.  
Moreover, the research found that the labelled GNP-Cit system outperformed the non-labelled 
system when combined with radiation therapy, showing a 38% increase in cellular uptake and 
32% decrease in cell viability. In this regard, it is known within the literature that gold 
nanoparticles may enhance the photo-induced DNA damage of radiotherapy through localized 
amplification of said radiation dose58-60. Accordingly, the RGD targeted GNP-Cit system 
affords increased cellular uptake and localisation of the particles bearing the anticancer agent 
Bleomycin within the MDA cells. This then subsequently leads to a localised delivery of a 
large payload of Bleomycin and the localised amplification of photo-induced DNA damage. 
The Yang et al system therefore represents a targeted GNP-Cit combination therapy system 




Figure 109: Unaltered representation of the chemical structure of Bleomycin as reported by 
Galba et al61 (figure 1 of the cited article). 
 
Another application of GNP-Cit is that of the targeted multi-modal imaging particles developed 
and reported by Schooneveld et al62. Schooneveld et al utilised a GNP-Cit core coated with a 
poly(ethylene glycol), paramagnetic and fluorescent lipid coating. These particles were then 
utilised as a trimodal contrast agent in macrophage cells via in vitro magnetic resonance 
imaging (MRI), X-ray computed tomography (CT) and fluorescence imaging (FI). The general 
structure of these particles is represented in Figure 110 as drawn from the literature62. 
 
Figure 110: Schematic representation of the Schooneveld tri-modal contrast agent particle as 
reported in the literature62.  
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As can be seen in Figure 110, the Schooneveld particles comprise a citrate capped gold 
nanoparticle core (capable of imaging via CT), a silica sub-layer and an outer PEG layer. The 
outer PEG layer further comprises fluorescently labelled PEG molecules for FI applications 
(Cyanine5.5 conjugated PEG) and paramagnetic labelled lipids (Gadolinium conjugated 
diethylene triamine pentaacetic acid di(stearylamide)). The research found that these tri-modal 
particles were successfully taken up by phagocytotic cells and generated contrast in MRI, CT 
and FI applications with approximately nanomolar (MRI/CT) and ~100 pM (FI) detection 
limits62.  
 
Applications of GNP-Fol 
As previously noted, whilst there is an abundance of research into the use of citrate capped 
GNPs that have had their surface subsequently functionalised with folate, there appears to be a 
lack of research into the use of folate capped GNPs63-66. As hypothesised, this likely stems from 
the seemingly under-developed synthetic protocol for such particles. However, one notable 
application of folate capped gold nanoparticles within the literature is that of J.Ai et al67. J.Ai 
et al. utilised the synthetic protocol of Wang et al. to synthesise GNP-Fol, which they 
subsequently labelled with a functionalised FITC dye by way of a thiol linker. These FITC 
labelled folate capped GNPs showed elevated uptake and emission in folate receptor positive 
HeLa cells (cervical cancer cell line) over folate receptor negative CCRF-CEM cells (a T 
lymphoblastoid cell line), as represented in confocal microscopy and flow cytometry studies. 
One key criticism of this research however is the utilisation of different cell lines as the folate 
receptor positive vs negative measure, as they likely present with significantly different 




Another example of the literature is the more recently published works of Jesna et al68. Jesna 
reports an alternative protocol for the direct synthesis of GNP-Fol, adapted from the Wang 
protocol56. Jesna utilises these folate capped GNPs to target folate receptor positive A549 cells 
(lung carcinoma), conjugating a thionene dye to the surface of the particles for cellular tracking 
applications. These folate targeted particles showed elevated levels of cellular uptake over non-
folate capped particles, displaying their potential as a targeted diagnostic system. The particles 
also exhibit therapeutic applications when irradiated, inducing localised cytotoxicity in vitro68. 
This research demonstrates the ability to track the surface binding of reagents to nanoparticles 
through the utilisation of Dynamic Light Scattering (DLS) and measuring changes in the 
Surface Plasmon Resonance of the particles.  
 
More particularly, it is known in the literature that gold nanoparticles present with a localised 
SPR as a result of oscillating surface electrons. Thus, the oscillating surface electrons interact 
with light waves and polarise one surface of the particle. Accordingly, the SPR induces an 
electromagnetic field52 & 69-72. A generalised representation of the GNP SPR / electromagnetic 
field interaction is depicted in Figure 111 below, as drawn from the literature72. As reported in 
the literature, the SPR band of a nanoparticle suspension can be monitored by UV-Vis 
spectroscopy and typically presents with a λmax between 500-750nm dependant on the size and 
shape of the particles71. Accordingly, as GNPs are surface functionalised, their shape and 
diameter change, thus inducing a shift in the density of the electric field and therefore a shift 
in the SPR λmax
72. Therefore, UV-Vis observations of the SPR band of a nanoparticle 




Figure 111: Localised SPR band of GNPs, as reported by Willets and Doyne72. 
 
1.2.5. Conclusions  
There is a wealth of research in the literature in the targeted delivery of citrate capped 
gold nanoparticles to cancer cells for the purposes of diagnostics and therapeutics. There is also 
a broad spectrum of research into the functionalisation of nanoparticles with folic acid for folate 
receptor targeting. However, there appears to be a substantial gap in the literature for the 
utilisation of directly folate capped gold nanoparticles for targeted delivery of agents to cancer 
cell lines. Accordingly, utilisation of folate capped gold nanoparticles for delivery of either 
imaging or therapeutic agents might present with reasonably unexplored research outcomes.  
 
1.3. Platinum Anticancer Agents 
1.3.1. Platinum(II) Complexes and Cisplatin Activity 
Platinum complexes remain one of the most widely utilised anticancer 
chemotherapeutics worldwide. At present, three platinum based anticancer agents are clinically 
approved worldwide for the treatment of cancer (cisplatin, carboplatin and oxaliplatin), whilst 
an additional three are approved for use in select countries only (nedaplatin, lobaplatin and 
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heptaplatin)44. The chemical structures for these complexes are depicted in Figure 112 as 
directly sourced from the literature.  
 
Figure 112: Chemical structures for clinically approved Pt based anticancer agents, as sourced 
from Lippard et al44. 
 
Perhaps the most notable application and success of these clinically approved Pt agents is that 
of the platinum(II) drug cisplatin in the treatment of testicular cancer, which now presents with 
cure rates which exceed 95%44, 73. Cisplatin’s mode of action is to form intra-strand covalent 
bonds to adjacent Guanine residues of the DNA helix within the nucleus of cancer cells. As a 
result of these covalent bonds, a ‘kink’ is formed in the structure which prevents replication 
and transcription, ultimately leading to apoptosis74. The mechanism of action of cisplatin is a 
result of intracellular activation by the aquation of one of the two chloride ligands, which 
subsequently enables cisplatin to covalently bind to DNA, forming DNA adducts75. This 
process is dependent on local Cl- concentration; where low concentrations allow these chloride 
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ligands to be more easily replaced with OH or OH2 ligands. It is thought that the active species 
of cisplatin is that shown in Figure 4 below: 
 
Figure 113: Structure of Active Cisplatin 
 
Whilst cisplatin is especially effective at treating testicular cancer, it has a significantly reduced 
anticancer efficacy in a number of other types of cancer. In this regard, the efficacy of treatment 
with cisplatin is determined by a number of factors. However, the most significant limiting 
factors in the broad utilisation of cisplatin are its lack of specificity for target cancer cells (i.e. 
uptake of cisplatin into non target cells) and the degree of resistance that the cancer cells 
possess towards cisplatin76. With regards to cisplatin resistance, this resistance can be split into 
two key categories; inherent resistance and developed resistance. 
 
Inherent Resistance refers to where cells seemingly have a significantly reduced uptake of 
cisplatin. Some research suggests that this may be as a result of a lack of copper membrane 
transporters (CTR1 and ATP7A/B) and / or Organic Cationic Transporters (OCT1-3) which 
are theorised to help transport cisplatin into the cells44, 74 & 77. Other research suggests that 
cisplatin may still enter the cells via passive diffusion, thus stipulating that these copper and 
OCT transporters play no significant role in cisplatin uptake78-80. Despite this latter point, it is 
still largely perceived within the literature that these active uptake proteins play a significant 




Developed cisplatin resistance arises during the cycles of chemotherapy, where cancers 
progressively display a lack of response to cisplatin and therefore an increased dose is required 
each cycle81. This developed resistance could be as a result of a number of key resistance 
mechanisms, which include: 
• down regulation of copper pumps (CTR1 and ATP7A) and / or Organic Cationic 
Transporters (OCT1-3), thus reducing cisplatin uptake; 
• increased efflux of cisplatin by upregulation of ATP7B, typically as a result of increased 
inactivation of cisplatin by naturally occurring cytosolic agents (glutathione (GSH) and 
methionine (MT)); and 
• increased DNA repair or increased DNA damage tolerance. 
An overview of cisplatin uptake, inactivation, activation, efficacy and efflux are depicted in 





Figure 114: Overview of potential uptake, activity of and tumour resistance to cisplatin as 
sourced from Lippard et al. and originally produced by Johnstone et al44, 82, with minor 
amendments.  
 
1.3.2. Utilisation of Platinum(II) agents within Research 
Leading on from the wealth of research into the utilisation of cisplatin (which of course 
led to its clinical approval and use) there have been a number of novel Pt(II) complexes 
developed in the literature in pursuit of an alternative Pt based anticancer agent whose structure 
loosely imitates that of clinically approved Pt(II) drugs. In this regard, it has been an objective 
of the field to develop Pt(II) agents which present with improved physical characteristics such 
as improved solubility, stability and targeting, whilst either maintaining the activity of the 
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founding drug or presenting with entirely new models of anticancer activity. These research 
goals are largely in the pursuit of anticancer agents that are more effective within select cell 
lines and / or display efficacy in typically Pt(II) drug (such as cisplatin) resistant cell lines.  
 
As per the thorough literature review of Lippard et al. there are a number of Pt(II) agents which 
incorporate targeting modalities into the structure of the complex44. Examples of such targeting 
include sugar receptors (such as glucose receptors)83, steroidal receptors (such as oestrogen 
receptors α and β)84 and peptide receptors (such as CD13)185. In addition to these targeting 
vectors, a number of folate receptor targeting Pt(II) agents have been developed in the 
literature. One notable example of such a complex is that developed by Aronov et al., whose 
Pt(II) complex comprised a PEG linked folic acid motif and mimicked the structure of 
carboplatin86. The structure of Aronov et al’s Pt(II) complex is represented in Figure 115 as 
drawn from the literature44, 86.  
 
Figure 115: Structure of Aronov et al’s carboplatin based folate receptor targeting Pt(II) agent, 
taken from Lippard et al44, 86.  
 
The Aronov et al. Pt(II) complex comprises a PEG spacer between the dicarboxylate chelating 
ligand and a folic acid unit, thus enhancing the water solubility of the complex over that of 
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carboplatin. Their research investigated the levels of uptake of various Pt(II) agents in folate 
receptor positive and negative cell lines, with the above complex displaying enhanced uptake 
and cytotoxicity in receptor positive lines. This enhanced uptake and efficacy was assumed to 
be as a result of folate receptor mediated endocytosis of the complex. Unfortunately, the 
complex was less cytotoxic than carboplatin, which was assumed to be as a result of fewer Pt-
DNA adducts being formed86.  
 
1.3.3. Platinum(IV) Chemotherapeutic Alternatives  
An alternative to the targeted Pt(II) agents of the literature is that of the more recently 
explored Pt(IV) pro-drugs. In this regard, whilst Pt(II) agents typically vary one or two of the 
ligands to present with novel structures loosely associated to clinically approved Pt(II) agents, 
Pt(IV) agents comprise octahedral structures, which thus afford the opportunity to incorporate 
and vary axial ligands. The general structure of Pt(IV) complexes is represented in Figure 116, 
as drawn from the literature87.  
 
Figure 116: General structure of Pt(IV) complexes and the opportunities afforded in alteration 
of the equatorial or axial ligands, taken from Wilson and Lippard87.  
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As a result of the octahedral geometry these complexes are typically much more kinetically 
inert than their square planar Pt(II) counterparts. As a result, Pt(IV) complexes are typically 
more resistant to ligand substitution reactions, which in turn inherently presents the complexes 
with enhanced resistance to unwanted side-reactions with biomolecules prior to DNA 
binding87. Perhaps the most beneficial aspect of Pt(IV) agents though is the additional two 
coordination sites (axial), which allows for further incorporation of ligands for alteration of the 
complex’s properties, such as; water solubility, lipophilicity, stability and additional targeting 
motifs44, 87. A number of key examples exist within the literature which presented with 
promising results, only to be ultimately ruled out through clinical trials. These complexes 
include satraplatin, ormaplatin, LA-12 and iproplatin, whose structures are given in Figure 117 
as taken from the literature44. 
 
Figure 117: Chemical structures of Pt(IV) complexes that have undergone clinical trials, taken 
from Lippard et al44. 
 
Each of the complexes presented in Figure 117 are examples of Pt(IV) pro-drugs. A pro-drug 
is a compound that originally enters the organism in an inactive form and is subsequently 
metabolised to form the active compound. Whilst there is a vast wealth of research into the use 
of Pt(IV) pro-drugs for anti-cancer purposes, there is still some debate surrounding the 
proposed mechanism of reduction of the Pt(IV) centre to give the desired Pt(II) drug at the 
target location. That being said, it is largely believed that this reduction is the result of the 
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hypoxic environment of the tumour and / or the presence of reductive species within 
endosomes88.  
 
Of the notable Pt(IV) complexes in Figure 117, satraplatin presented with the most promising 
results, displaying oral activity, increased cytotoxicity over cisplatin and efficacy in cisplatin 
resistant cell lines. Unfortunately the complex did not progress through stage three clinical 
trials as it was found that the complex negatively affected the efficacy of prednisone when used 
in combination therapy44, 89 – 91. Pt(IV) structures remain a prominent area of interest within the 
literature, with a number of promising pro-drug candidates. One example is that reported by 
Dabrowiak et al, who developed a Pt(IV) pro-drug which may be reduced in situ to form the 
active drug cisplatin and may also be tethered to the surface of citrate capped gold nanoparticles 
for targeted cellular uptake92. The chemical structure of this Pt(IV) pro-drug is represented in 
Figure 118.  
 
Figure 118: Chemical structure of the Pt(IV) pro drug developed by Dabrowiak et al, taken 
from Dabrowiak et al92. 
The surface of the citrate capped gold nanoparticles was loaded with the above Pt(IV) 
compound and subsequently further functionalised with a thiolate modified β-cyclodextrin for 
incorporation of receptor targeting. Unfortunately, this pro drug was found to be less cytotoxic 
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than cisplatin when administered to neuroblastoma SK-N-SH cells, irrespective of 
nanoparticular loading92.  
 
1.3.4. Conclusions  
A number of platinum anticancer agents have been developed within the literature as 
Pt(II) and Pt(IV) complexes. Despite a wealth of research efforts, traditional Pt(II) complexes 
such as cisplatin and carboplatin remain as the most clinically viable models. Despite the 
promising opportunities which might be afforded to Pt(IV) complexes, there are still no 
clinically approved Pt(IV) agents to date. Research into the use of Pt(IV) agents has also 
investigated their potential as therapeutic agents within nanoparticle systems. Pt(IV) agents 
remain a promising prospect within chemotherapeutics and may yet form the clinically 
approved Pt drugs of the near future.  
 
1.4. Transition Metal Imaging Agents 
1.4.1. Ru(II) polypyridyl complexes and their properties 
Inorganic imaging agents present with a number of favourable physical properties and 
have thus been utilised across a broad range of applications within the literature. Of these 
agents, transition metal based polypyridyl complexes have been of particular interest and use 
on account of their strong fluorescence within the visible region, long excitation state lifetimes 
(typically in the nano-seconds), comparatively high photostability and facilitation of photo-
induced energy transfer processes52, 93, 94. 
 
Ruthenium(II) based polypyridyl complexes in particular present with characteristic absorption 
bands in the blue range (typically around 290 and 460nm), corresponding to the 1(π−π*) and 
singlet metal-to-ligand charge transfer (1MLCT) bands respectively95. These complexes also 
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typically present with a 3MLCT based broad emission band centred in the red field (~620-
680nm). These complexes therefore typically present with large stokes shifts, in the region of 
~200nm, thus significantly reduces the amount of emission that might otherwise be re-absorbed 
by the very same probe. The origin of MLCT and the formation of the different states (singlet 
(1MLCT) and triplet (3MLCT)) are depicted in Figures 119 and 120 and are briefly discussed 
below. 
 
Figure 119: MLCT for a typical d6 transition metal complex, such as those of Ru(II) 
polypyridyl complexes. MLCT is the result of electrons being excited from lower lying metal 
based orbitals (d orbitals) to higher in energy vacant orbitals provided by ligands as a result of 
absorption of energy from photons, serving as the origin of the fluorescence found in 





Figure 120: Jablonski Diagram, showing the typical energy state of Ru(II) polypyridyl 
complexes and the associated pathways for release of energy absorbed from photons95.  
 
Upon excitation of an electron to one of the vacant π* ligand based orbitals, the electron is said 
to be in an excited singlet state or 1MLCT. From this excited singlet state, the electron can relax 
back down to its ground state and give fluorescent emission, or it can undergo a process known 
as intersystem crossing (ISC). Intersystem crossing is the non-radiative transition of an electron 
from its singlet state multiplicity to a triplet state multiplicity or 3MLCT. From this excited 
triplet state, the electron can relax back to its original ground state and in turn give 
phosphorescent emission. This phosphorescent emission is typically saught after for emissive 
probes as it is spin-forbidden and therefore presents with longer emissive lifetimes96.  
 
Due to the restricted depth penetration of the excitation and emission wavelengths for these 
imaging probes they are typically limited to utilisation as cellular tracking agents within cells 




1.4.2. Utilisation within Research 
One of the most prominent examples of a Ru(II) polypyridyl complex in the literature is 
that of [Ru(bpy)3]
2+, as originally developed by Cook et al52, 97. [Ru(bpy)3]
2+ is a low spin d6 
complex that is typically stabilised by cl- counter ions, displaying water solubility and stability 
as a result of its slow rate of ligand exchange. This complex possesses a strong 1MLCT 
absorption at 450nm (ε13000 mol-1 cm-1), a relatively strong 3MLCT emission at 650nm, a 
quantum yield of 3% and typical lifetimes of ~370-400 nano-seconds. Examples of the 
absorption and emission spectra of this complex are represented below in Figure 121, as 
sourced from the literature.  
 
 
Figure 121: A) absorance and B) emission spectra of [Ru(bpy)3]
2+ taken from Yoko et al98. 
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Stemming from the conceptualisation and broad utilisation of [Ru(bpy)3]
2+, a number of Ru(II) 
polypyridyl based imaging agents have been developed. Of particular interest are those that 
have been utilised within cellular imaging application. In this regard, one notable application 
of the literature is that of Turro et al, who synthesised [(Ru(bpy)2)2(tpphz)]
4+, whose structure 
is depicted in Figure 12299, 100.  
 
Figure 122: Chemical structure of Turro et al’s Ru(II) polypyridyl complex100, taken from 
Gill and Thomas99. 
 
The Turro Ru(II) imaging agent was found to selectively bind within the major groove of the 
DNA helix. Upon major groove binding, the photophysical properties of the probe are changed 
and a substantial shift in the emission wavelength is observed. Accordingly, these imaging 
probes inherently present with a positive means of differentiating between bound and unbound 
molecular probe, thus making them a potent cellular tracking agent.  
 
Alternative Ru(II) polypyridyl imaging agents have also been utilised within research as 
nanoparticle tracking agents. In this regard, Osborne et al synthesised and investigated a 
number of novel Ru(II) polypyridyl based imaging probes comprising variable ligands for 
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surface functionalisation of citrate capped gold nanoparticles101. Some of these structures are 
represented in Figure 123 below, as drawn from the literature.  
 
Figure 123: Diagrammatic representation of three novel Ru(II) polypyridyl based imaging 
agents as developed by Osborne et al. Taken from Osborne et al101.  
 
Osborne et al utilised the above structures to investigate the effect of Ruthenium core distance 
from the nanoparticle surface and what effect this might have on the probes emissive properties. 
It was found that a combination of the probe distance from the particle surface, the nature of 
the nanoparticle surface and any surface stabilising agents (such as the surfactant Zonyl FSA) 
lead to varying degrees of quenching. Optimal emissive conditions were found for Ru(II) 
probes with longer surface tethering linkers, such as that of RuS12 as depicted in Figure 123.  
 
1.4.3. Conclusions 
There is a wealth of research into the photo-physical properties of Ru(II) polypyridyl 
imaging agents within the literature. These ligands have been utilised in cellular imaging and 
present with different methods of action, including DNA major groove binding and 
nanoparticle tracking studies. The number of desirable physical and photo-physical properties 
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make Ru(II) polypyridyl complexes desirable cellular imaging agents within confocal 
microscopy and flow cytometry studies. Accordingly, utilisation of such complexes within a 
theranostic imaging agent may present with favourable nanoparticle tracking capabilities.  
 
1.5. Thesis Aims 
This thesis focusses on the development of a folate receptor targeting theranostic gold 
nanoparticle system. Accordingly, chapter 2 addresses the development of a new protocol for 
the synthesis of folate capped gold nanoparticles. This new protocol was developed to address 
the lack of a robust and reliable method for the production of such particles, as has been 
discussed in the above literature review.  
 
Chapter 3 addresses the loading of both citrate and folate capped gold nanoparticle systems 
with a ruthenium based polypyridyl probe that has been previously synthesised by the 
Pikramenou group. These fluorescent gold nanoparticle systems were then subjected to in vitro 
cellular studies and their uptake in folate receptor positive and negative cells investigated. In 
particular, different methods of adjusting the levels of folate receptors within a single cell line 
were investigated, so as to give a more representative measure of folate receptor mediated 
uptake only.  
 
Chapter 4 investigates the development of a novel Pt(IV) pro drug that has the potential to be 
administered on its own or as part of a surface functionalised agent on citrate or folate capped 
gold nanoparticles for targeted delivery. Its potential as a chemotherapeutic agent was 
investigated via MTT assays, ICPMS studies and immunocytochemical analysis utilising a 
commercial antibody for cisplatin-DNA adduct recognition.  
 
Chapter 5 investigates the utilisation of the ruthenium based polypyridyl probe and novel 
Pt(IV) agents as part of surface functionalised citrate and folate capped gold nanoparticle 
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Chapter 2 – GNP Preparation & Probe Development  
2.1. Nanoparticle Development 
2.1.1. GNP-Cit and GNP-GSH-Folate 
Nanoparticles have been used extensively in the literature for the delivery of payloads, 
be it therapeutic compounds and / or imaging agents, to cancer cells and tissues (see section 
1.2.4). One of the most common gold nanoparticle systems to be utilised for the delivery of 
imaging agents or therapeutics is citrate capped gold nanoparticles. There are well-established 
synthetic protocols for the development of specific size batches of these GNPs, displaying little 
standard deviation (5-8%) and polydispersity (average <3%)1. An example of such a protocol 
is that of the Turkevich method2, or the more frequently used, advanced Turkevich method 
developed by Vossmeyer et al3. An adaptation of this method was used in the present research 
for the development of 13nm citrate capped gold nanoparticles, said adaptation was published 
in the works of Osborne et al4. This nanoparticle preparation protocol allows for the 
development of 13nm, 25nm, 50nm and 100nm citrate capped gold nanoparticles batches 
sequentially through the implementation of a simple batch method, delivering improved batch 
uniformity (over the literature) and consistently reproducible results. 
 
Whilst the development of specific sized citrate capped gold nanoparticles is well established 
within the field, a method for the preparation of consistently sized, low polydispersity folate 
capped gold nanoparticles is yet to be documented. As previously stated, there is ongoing 
research and indeed published works into the development of such a protocol. Therefore, initial 
efforts in the present research were made towards the synthesis of consistently sized folate 




One such example of a folate capped gold nanoparticle preparation is that developed by Zhang 
et al5. This method utilises 13nm citrate capped gold nanoparticles with folic acid tethered to 
their surface via a glutathione linker. An overview of this surface adaptation is depicted in 
Figure 201. 
 
Figure 201: Schematic representation of surface modification of citrate capped gold 
nanoparticles for the tethering of folic acid via glutathione5. 
GSH = Glutathione. FA = Folic Acid. Au = GNP surface. 
 
A batch of 13nm citrate capped gold nanoparticles (GNP-CIT) was prepared as per the 
improved Turkevich method (see experimental section 2.3.2 for full details) and their size 
characterised by DLS (see Figure 202). The surface of the citrate capped GNPs were then 
functionalised with glutathione molecules via thiol tethering. The carboxylic acid moieties at 
the distal ends of said glutathione tethers were functionalised to the NHS ester and then 
subsequently formed amide linkages to the amino groups of folic acid as per the schematic 
representation in Figure 201 (see experimental section 2.3.2 for full details). It should be noted, 
given that folic acid comprises only one primary amine group, there is theoretically little 







Figure 202: a) Size by intensity of GNP-Cit as prepared by Turkevich method, showing 
monodisperse sample with good PDI and standard deviation, b) Size by number of the same 
GNP-Cit batch, giving a more accurate representation of the actual nanoparticle size range. 
 
Theoretically, this glutathione tethering method gives a good loading potential as it allows for 
two units of folic acid per unit of glutathione. However, in practice, this method proves to make 
the nanoparticles unstable, with the literature noting that the nanoparticles “may” aggregate 





loading volume, nanoparticle concentration) in order to improve stability and it was their 
optimal reported conditions that were employed in the present research. 
 
Despite using the optimal conditions as reported in the literature, the present research observed 
the same instability, with aggregation seemingly occurring more frequently than reported. The 
resulting GNP-GSH-Folate particles displayed a typical stability of 24 hours, after which, 
aggregation was evident by colour change and DLS (large peak ~1µm, size by intensity). The 
large polydispersity (PDI - 0.522) and standard deviation (StDev - 20.03) of the GNP-GSH-
Folate particles (as can be seen in Figure 203) prevented an accurate calculation of the mean 
size of the particles as it was not possible to obtain clean TEM data.  It was anticipated that the 
particles would be further de-stabilised upon loading with imaging and therapeutic agents in 




Figure 203: a) Size by intensity for GNP-GSH-Folate, showing highly polydisperse nature of 
the sample, with a high PDI and standard deviation, b) Size by number for the same sample of 
GNP-GSH-Folate, showing the variation in computed size as a result of the highly polydisperse 
nature of the sample.  
 
2.1.2. GNP-Folate 
Subsequent investigations were made into the direct synthesis of folate capped gold 
nanoparticles (GNP-Fol). Zhang et al.6 utilised a microwave reactor as opposed to a heating 





methods, including that of the Turkevich method. Heating mantles are typically utilised in GNP 
research as they allow for a more progressive heating and cooling method of the GNP solution. 
This progressive heating and cooling is believed to be significant in the literature for assisting 
with polydispersity and batch consistency. 
 
The Zhang et al microwave method does afford a somewhat consistent method for the 
production of GNP-Fol. However, it does still suffer from poor overall yield of particles 
(~10mL, 0.5nM), unused starting materials that must be dialysed out of solution and a varying 
degree of polydispersity. However, it was this preparation that was optimised by former 
Hannon Group Post-Doctoral researcher Ana Caballero and formed the scope for initial GNP-
Fol protocol studies within the present research.  
 
Caballero’s method maintained the use of the microwave reactor whilst adjusting the ratios, 
concentrations, volumes and order of addition of the reagents employed (see experimental 
section 2.3.2 for full details). Through these preparation amendments the Caballero method 
increased the yield of the reaction to ~15ml (a 50% increase) whilst maintaining a comparable 
size, polydispersity and batch consistency to that of the originating Zhang method. As 
aforementioned, the Caballero method was employed for much of the foundation work on 
folate capped gold nanoparticles within this research, however, it still lacked sufficient batch 
consistency, with the nanoparticles ranging anything from 10nm to 30nm (see Figure 204 for 
typical DLS data). Furthermore, this 15mL batch protocol affords GNP-Fol with a 
concentration of ~0.3nM that is quite frequently polydisperse. To emphasise the batch 
variability of the Caballero method, Table 201 presents a range of the nanoparticle data 





Figure 204: Typical sizing data for GNP-Fol as prepared by the Caballero method, recorded 
by DLS. a) Size by number for GNP-Fol, with an acceptable PDI (0.182) and relatively broad 
standard deviation (4.701), b) Size by intensity for the same sample of GNP-Fol, showing the 
variation in computed size as a result of the broad distribution of nanoparticle size, with the 








Size by Number (nm) 
Average Nanoparticle 
Size by Intensity (nm) 
Average PDI StDev (nm) 
1 13.23 21.48 0.253 3.425 
2 28.76 35.87 0.513 6.78 
3 17.70 27.88 0.208 4.525 
4 17.95 28.55 0.197 4.650 
5 24.45 33.27 0.44 7.23 
Table 201: Tabulated key experimental data to exemplify the variation in batch consistency 
for the Caballero GNP-Fol synthesis. Experiments 1) – N) were run under identical conditions 
with the same protocol.  
 
From Figure 204 and Table 201, the batch variation for the Caballero method is rather 
significant. From the tabulated data alone, it is evident that there is a spread in the average size 
by number of the batches of 15.53nm, with a PDI as high as 0.513, which is a measure of 
significant polydispersity within the system. With regard to the latter, it can be seen in figure 
201, the size by intensity plot (Figure 204, b)) shows a typical peak broadness, signifying an 
acceptable degree of polydispersity, for which, the PDI value was 0.182. It is generally known 
amongst users of such DLS instrumentation, a PDI above 0.24 is tending toward being quite 
polydisperse.  
 
Given that one of the key research goals was to draw comparisons on cellular uptake of GNP-
Cit and GNP-Fol the size range and batch consistency of GNP-Fol is of utmost importance. 
Given that the improved Turkevich preparation yields GNP-Cit that are ~13nm (±2nm), 
monodisperse and with a concentration of ~1nM consistently. GNP-Fol must be of a 
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comparable size, polydispersity and concentration to the GNP-Cit system. Accordingly, a new 
preparation for GNP-Fol was developed and utilised throughout the present research. 
 
2.1.3. Young GNP-Fol Preparation 
Initial efforts utilised the lessons of both the Caballero and Turkevich methods. It was 
assumed that the polydispersity issues of the Caballero method were likely stemming from the 
use of the microwave reactor over the conventional heating mantle. It was noted that upon 
completion of the heating stage in the microwave reactor of the Caballero method (see 
experimental section 2.3.2 for full details), the reactor not only cooled the solution rapidly, but 
it also appeared to stop stirring the nanoparticle solution. Therefore, whilst the nanoparticles 
were still being produced / growing, the solution was being cooled and no longer stirred, which 
could potentially account for the inconsistent and abnormal nanoparticle growth within the 
solution. By comparison, in the Turkevich method, the nanoparticles are allowed to gradually 
cool down to room temperature whilst being constantly stirred, which is believed to be a key 
contributing factor to the development of monodisperse and significantly spherical 
nanoparticles.  
As a result of these hypotheses, early adaptations looked to utilise the apparatus of the 
Turkevich method, along with the orders of addition and reaction times, whilst replacing like 
for like reagents and maintaining ratios and concentrations of the respective reagents.  
 
Variation 1 
The first variation (Variation 1) toward the development of a new protocol for GNP-Fol sought 
to mimic the exact method of the improved Turkevich method3. Trisodium citrate and citric 
acid were replaced with sodium folate and folic acid respectively, maintaining their molar 
equivalents and ratios. EDTA was also utilised as the literature cited this compound as playing 
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a key (yet, not fully understood) role in the production of more spherical GNP-Cit. Variation 1 
did not successfully synthesise gold nanoparticles and no changes were observed to the colour 
or composition of the solution were observed.  
 
This result was not overly unexpected as there were a significant number of changes made to 
the original Caballero protocol and furthermore, no protocol of the literature (for GNP-Fol 
synthesis) featured concurrent use of folic acid and sodium folate, or the use of EDTA. 
Additional efforts were made into adjusting the ratios of the reagents employed and the overall 
volume of the reaction, however, there was still no successful production of nanoparticles. 
Given that no nanoparticles were being formed the most likely conclusion was that the gold 
salt was not successfully being reduced in solution and therefore no nanoparticles were being 
seeded for growth. 
 
pH Dependent Reduction 
It was hypothesised that the pH of the solution may have been a key factor in the lack of 
reduction events, noting that Caballero emphasised substantial efforts into optimising the 
amount of sodium hydroxide titrated post addition of sodium folate to the stirring solution of 
gold salt (see experimental section 2.3.2), indicating that a specific pH range was essential. 
Furthermore, Vossmeyer et al.3 emphasise that a pH of 5.6 is optimal for the improved 
Turkevich synthesis, indicating a potentially fundamental reliance on pH. Accordingly, the pH 
was recorded for the optimised Caballero method at four time points; 1) primed reaction 
solution, 2) post reagent addition, 3) post sodium hydroxide addition and  4) end of the reaction. 
Once these key pH points were established, the pH of Variation 1 and the Turkevich protocol 
at points 1), 2) and 4) were measured (point 3 could not be measured as there is no additional 
sodium hydroxide addition step or equivalent). These measurements were taken so as to allow 
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for a more complete overview of the pH range and to potentially allude to the reason for the 
lack of production of GNP-Fol (these pH’s can be seen in Table 202).  
 
 Measured pH at Respective Time Point 
Method 1 2 3 4 
Caballero 5.1 8.5 11.2 10.5 
Variation 1 5.8 5.5 - 5.6 
Turkevich 5.6 5.3 - 5.5 
Table 202: Tabulated pH measurements associated with various stages of the Caballero 
protocol, Variation 1 and the Turkevich protocol, at various time point equivalents, which 
include; 1) primed reaction solution, 2) post reagent addition, 3) post sodium hydroxide 
addition and 4) end of the reaction. The data showing the significantly basic pH range of the 
Caballero protocol by comparison to the mildly acidic pH range of the improved Turkevich 
protocol, with Variation 1 expectedly showing a pH range toward that of improved Turkevich.  
 
It is evident from the data of Table 202 that the Caballero protocol operates under severely 
basic conditions, exhibiting a pH of 8.5 post the addition of sodium folate and a pH of 11.2 
post the addition of sodium hydroxide, and exhibiting a final pH of 10.5. By comparison, the 
Turkevich protocol operates under somewhat acidic conditions, exhibiting a pH of 5.3 post the 
addition of gold salt and a final pH of 5.5. It was therefore hypothesised that no nanoparticles 
were successfully formed in Variation 1 as a result of the difference in pH and, more 
specifically, fundamental differences in the mechanism for reduction of the gold salt between 
the citrate and the folate systems. The hypothetical mechanism for gold salt reduction in the 
citrate nanoparticle method as set forth by Vossmeyer et al is highlighted in Figure 205, whilst 
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the structure of folic acid and potential equivalent redox reaction sites is depicted in Figure 
206.  
 
Figure 205: Adaptation of Figure 1 from Vossmeyer et al.3 paper on the advanced Turkevich 
method, reporting the proposed mechanism of the Turkevich synthesis. Redox reaction of 
citrate and the gold salt (Au(III) precursor) produces Au(I) ions and acetonedicarboxylate. 
Disproportionation of Au(I) produces Au(0) and Au(III), with the former initiating nucleation 
and growth to form citrate coated gold nanoparticles. 
 
 
Figure 206: Proposed sites capable of being oxidised to produce electrons which can 
subsequently partake in a redox reaction with gold salt, reducing Au(III) to form Au(I), which 
may then subsequently go on to form Au(0) and undergo  nucleation / growth of folate capped 




As taught by Vossmeyer, and therefore, in the case of citrate capped gold nanoparticle 
formation, there is a hydroxyl group bound to the same carbon as a carboxylic acid (see Figure 
205) and it is oxidation at this site which produces the electrons required to then reduce the 
gold salt (Au(III)) to Au(I) and go on to initiate nanoparticle formation (see introduction section 
1.2.2 for full details)3. In contrast, there is no comparable hydroxyl group available in folic acid 
and therefore the gold salt must be reduced via the formation of some other intermediate. It is 
proposed that this may be at either of the amide / amine bonds highlighted in Figure 206. Such 
species could theoretically mimic the function of acetonedicarboxylate, organizing Au(I) into 
polymolecular complexes, whilst also facilitating the production of the electrons required for 
gold salt reduction, the combination of which ultimately leads to the nucleation and growth of 
Au(0) to Au NP’s.  However, this hypothesis requires much further experimentation and 
deliberation. In particular, the intermediate structure responsible for subsequent gold salt 
reduction must be identified so as to better understand the process. A potential experiment for 
this might be to take samples at different time points of the experiment and analyse them via 
IR Spectroscopy so as to analyse the functional groups present. Additionally, mass 




In light of these pH investigations, and upon review of the literature regarding the 
aforementioned mechanism for the production of citrate capped gold nanoparticles, the pH of 
the system was systematically adjusted across a series of reactions. Accordingly, to reduce the 
pH of the reaction mixture that was heated prior to the addition of the gold salt (see experiment 
section 2.3.2) the ratio of sodium folate to folic acid was adjusted. Incremental increases in the 
ratio of sodium folate to folic acid were investigated, maintaining the ratio of folic moieties to 
56 
 
gold salt moieties, effectively lowering the pH of the system whilst maintaining other key 
parameters. These pH dependent experimental studies are not tabulated, however, it is 
noteworthy that GNP-Fol formation was unsuccessful until a minimum pH of 10.5 was 
attained, whereupon GNP-Fol formation was feasible, but with poor resulting nanoparticle 
suspensions (Variation 2). 
 
Variation 2 required overnight refluxing of the reaction mixture before nanoparticles were 
successfully formed. It is believed that the point of nanoparticle seeding and subsequent growth 
was after approximately 12 hours of reflux. It is believed that this very slow rate of gold salt 
reduction led to an uneven rate and distribution of nanoparticle seeding events, which 
subsequently gave batches of GNP-Fol that were of a high polydispersity (PDI 0.4), highly non 
spherical and inconsistent in concentration (1-2nM) and average size (16nm – 25nm, 
characterized only by DLS, size by Number and Intensity). This theory is supported by the 
literature, with Vossmeyer et al emphasising the importance of rapid reductive events in the 
GNP-Cit method, which is believed to facilitate a nanoparticle system where the majority of 
nanoparticle growth events are initiated largely simultaneously3. Simultaneous nanoparticle 
seeding and rate of growth gives a significantly greater chance of monodisperse and uniform 
nanoparticles, the kind of which are of course sought after for the GNP-Fol system so as to 
afford a comparable platform for nanoparticle investigations. 
 
Variation 3 
Further investigation of GNP-Fol synthesis utilising the core methodology of Vossmeyer was 
conducted, systematically altering further parameters including temperature (80-150°C), 
volume (50-125mL), molar ratios, heat source (mantle vs oil bath) and reaction time (10 mins 
to overnight). None of these alternative parameters afforded a GNP-Fol system with 
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comparable polydispersity, size, shape, concentration and batch consistency of the Turkevich 
GNP-Cit method. Subsequent efforts therefore reverted to the system and parameters of the 
Caballero method. 
 
Whilst the Caballero method gave poor parameters for GNP-Fol (batch consistency, 
polydispersity, concentration etc), it was re-visited as it was at the very least able to produce 
GNP-Fol within a comparable reaction time to that of GNP-Cit (Osborne / Vossmeyer) 3 / 4. As 
such, the reductive events of the reaction must also have been occurring within a significantly 
shorter timeframe than that of the aforementioned GNP-Fol experiments and therefore, is a 
step closer to nanoparticle uniformity and batch consistency. It was previously postulated that 
the resulting poor polydispersity and batch consistency of the Caballero method may be as a 
result of the microwave reactor employed, with aggressive heating and cooling windows and 
non-continuous stirring of the reaction mixture. Accordingly, efforts leading on from this 
research utilised alternative heat sources such as a heating mantle or a stirrer hotplate with an 
oil bath.  
 
Variation 3 utilised a stirrer hotplate and oil bath as an alternative heat source so that the 
reaction may be gradually heated and cooled and the solution stirred at all times. For this first 
deviation from the Caballero method, the entirety of the method was maintained, only the heat 
source was replaced. Initial efforts were unsuccessful, however, after amending the order of 
addition of sodium folate and sodium hydroxide, Variation 3 successfully formed GNP-Fol. 
However, with a PDI of 0.3 and a particle size range of ±10, it was evident that polydispersity 
and batch consistency issues still remained. Moreover, it was noted that the reduction of the 
gold salt still took significantly longer than that of the literature (~10 minutes) and therefore 




In addition to the slow rate of gold salt reduction, it was theorised that these poor metrics were 
potentially the result of the difference in the “charged reaction mixture” of the method3. That 
is to say, the improved Turkevich method effectively primes the reaction before adding the 
gold salt, heating a solution of citric acid, trisodium citrate and EDTA, thus priming the system 
with the reductive species required prior to adding the gold salt. The Caballero method on the 
other hand primes a gold salt solution and then relies on uniformity of the incurred reductive 
events upon addition of the sodium folate and sodium hydroxide. It was therefore hypothesised 
that the poor nanoparticle uniformity may be as a result of an effective lag in the production of 
the reductive species as opposed to having the system primed with these in the first instance.  
 
Variation 4 
Accordingly, the subsequent reaction, Variation 4, saw almost the inverse of the charged 
mixture of Caballero, with a solution of sodium folate refluxed prior to the addition of the gold 
salt, followed by sodium hydroxide to keep the pH of the solution within the 10.5 – 12 range 
believed to be required. Variation 4 achieved gold salt reduction within 15 seconds and was 
the first successful adaptation of the Caballero method in view of the teachings of Vossmeyer 
et al.  
 
The metrics for GNP-Fol produced by Variation 4 were an improvement over those of the 
Caballero method, with a PDI of 0.16 and a StDev of ±8, however, they were considered to 







Further experiments varied reagent volumes (for nanoparticle uniformity and for scale up), 
reagent concentrations (for nanoparticle yield) and reaction conditions (for rate of reduction 
and nanoparticle uniformity). In relation to reagent volume, a first adaptation utilised a 
significantly more concentrated solution of gold salt, dissolving the same quantity in 1mL of 
deionised water, as opposed to 18mL in the Caballero method and 25mL in the improved 
Turkevich method. This adaptation allowed the gold salt to be added in a single movement, 
directly and rapidly into the vortex of the stirring reaction mixture via a 1000µL Gilson pipette. 
The effect of which was a significantly improved polydispersity index and standard deviation 
of nanoparticles formed. It is believed that this is as a result of a more homogenised solution 
of reductive events, with a significantly improved proportion of the gold salt being converted 
to Au(0) simultaneously and thus, the majority of the nanoparticles being formed at a similar 
rate and from a similar time point. Variation 5 yielded a 20mL suspension of ~1nM GNP-Fol, 
with an average size of ~15nm ±3nm.  
 
Variation 6 
A second adaptation scaled up the volumes of all reagents employed, looking to increase the 
yield of the protocol to comparable volumes of the improved Turkevich method. Unlike 
previous scale up attempts, Variation 6 utilised the methodology of Variation 5 and merely 
scaled up the reaction with the exception of the volume of gold salt, which was maintained at 
1mL in water and had its concentration altered. This scale up successfully a GNP-Fol 
suspension, however, the metrics for this method were significantly poorer than required, with 
hgh polydispersity, standard deviation and a weak particle concentration (~0.2nM). The most 
significant metric perhaps is the concentration of the reaction, which, despite using 10 times 
more gold salt and more sodium folate, the effective nanoparticle yield the reaction only 
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increased by 70%. Thus, the protocol was successfully scaled up in volume, but was 
significantly less efficient at nanoparticle formation, yielding a dilute suspension with a 
significant proportion of starting materials or undesired side reactions.  
 
Summary of Findings 
Extensive efforts were invested in the development of a novel direct synthetic protocol for the 
production of folate capped gold nanoparticles. All key reaction parameters were varied, 
including equipment used, order of addition of reagents, volumes, and concentration etc. 
Variation 5 was the most successful protocol, representing an adaptation of the Caballero 
method with teachings drawn from the Osborne and Vossmeyer protocols3, 4. Variation 5 
presents a protocol for the production of GNP-Fol in a comparable timeframe to Caballero, 
with significantly improved metrics of the system into a comparable range to those afforded by 
the Osborne method for GNP-Cit. Variation 5 was therefore utilised for all nanoparticle studies 
reported hereafter and is termed the “Young Protocol”.  
 
2.2. Imaging Agent Development 
2.2.1. Transition Metal Based Probes 
Ruthenium and Iridium based transition metal imaging agents have been studied within 
the Pikramenou group for a significant period of time and, accordingly, extensive research 
efforts have been invested into novel agent development and full characterisation of the 
emissive capabilities of the probes both on their own and when loaded onto GNP-Cit (see 
introduction section 1.4.2 for full details). As such, no efforts were made in the present research 
into the development of novel probes, nor into ascertaining the emissive parameters of such 
agents. Instead, the loading capacity of a selection of established probes was investigated when 
loaded onto the surface of GNP-Fol as prepared by the Young protocol. The probes of interest 
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were RuBpySS, IrBpySS and RuPhenSS, affording a comparison to be drawn between the 
metal core employed and the nature of the ligands facilitating MLCT (see introduction section 
1.4.1). These transition metal based probes are well established within the literature by both 
Adams7 and Osborne4 and their structures can be seen in Figure 207. The associated synthetic 
pathways to the production of RuBpySS and IrBpySS are represented in Figure 208. It shall be 
appreciated that the pathway to RuPhenSS varies only in the production of [RuPhen2Cl2] as the 
intermediary complex as opposed to [RuBpy2Cl2], the tethering ligand remains the same (full 
details in experimental section 2.3.3).  
 
Figure 207: Chemical structures of the transition metal based imaging agents employed within 





Figure 208: Synthetic route to RuBpySS and IrBpySS as outlined by Adams et al.7. 
In addition to the benefit of the established nature of the aforementioned probes within the 
research group, such transition metal probes typically exhibit numerous favourable properties, 
which include; a good stokes shift and relatively strong emissions (outlined in more depth in 
section 1.4.1 of the introduction), hence justifying their utilisation.  
 
2.2.2. GNP Folate Loading Studies 
The degree of stability of a nanoparticle system is a somewhat speculative and qualitative 
measure. As previously discussed (see introduction section 1.2), the most common parameters 
for ascertaining the stability of a nanoparticle system are: 
• the degree of shift and broadening of the SPR (Surface Plasmon Resonance) band of 
the UV-Vis absorption spectrum; 
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• any induced polydispersity or general aggregation of the nanoparticles; and 
• change in colour of the solution. 
The binding of structures to the surface of gold nanoparticles induces a shift in the SPR band 
of the system. Upon binding, the SPR band will generally broaden and shift, with the latter 
being an increase or decrease in the absorption intensity and / or peak wavelength (λmax). 
Therefore, the UV-Vis absorbance spectrum of each nanoparticle system was measured after 
incremental titrations with the respective fluorescent probe, with the degree of SPR band 
broadening and shifting recorded accordingly. With regards to induced polydispersity and 
aggregation, the polydispersity and average nanoparticle size of the systems were ascertained 
via DLS measurements at selective titration points. Any potential colour change of the 
respective nanoparticle suspension was qualitatively noted after each titration of the respective 
transition metal probe. The UV-Vis absorption spectra for these titration experiments are 









Figure 208: UV-Vis absorption spectra recorded for titrations of transition metal probes into a 
suspension of GNP-Fol (1mL ~1nM). a) Titration of RuBpySS (1mM), b) titration of IrBpySS 
(1mM) and c) titration of RuPhenSS (1mM). 
 
 λmax (nm) Shift (nm), Intensity and wavelength 
Titration 
Volume (uL) 
RuBpySS IrBpySS RuPhenSS RuBpySS IrBpySS RuPhenSS 
0 526 “ “ 0 0 0 
5 528 528 526 +0.01, +2 +0.01, +2 -0.02, 0 
10 529 528 528 +0.01, +3 -0.02, +2 -0.03, +2 
15 532 530 528 +0.02, +6 +0.04, +4 -0.13, +2 
20 535 536 528 +0.04, +9 +0.01, +8 -0.19, +2 
25 536 537 528 
+0.05, 
+10 





Table 203: Tabulated UV-Vis data in relation to shift of the SPR band in the UV-Vis 
absorption spectrum of GNP-Fol solutions upon titration with their respective transition metal 
probe. Data shows a significantly less affected λmax shift for RuPhenSS titrations by comparison 
to the other probes, whilst a significant decrease in the absorption intensity is observed by 
comparison to the other probes.   
 
It is evident from the data displayed in Figure 208 and Table 203 there are some quite important 
differences that can be observed in the aforementioned titration experiments. With regards to 
the RuBpySS and IrBpySS titrations, there is a steady incremental increase observed in the λmax 
with incremental increases in the number of transition metal probe units available to bind to 
the surface of the nanoparticles. With each titration of 5µL of the respective fluorescent probe, 
there is a general shift of 1-4nm in the λmax for the respective system. Where these systems 
differ however, is in the change in the intensity of the SPR band, with the band generally 
increasing in intensity for RuBpySS, whilst the band fluctuates and stays relatively similar in 
the IrBpySS system. Theoretically, it is assumed that upon successful binding of agents to the 
surface of nanoparticles the intensity of the SPR band should increase or decrease dependent 
upon the nature of the agent that is now bound.  
 
Therefore, it might be assumed that the IrBpySS probes were not binding as successfully as the 
RuBpySS probes and therefore are less feasible for imaging studies. This theory is somewhat 
hard to prove / disprove on account of the differences in the excitation and emission profiles 
of the respective probes. An alternative owould be to utilise ICPMS so as analyse and quantify 
any present Ir within a nanoparticular system. ICPMS was not used within these loading studies 
as the unsuccessful loading was proved via nanosight nanoparticle fluorescence. This 
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equipment allows for live tracking of nanoparticles in solution via scatter or, alternatively, 
tracking via monitoring emissions. The latter was employed as a means to ascertain whether 
the imaging probe had indeed bound to the surface of the nanoparticles or whether it was merely 
suspended in solution. The IrBpySS solution displayed no measurable fluorescence and 
therefore was no longer considered for cellular imaging studies.  
 
Upon reviewing RuPhenSS loading studies it is evident that the system displays  reduced 
shifting of the λmax of the system, displaying an overall shift of 2nm vs the 10nm and 11nm of 
RuBpySS and IrBpySS respectively. Moreover, the RuPhenSS system showed a quite 
significant decrease in the intensity of the SPR band (-0.27), which as aforementioned, is 
considered indicative of more efficient loading of the probe onto the surface of the nanoparticle 
system. Similar to the IrBpySS case, direct comparison of loading efficiency is theoretically 
difficult between RuBpySS and RuPhenSS on account of the fact that the two probes have 
different ligands and therefore, difference in loading efficiency could actually be miss-
represented by emissive capabilities. Accordingly, the emissive capabilities of the two systems 
were compared via the use of nanosight live nanoparticle fluorescence studies, with some of 
the key data represented in Figure 209. Further research should look to incorporate ICPMS so 
as to quantify the amounts of RuBpySS and RuPhenSS that may be loaded onto the surface of 
the particles. This data, in combination with the emissive data reported herein, would allow for 








Figure 209: Screen shots from Nanosight live nanoparticle tracking system for GNP-Fol-
RuBpySS system, left – scatter channel and right-fluorescence channel (using a 488nm laser 
for excitation and 500nm filter).  
 
  
Figure 210: Screen shots from Nanosight live nanoparticle tracking system for GNP-Fol-
RuPhenSS system, left – scatter channel and right-fluorescence channel (using a 488nm laser 
for excitation and 500nm filter).  
 
A number of observations can be drawn from the nanosite data of Figures 209 and 210 for the 
RuBpySS and RuPhenSS systems respectively. The first and perhaps most notable observation 
is that both fluorescent probe systems afford nanoparticles that display measurable 
fluorescence. That is to say, the nanosite data collected has confirmed successful binding of 
the respective fluorescent probes to the surface of the respective nanoparticle systems and, 
furthermore, that the fluorescence capabilities of the probes remain intact. There appears to be 
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a relatively consistent degree of emission across the populations which is most likely indicative 
of even surface functionalisation of the particles with the probes across the respective 
suspensions. Any uneven loading would likely result from variations in particle size across the 
suspension and therefore variation in surface area available for binding. It is also noteworthy 
that this instrument uses a 488nm laser, which falls well outside of the primary absorbance 
band of 290nm. Accordingly, the systems may actually be capable of significantly stronger 
emission.  
 
2.3. CONCLUSIONS  
A new protocol for the direct synthesis of folate capped gold nanoparticles was 
developed in the present research. This protocol produces folate capped gold nanoparticles that 
are more batch consistent, mono disperse and are typically more stable than those reported in 
the literature.  
 
The capacity of these particles to be surface functionalised with ruthenium based polypyridyl 
probes was investigated and compared to the capacity of citrate capped gold nanoparticles that 
had previously been reported by the Pikramenou group. The specific probes of use were 
RuPhenSS and RuBpySS. It is evident that these citrate and folate capped gold nanoparticle 
systems have comparable loading capacities with these probes and that the emissive properties 
of the probes appear unaffected. Later research by the Pikramenou group ascertained that the 
RuPhenSS probe displays fluorescence with improved photophysical properties when loaded 
onto the GNP-Cit system over the RuBpySS probe. Key parameters of improvement were 
emission strength and lifetime. These findings and conclusions for the RuPhenSS were 
therefore carried over in the present research and the RuPhenSS probe utilised for the resulting 





Future research into this area should look to quantitatively assess the photophysical parameters 
of the GNP-Fol-RuBpySS and GNP-Fol-RuPhenSS systems for potential optimisation before 




All materials were purchased from Sigma-Aldrich (now Merck), Fischer Scientific, 
ThermoFisher, VWR or MatTek. All solvents were of standard grade and were used without 
purification unless otherwise stated. All synthesis under N2 employed standard Schlenk line 
techniques. 
 
2.4.2. General Analytical Techniques 
All characterisation techniques were conducted within either the School of Chemistry 
or Biosciences at the University of Birmingham. Nuclear Magnetic Resonance (NMR) spectra 
were recorded in CDCl3, CD3CN, MeOD and d6-DMSO. 
1H-NMR and 13C-NMR spectra were 
recorded on either a Bruker AV(III)300 or AV(III)400 spectrometer. Electrospray mass 
spectrometry and Matrix Assisted Laser Desorption Ionisation Time of Flight (MALDI-TOF) 
spectra were collected by Dr. Chi Tsang (Analytical Facility). Spectra were recorded on a 
Waters LCT Time of Flight Spectrometer. UV-Visible (UV-Vis) spectra were recorded on a 
Varian Cary 5000 spectrometer. Dynamic Light Scattering (DLS) sizing measurements were 
carried out on a Malvern Zetasizer ZSP (Malvern Instruments) and nanoparticle fluorescence / 
scatter flow imaging was carried out on a Malvern Nanosight NS300. Transmission electron 
microscopy (TEM) was performed at the Centre for Electron Microscopy, University of 
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Birmingham by Theresa Morris, using a JEOL JEM-1200EX electron microscope. Inductively 
coupled plasma optical mass spectrometry (ICP-MS) measurements were performed on a 
7500cx IPC-MS at the University of Warwick by Lijiang Song. Metal concentrations were 
determined using PlasmaCal calibration standards (QMX laboratories), with R2 > 0.999 linear 
calibration curves. Samples were digested in freshly prepared ultrapure aqua-regia and 
concentrated Nitric acid, samples were subsequently diluted accordingly. 
 
2.4.3. Synthesis of Gold Nanoparticles 
GNP-Cit (Citrate capped 13nm Gold Nanoparticles) 
This method was developed by Shani Osborne3 and based on the protocol of Vossmeyer et al4.  
A solution of trisodium citrate dihydrate (60 mg, 0.2 mmol), citric acid (13 mg, 0.07 mmol) 
and ethylenediaminetetraacetic acid (EDTA) (1.5 mg, 0.004 mmol) in deionised water (100 
mL) brought to reflux for 10 minutes under aggressive stirring. A preheated (~80°C) solution 
of gold(III) chloride trihydrate H[AuCl4].3H2O (8 mg, 0.02 mmol) in deionised water (25 mL) 
was added rapidly to the centre of the vortex and the solution refluxed for a further 15 minutes. 
The solution was allowed to gradually cool to room temperature within the heating mantle to 
form a ~1nM solution of GNP-Cit. λmax 517nm (SPR). The resulting particles were then stored 
in a stoppered round bottom flask wrapped in foil. Diameter / nm = 13 ± 3 (DLS number 
distribution), PDI = 0.2.  
 
GNP-GSH-Fol (Citrate capped 13nm Gold Nanoparticles with Folate Moieties Tethered)  
These particles were developed exactly as per the method of the published work of Zhang et 
al5. For the citrate capped foundation particles, a ~1nM solution of GNP-Cit was freshly 
prepared as per the S.Osborne protocol above.  
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50µl of a 0.05mol glutathione (GSH) solution was added to 10mL of ~1nM GNP-Cit, with the 
resulting solution stirred overnight at room temperature for surface conjugation (~12 hours). 
The resulting solution was dialysed in a semi permeable membrane (Spectra-Por® Float-A-
Lyzer® G2, 5 mL, MWCO 8-10 kDa) in deionised water for 6 hours to remove unreacted 
materials. 25µL each of a 0.05mol DCC solution in DMSO and a 0.05mol NHS solution in 
DMSO were added and the solution further stirred for an hour. An excess of folic acid was 
added to the solution and stirred overnight (~12 hours) before being dialysed for a further 12 
hours to remove excess and unreacted materials, yielding ~0.6nm GNP-GSH-Fol. λmax 526nm 
(SPR), Diameter / nm = 41.71 ± 20 (DLS number distribution), PDI = 0.52.  
 
GNP-Fol (Zhang Method) 
These particles were developed exactly as per the method of the published work of Zhang et 
al6. 
Approximately 30-40µL 1M sodium hydroxide (NaOH) was added to a suspension of folic 
acid (0.012g) in 10mL deionised water, generating soluble sodium folate. This sodium folate 
solution was added dropwise to a stirring solution of H[AuCl4].3H2O (5mL, 1mM) and a 
further 50µL of 1M NaOH added, with the resulting solution stirred at room temperature for a 
further 30 minutes. The solution was heated to 50°C for 8 hours, yielding ~0.5nm GNP-Fol. 
λmax 540nm (SPR), Diameter / nm = 38 ± 15 (DLS number distribution), PDI = 0.36.  
 
GNP-Fol (Caballero Method) 
This method was developed by Ana Caballero and based on the above protocol of Zhang et al6.  
A mixture containing 18 mL of 0.8 mM solution HAuCl4, 90 µl NaOH 1 M and 0.72 mL of 
sodium folate 1 mM (prepared by adding 21 uL NaOH 1M to 5 mL folic acid 1 mM solution) 
was stirred at room temperature for 30 min. Subsequently, the mixture was heated to 180 ºC 
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for 5 minutes within a single-mode microwave reactor (CEM Instruments) at 200 W and left 
to cool slowly until room temperature. The solution was purified via dialysis (Spectra-Por® 
Float-A-Lyzer® G2, 5 mL, MWCO 8-10 kDa) for two days against deionized water with 
NaOH (pH 10), yielding ~0.3nm GNP-Fol. λmax 530nm (SPR), Diameter / nm = 30 ± 10 (DLS 
number distribution), PDI = 0.18.  
 
GNP-Fol (Young Protocol, used for the remainder of the research) 
This method was developed by Richard Young in the present research and was based on the 
protocols of Caballero and Vossmeyer4.  
A solution of sodium folate (0.72mL, 2mM) was added to 20mL deionised water and refluxed 
for 10 minutes with stirring in an oil bath. 1mL of a pre-heated (~80°C) HAuCl4.3H2O solution 
(5.7mg, 0.015mmol) was added rapidly by a Gilson pipette to the centre of the vortex, followed 
immediately by 90µL of a 1M NaOH solution. The resulting solution was refluxed for a further 
20 minutes and allowed to gradually cool to room temperature within the oil bath, yielding 
~1nm GNP-Fol. λmax 530nm (SPR), Diameter / nm = 15 ± 30 (DLS number distribution), PDI 
= 0.18.  
 
HAuCl4.3H2O (5.7mg, 0.015mmol) dissolved in 1mL deionised water and heated to ≈120°C 
in oven. HAuCl4.3H2O (6mg, 1mL) added in one go from a Gilson pipette followed 
immediately by NaOH (90uL, 1M). Refluxed for 20 mins and allowed to cool gradually in the 







2.4.4. Imaging Agent Synthesis 
RuPhenSS 
Compound 201:  N-(Boc)-5-amino-1-pentanol 
 
Compound 1 was synthesised as per the method developed by Sam Adams7. 
Potassium bicarbonate (14.12g, 141.1 mmol) was suspended in a solution of 5-amino-1-
pentanol (4.96, 48.0 mmol) in H2O:THF (70mL1:1). The white suspension was cooled to 
approximately 0°C and a solution of di-tert-butyl dicarbonate (11.11g, 50.9mmol) in H2O:THF 
(80mL 1:1) was added dropwise over 15 minutes. The resulting biphasic mixture was then 
heated to 50°C and stirred for 24hours. The organic phase was separated and reduced under 
vacuum until the solution formed an opaque white microsuspension. Diethyl ether (50mL) was 
added and the resulting solution washed with deionised water (4 x 25mL). The organic layer 
was separated, the aqueous fractions washed with diethyl ether (50mL) and organic fractions 
combined. The organic solution was then dried over Na2SO4, filtered and solvent removed 
under vacuum, yielding the product as a clear oil (7.55g, 77%). Characterisation agrees with 
that of the literature. δH(300 MHz; CDCl3); 1.32-1.63 (6 H, m, H-3,4,5), 1.42 (9 H, s, H-8),  
2.05 (1 H, s, OH), 3.11 (2 H, dd, J = 6.3, 12.7, H-6), 3.54 (2 H, dd, J = 6.4, 11.6, H-2) and 4.59 




Compound 202:  N-(Boc)-5-amino-1-tosylpentane 
 
Compound 2 was synthesised as per the method developed by Sam Adams7. 
 
A solution of N-(Boc)-5-amino-1-pentanol (7.80g, 38.4mmol) and pra-toluene sulfonyl 
chloride (9.76g, 51.24mmol) in anhydrous DCM (50mL) was cooled to approximately 0°C 
under nitrogen. Pyridine (11mL, 149.0mmol) was added dropwise over 5 minutes and the 
resulting reaction mixture was allowed to come to room temperature and stirred for 24 hours. 
The mixture was concentrated under vacuum yielding a white suspension. The suspension was 
added to H2O:Et2O (100 mL 1:1) and separated, followed by washing the organic layer with 
aqueous NaHCO3 (50 mL) and brine (50 mL). The solution was dried (Na2SO4), filtered, and 
the solvent was removed under vacuum to give a clear oil, which was triturated in hexane (50 
mL), with the resulting solid filtered and washed with cold hexane (2 x 30 mL) to give a white 
solid N-Boc-5-amino-1-tosylpentane (5.8g, 44%). Characterisation agrees with that of the 
literature. δH(300 MHz, CDCl3); 1.40-1.72 (6 H, m, H-5,6,7), 1.52 (9 H, s, H-10), 2.59 (3 H, s, 
H-1), 3.18-3.29 (2 H, m, H-8), 4.13 (2 H, t, J = 6.6, H-4), 4.71 (1 H, s, NH), 7.46 (2 H, d, J = 




Compound 203:  4,4’-dihydroxy-2,2’-bipyridine  
 
Compound 3 was synthesised as per the method developed by Sam Adams7. 
A solution of 4,4’-dimethoxy-2,2’-bipyridine (2.48g, 12 mmol) in hydrobromic acid (48 % 
w/v, 20 mL, 180mmol) and glacial acetic acid (150 mL) was heated under reflux for 6 hours. 
The mixture was cooled and the solvent was removed under vacuum, affording a white/cream 
solid which was dissolved in H2O (125 mL) and neutralised with aqueous ammonia solution 
(31% by weight, dropwise). The resulting precipitate was filtered and washed with H2O (50 
mL) and ice cold acetone (2 x 10 mL) before being dried at 60 °C for 1 hour to give the product 
as a white solid (1.65g, 73%). Characterisation agrees with that of the literature. m/z (ES); 
[M+H]+ 189.  
 
Compound 204:  4,4’-di-(N-(Boc)-5-amino-1-pentoxy)-2,2’-bipyridine 
 
Compound 4 was synthesised as per the method developed by Sam Adams7. 
Potassium carbonate (2.22 g, 15.8 mmol) was suspended in a solution of N-(Boc)-5-amino-1-
tosylpentane (6.67 g, 15.7 mmol), 4,4’-dihydroxy-2,2’-bipyridine  (0.94 g, 4.9 mmol) and 18-
crown-6 (catalytic) in acetone (208 mL). The mixture was heated to 60 °C and stirred for 36 
hours. The reaction mixture was hot filtered to give a yellow filtrate, which afforded a 
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precipitate as it cooled to room temperature. The precipitate was filtered and washed with ice 
cold acetone (20 mL). The filtrate was concentrated under vacuum (~30 mL), affording a 
precipitate which was filtered at 0-5 °C and washed with ice cold acetone (20 mL). The two 
crops were combined to give a pale yellow solid (0.91g, 35%). Characterisation agrees with 
that of the literature. δH(300 MHz; CDCl3; 1.43 (18 H, s, H-1), 1.48-1.61 (8 H, m, H-4,5), 
1.87 (4 H, qu, J = 6.9, H-6), 3.14 (4 H, m, H-3), 4.13 (4 H, t, J = 6.5, H-7), 4.59 (2 H, s, NH), 
6.80 (2 H, dd, J = 2.6, 5.5, H-10),  7.91 (2 H, d, J = 2.7, H-8) and 8.45 (2 H, d, J = 5.6, H-9) 
m/z (ES); [M+H]+ 559, [M+Na]+ 581.  
 
Compound 205:  4,4’-di-(5-amino-1-pentoxy)-2,2’-bipyridine 
 
Compound 5 was synthesised as per the method developed by Sam Adams7. 
A solution of 4,4’-di-(N-(Boc)-5-amino-1-pentoxy)-2,2’-bipyridine (0.97 g, 1.7 mmol) in 
trifluoroacetic acid (14.9 mL) was stirred under N2 for 1 hour, affording a white 
microsuspension. The solvent from the suspension was removed under vacuum, before 
separation (approximately NaOH (1M) to neutralise the pH/ 50 mL chloroform). The aqueous 
layer was extracted with chloroform (8 x 30 mL), and the combined organic extracts were dried 
(Na2SO4) and filtered. The solvent was then removed under vacuum to give a white solid 
(0.34g, 84%). Characterisation agrees with that of the literature. δH (300 MHz; CDCl3); 1.19 
(4 H, s, NH2), 1.49-1.59 (8 H, m, H-4,3), 1.79-1.92 (4 H, m, H-5), 2.69-2.78 (4 H, m, H-2), 
4.13 (4 H, t, J = 6.6, H-6), 6.81 (2 H, dd, J = 5.9, 2.5, H-8), 7.92 (2 H, d, J = 2.7, H-7) and 




Compound 206 (BpySS): 4,4’-di-(5-lipoamido-1-pentoxy)-2,2’-bipyridine
 
Compound 6 was synthesised as per the method developed by Sam Adams7. 
A solution of α-lipoic acid (0.48 g, 2.3 mmol) and 1-hydroxybenzotriazole hydrate (0.36 g, 2.7 
mmol) in anhydrous DMF (8.8 mL) was cooled to 0-5 °C, upon which 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (0.41 g, 2.6 mmol) was added and stirred, 
maintaining this temperature until the EDC had dissolved (ca. 1 hour). The solution was 
allowed to warm to room temperature and stirred for a further hour. A solution of N-
ethylmorpholine (N-EM) (0.27 g, 2.4 mmol), and 4,4’-di-(5-amino-1-pentoxy)-2,2’-bipyridine 
(0.35 g, 0.98 mmol) in anhydrous DMF (12.3 mL) was added to the reaction mixture and the 
resulting cream precipitate was stirred overnight, filtered and dried in air to give a cream 
powder. The crude product was slurried in CHCl3 (50 mL) and filtered again, before washing 
with CHCl3 (2 x 10 mL) to give a pale yellow powder bpySS (0.35g, 33%). Characterisation 
agrees with that of the literature. δH (300 MHz; CDCl3) 1.31-1.56 (12 H, m, H-5,6,7), 1.56-
1.68 (8 H, m, H-11,12), 1.74-1.89 (6 H, m, H-13,15’), 2.11 (4 H, t, J = 7.3, H-10), 2.38 (2 H, 
m, H-15), 2.99-3.15 (4 H, m, H-16), 3.22 (2 H, q, J = 6.5, H-14), 3.45-3.54 (4 H, m, H-8), 4.06 
(4 H, t, J = 6.3, H-4), 5.48 (2 H, s, NH), 6.75 (2 H, dd, J = 5.7, 2.6, H-3), 7.87 (2 H, d, J = 2.6, 




Compound 207:  cis-Ru(Bpy)2(Cl)2 
 
cis-Ru(Bpy)2(Cl)2 was prepared as per the synthetic procedure developed by Sullivan, 
Salmon and Meyer8. 
RuCl3.3H20 (0.7852g, 3mmol), bipyridine (0.9371g, 6mmol), and LiCl (0.84g, 0.2 mmol) were 
heated at reflux in dimethylformamide (10 mL) for 8 h with stirring. After the reaction mixture 
was cooled to room temperature, 250 mL of reagent grade acetone was added and the resulting 
solution cooled at 0°C overnight. Filtering yielded a red to red-violet solution and a dark green-
black microcrystalline product. The solid was washed three times with 25mL portions of water 
followed by three 25mL portions of diethyl ether and then it was dried by suction filtration, 
yielding the final product (40%). Characterisation agrees with that of the literature. δH (300 
MHz; CDCl3); 7.11 (1H, m, H-1), 7.52 (1H, m, H-2), 7.69 (1H, m, H-3), 7.78 (1H, m, H-6), 
8.08 (1H, m, 5-H), 8.49 (1H, m, 4-H), 8.66 (1H, m, 7-H), 9.94 (1H, m, 8-H). m/z (ES); [M+H]+ 
481 (one chloride ligand exchanged with a Cl ligand) [M+Na]+ 503. 
 




A solution of bpySS (0.12 g, 0.16 mmol) and Ru(bpy)2Cl2 (0.08 g, 0.16 mmol) in ethanol (80 
mL) was heated under reflux (95°C) for 16 h. The red/orange solution was cooled to room 
temperature and concentrated under vacuum (∼25 mL). H2O (35 mL) was added, forming a 
fine cream precipitate, which was filtered. A saturated methanolic solution of ammonium 
hexafluorophosphate (0.25 g, 1.5 mmol in 2 mL of MeOH) was added to the filtrate to give an 
orange precipitate. The precipitate was filtered and washed with ice cold H2O and ice cold 
Et2O to give the crude product as an orange/red solid. The solid was dissolved in a minimal 
amount of acetonitrile and the solvent removed under vacuum to give a red crystalline solid 
RubpySS (0.1866 g, 80%). Characterisation agrees with that of the literature. δH (300 MHz; 
CDCl3); 1.32−1.75 (16 H, m, H-5,6,12,13), 1.75−1.81(4 H, m, H-11), 1.84−1.94 (6 H, m, H-
7,H-15’), 2.14 (4 H, t, J= 7.0,H-10), 2.39−2.50 (2 H, m, H-15), 3.04−3.12 (4 H, m, H-16), 
3.12−3.22 (4 H, m, H-8), 3.52−3.61 (2 H, tdd, J=2.8, 6.5, 6.6, H-14), 4.19 (4 H, t, J= 6.7, H-4), 
6.39 (2 H, m, NH), 6.91 (2 H, m, H-3), 7.39 (2 H, m, H-1), 7.42 (4 H, m, H-b,g), 7.70 (2 H, m, 
H-a/h), 7.82 (2 H, m, H-a/h), 8.00−8.09 (4 H, m, H-c,f), 8.08 (2H, m, H-2), and 8.48−8.52 (4 
H, m, H-d,e). m/z (ES); [M-2(PF6)]
+2 574.  
 




cis-[IrBpy2Cl]2 was prepared as per the synthetic procedure developed by Choe et al.
9 & 10 and 
as provided by Siobhan King of the Pikramenou group. Iridium trichloride hydrate (0.35g, 
1mmol) was combined with 2-phenylpyridine (0.8g, 5mmol) and dissolved in  a  mixture  of 
ethanol (30 mL) and deionised water (10 mL), and refluxed overnight (~24 hours).  The 
solution was allowed to cool to room temperature and the yellow precipitate was subsequently 
collected via filtration. The precipitate was washed with ethanol (~60 mL) and acetone (~60 
mL) and subsequently dissolved in DCM (~60mL). Toluene (25 mL) and hexane (10 mL) were 
added to the filtrate and the resulting mixture reduced in vacuo to approximately 30 mL. The 
concentrated solution was cooled to ~4°C and the crystalline product collected [Ir(ppy)2Cl]2 
(0.479 g,  81%). Characterisation agrees with that of the literature. δH (300 MHz; CDCl3); 5.91 
(1H, d J = 7.9, H-1), 6.63 (1H, m, H-2), 6.88 (2H, m, H-3), 7.54 (1H, d, J = 78.0, H-6), 7.78 
(1H, m, H-5), 7.92 (1H, d J = 7.8, H-4), 8.23 (1H, m, H-7),  9.30 (1H, d, J = 5.9, H-8); MS 
(ESI+) m/z: 1078 (M)+. 
Compound 10:  [IrBpySS](PF6)2 
 
This method was developed by Sam Adams7 and was based on the method of Slinker et al.10  
[Ir(Bpy)2Cl]2 (66.6 mg, 0.06 mmol) and BpySS (100 mg, 0.14 mmol) were suspended in 
ethanol (6.5 mL) and heated to 150 °C for 19 hours. The solution was allowed to cool to room 
temperature, H2O (~150 mL) was added, and the mixture re-heated to 60-70 °C. Saturated 
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aqueous ammonium hexafluorophosphate (1 g in 2.5 mL H2O) was added and the solution 
cooled to ~4°C, forming a yellow precipitate. The precipitate was filtered and washed with 
H2O, before being re-suspended in minimal acetone and the solvent removed in vacuo to give 
IrBpySS (117.4 mg, 69%). Characterisation agrees with that of the literature. δH (300 MHz; 
d6-acetone) 1.15-1.66 (20 H, m, H-5,6,7,11,13), 1.60-1.83 (6 H, m, H-12,15’), 2.05 (4 H, t, J 
= 7.3, H-10), 2.20-2.41 (2 H, m, H-15), 2.86-3.10 (8 H, m, H-8,16), 3.30-3.57 (2 H, m, H-10), 
4.23 (4 H, t, J = 6.7, H-4), 6.29 (2 H, dd, J = 1.1, 7.9, H-h), 6.84 (2 H, td, J = 1.4, 7.3, H-g), 
6.94 (2 H, td, J = 1.3, 7.4, H-f), 6.94 (2 H, s, NH), 7.09-7.15 (4 H, m, H-3,c), 7.65 (2 H, d, J = 
6.6, H-1), 7.70-7.88 (4 H, m, H-d,e), 7.92 (2 H, dd, J = 1.4, 7.7, H-b), 8.17 (2 H, d, J = 8.5, H-
a) and 8.25 (2 H, m, H-2); m/z (ES+) 1235 ([M-PF6]+).  
 
Compound 11:  RuPhenCl2 
 
This method was developed by Shani Osborne and was based on the method of Gunlaugsson 
et al.12  
Ruthenium trichloride (0.8g, 3mmol), 1,10 phenanthroline (1.1g, 6mmol) and lithium chloride 
(0.8g, 20mmol) were dissolved in 5 mL DMF and refluxed under N2 for 6 hours. Acetone (20 
mL) was added and the solution cooled to ~4°C overnight. The suspension was filtered and the 
precipitate washed with water (~100 mL) and diethyl ether (~50 mL) to produce a black 
compound (0.64g, 1.2 mmol, 40%). δH (300 MHz; DMSO): 7.30-7.40 (4H, m, H-2,7); 7.79 
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(2H, d, 5.4, H-4); 7.85 (2H, d, 8.3, H-5); 8.3 (4H, m, H-3,6); 10.10 (4H, m, H-1,8). m/z (TOF 
MS ES+) 497.0 ([M-Cl]+). 
Compound 12:  RuPhenSS 
 
This method was originally developed by Shani Osborne based on the method of Gunlaugsson 
et al.12 The method herein represents a minor modification in the purification step.  
RuPhen2Cl2 (50mg, 0.09mmol) and 4,4-dimethyllipoamide 2,2-bipyridine (100 mg, 0.14 
mmol) were suspended in ethanol (40mL) and refluxed overnight (~12 hours). The solvent was 
removed under vacuum and the resulting red solid was dissolved in minimal water (~8mL), 
cooled to ~4°C and the subsequent precipitate filtered. A saturated methanolic solution of 
ammonium hexafluorophosphate (0.25 g, 1.5 mmol in 2 mL of MeOH) was added to the filtrate 
to give a red precipitate. The precipitate was filtered and washed with ice cold H2O and ice 
cold Et2O to give the crude product as a red solid. The solid was dissolved in a minimal amount 
of acetonitrile and the solvent removed under vacuum to give a red solid RuPhenSS (43 mg, 
0.034 mmol, 38%). Characterisation agrees with that of the literature. δH (300 MHz; MeOD): 
1.27 (4H, m, H4); 1.45 (16H, m, H5,6,12,13); 1.78 (10H, m, H-7,11,15’); 2.09 (4H, m, H-10); 
2.30 (2H, m, H-15); 2.94 (4H, m, H-16); 3.17 (4H, m, H-8); 3.19 (2H, m, H-14); 4.14 (4H, dt, 
6.4, 1.3, H-4); 6.57 (2 H, m, NH), 6.94 (2H, m, H-3); 7.45 (2H, m, H-1); 7.56-7.84 (4H, m, H-
b,g); 7.88 (2H, m, H-d); 8.25 (6H, m, H-2,e); 8.35 (2H, m, H-c); 8.57 (2H, m, H-f); 8.75 (4H, 
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Chapter 3 - Cellular Uptake Studies 
3.1. Principle Uptake 
Following the loading studies of ruthenium probes (RuBpySS and RuPhenSS) onto GNP-
Fol and GNP-Cit nanoparticular systems (see Section 2.2.2), cellular uptake was investigated 
using confocal microscopy, TEM and Flow Cytometry (Fluorescence-Activated Cell Sorting 
(FACS)). Cellular uptake of GNP-Cit is well established in the literature and has also been 
investigated thoroughly by the Pikramenou group, the latter research utilising the Ruthenium 
based probes of the present research, as well as Iridium based alternatives1. By contrast 
however, and as previously discussed (see introduction section 1.2), the cellular localisation of 
folate coated gold nanoparticles is relatively unexplored within the literature. Accordingly, 
initial cellular uptake studies of the present research sought to establish the feasibility of 
cellular uptake for the ruthenium loaded GNP-Fol system. The system was investigated 
utilising folate receptor positive cell lines (HeLa and A549) and folate receptor negative cell 
lines (MSC), seeking to establish any relationship between degree of uptake and presence of 
folate receptors.  
 
Cellular studies were conducted with GNP-Fol that was freshly synthesised and dialysed no 
more than one week prior to the experiments employed, with the nanoparticles being sonicated 
for 30 minutes before being loaded with RuPhenSS. Cells were seeded at a density of 0.8x106 
cells per MatTek culture dish (as per the advised cellular confluency for a 35cm2 culture well2), 
cultured at standard incubation conditions for 24 hours to allow the cells to adhere, before 
dosing each MatTek dish with GNP-Fol-RuPhenSS (1mL of ~1nM GNP-Fol, loaded with 
12µL of 1mM RuPhenSS) and incubating for 24 hours. The cells were then washed three times 
with PBS before being re-suspended in live cell imaging solution and analysed immediately 












Figure 301: Confocal images collected for cellular dosing with GNP-Fol (900uL of ~1nM 
GNP) loaded with RuPhenSS (12uL of 1mM solution) suspended in 2mL of media for 24hours. 
Culture dishes were washed three times with PBS, immersed in 2mL of imaging media and 
immediately imaged under live cell chamber conditions. a) – c) represent MSCs at 100x 
magnification, where a) is brightfield, b) is the RuPhenSS fluorescence signal (λex 488nm, λem 
580-680nm) collected from a z stack profile and averaged, c) is an overlay of a) and b) with 
the corresponding z stack profile rotated 90° anti-clockwise, aligned side on to represent probe 
penetration through the sample. No auto-fluorescence was observed under the 




Figure 302: Confocal images collected for cellular dosing with GNP-Fol (900uL of ~1nM 
GNP) loaded with RuPhenSS (12µL of 1mM solution) suspended in 2mL of media for 24 
hours. Culture dishes were washed three times with PBS, immersed in 2mL of imaging media 
and immediately imaged under live cell chamber conditions. d) – f) represent HeLa cells at 60x 
magnification, where d) is brightfield, e) is the RuPhenSS fluorescence signal (λex 488nm, λem 
580-680nm) collected from a z stack profile and averaged, f) is an overlay of d) and e) with the 
corresponding z stack profile rotated 90° anti-clockwise, aligned side on to represent probe 
penetration through the sample. No auto-fluorescence was observed under the 




Figure 303: Confocal images collected for cellular dosing with GNP-Fol (900uL of ~1nM 
GNP) loaded with RuPhenSS (12µL of 1mM solution) suspended in 2mL of media for 24 
hours. Culture dishes were washed three times with PBS, immersed in 2mL of imaging media 
and immediately imaged under live cell chamber conditions. g) – i) represent A549 cells at 60x 
magnification, where g) is brightfield, h) is the RuPhenSS fluorescence (λex 488nm, λem 580-
680nm) signal collected from a z stack profile and averaged, i) is an overlay of g) and h) with 
the corresponding z stack profile rotated 90° anti-clockwise, aligned side on to represent probe 
penetration through the sample. No auto-fluorescence was observed under the 
excitation/collection conditions utilised.  
89 
 
The images of Figures 301-303 demonstrate that folate capped GNPs loaded with RuPhenSS 
are able to penetrate into and throughout cells that are both folate receptor positive (HeLa and 
A549s, Figures 302 and 303 respectively) and negative (MSCs, Figure 301) within a 24 hour 
window at the concentrations and conditions employed (see experiment section 3.8.1 for full 
details). It is noteworthy that there is no visible probe signal emitted from the nucleus of the 
cells, which may be indirect evidence that the probes are still bound to the surface of the 
nanoparticles: one would assume that within a 24 hour window there would be some degree of 
diffusion of the free probe into the nucleus. The nanoparticles are likely to be too large to pass 
through the nuclear pores and therefore present no measurable signal. Samples were also 
incubated with the same concentration of imaging probe alone (6uL 1mM RuPhenSS) as a 
control to investigate whether there would be measurable fluorescence (and therefore uptake) 
of the probes if they were not bound to the nanoparticles. These samples showed no 
fluorescence signal at the same microscope settings, which might be indicative that the free 
complex does not accumulate in sufficient concentrations to be visible, or indeed that the free 
complex may not be taken up by the cells. The laser power was increased in an attempt to 
capture very weak signals; however, instrumental noise was prolific and weak auto-
fluorescence was observed in the control. Thus, no measurable probe signal was achieved 
without nanoparticular loading / uptake within the cellular systems. 
 
3.2. Dose-Time Optimisation 
Following on from these 24 hour uptake studies the minimum treatment time required 
to record a sufficiently visible signal from GNP-FOL-RuPhenSS was investigated. This is 
important given that both the nanoparticular systems being investigated (folate or citrate 
capped) have been proven to show significant uptake within folate receptor positive and 
negative cell lines within a 24 hour dose period. Therefore, in order to prove selectivity, or at 
90 
 
least preferential or rapid uptake of folate capped nanoparticles over citrate, in a folate receptor 
positive cell line, the treatment times must be sufficient to allow for measurable uptake, whilst 
being short enough to limit passive uptake of nanoparticles. Non folate receptor mediated 
uptake (be it passive diffusion or any other viable uptake methodology) would essentially 
nullify or at least reduce the clarity and perceived impact of the efficacy of the folate receptor 
mediated pathway and hence must be limited as much as possible.  
 
Initial uptake studies ascertained that measurable uptake was achieved after as little as 4 hours, 
however, it was also found that comparable levels of uptake of the citrate capped nanoparticular 
system were evident even in the folate receptor positive cell lines. It was hypothesised that the 
levels of folate receptor expressed by the cell lines employed as well as their metabolic rates 
would most likely vary quite significantly from one another. As such, it is desirable to conduct 
all competitive uptake studies within one cell line and to ideally modulate that cell lines ability 
to express the folate receptors. The ideal scenario therefore would be a cell line that inherently 
expresses high levels of folate receptor which is capable of being manipulated in a manner that 
the genes coding for folate receptor generation are knocked down. This would therefore 
generate two sub-types of the cell line that are otherwise identical except for the presence or 
lack thereof of folate receptors.  
 
While gene knockdown studies are commonplace in the literature for various cell lines3, 4, to 
the best of our knowledge, there has not been any published work on the knockdown of all 
three folate receptor genes (FOLR1 (α), FOLR2 (β), FOLR3 (γ)). Whilst it is possible to 
purchase CRISPR (Clustered Regularly Interspaced Short Palendromic Repeats) products 
which may allow for the eventual knockdown of folate expressing genes, this approach would 
be time consuming to establish. An alternative therefore, was to adopt the methodology of 
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Mornet et al and manipulate the levels of folate receptor α in a given cell line5. This research 
showed that by culturing different folate receptor positive cell lines in high and low folic acid 
containing culture medias, it is possible to lower and raise (respectively) the levels of folate 
receptor α expression. Examples of this manipulation can be seen in Figure 304 below, taken 
from Mornet’s study. 
 
Figure 304: Image and figure description were accessed and utilised on 19/02/2017 from 
Mornet et al’s paper in the International Journal of Molecular Sciences5.  
FR-α receptor expression on the membrane surface of HeLa, A549 and 16HBE14o(-) cells 
after indirect immunocytochemistry staining, showing the impact of folate content within the 





Folate receptors α and β are believed to be responsible for the vast majority of folic acid based 
compound uptake, whereas γ is primarily an efflux protein (see introduction section 1.1.1). It 
is believed that β receptor levels are typically significantly fewer than those of α receptors. 
Accordingly, it was hypothesised that manipulating the levels of α receptor expression within 
a given cell line would have a significant impact on folic acid based compound uptake, perhaps 
even to a comparable level associated with complete folate receptor gene knockdown.  
 
Building upon the research conducted by Mornet et al, three cell lines were explored, HeLa, 
A549 and A2780s, employing the high and low folate media manipulation technique of the 
literature5. This research looked to ascertain whether any of these cell lines would show a 
significant shift in folate receptor α expression. Moreover, establishment of whether these cell 
lines might exhibit lesser levels of β and γ receptors, or indeed, no expression at all was 
favourable. In this regard, it was hoped that a cell line would be discovered that would exhibit 
high levels of folate receptor α, whilst exhibiting minimal or no expression of folate receptors 
β and γ, so that manipulation of folate receptor α levels would theoretically yield a folate 
receptor negative variant of an otherwise folate receptor positive cell line, without the need for 
gene knockout experiments.  
 
3.3. Polymerase Chain Reaction (PCR) Studies 
To investigate the extent of folate receptor expression within these cell lines, PCR 
experiments were employed. The principle of PCR is that it allows for the amplification (and 
for qPCR, quantification) of levels of specific gene expression within a given cell culture. 
Therefore, by investigating the expression of the genes which code for folate receptors α, β and 
γ via PCR, it is possible to establish which receptors are present, and, the potential extent of 
their expression6. PCR itself is the final stage of a number of precursor experiments, the first 
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of which is the purification and isolation of RNA from a cultured cell line using an RNA 
isolation kit (see Experimental section 3.8.2 for further details). Subsequently, the isolated 
RNA is converted to complementary DNA (cDNA) via the use of a cDNA synthesis kit, which 
utilises various solutions which include oligomers, dNTPs (Nuclear Triphosphates), buffers, 
an RNAse inhibitor and a reverse transcriptase enzyme. Finally, PCR is conducted, utilising 
the cDNA, gene specific primers (forward and reverse), buffers, dNTPs, and a Taq Polymerase 
solution (DNA polymerase enzyme). In short, the PCR stage allows for significant replication 
of specific genes by repeated cycles of separation of cDNA strands and pairing with 
complementary primers. Flow diagrams are depicted in Figures 305 and 306 to represent a 
broad overview of each of these processes. 
 
  
Figure 305: a) Diagrammatical representation of the various steps associated with the 
employment of a typical RNA isolation kit. Cells are lysed and homogenised (1) before being 
loaded onto the spin column (2 + 3). The column is then washed with various solutions (4) 




website on the 22/02/2017 at 12:307. b) Depiction of the steps associated with cDNA synthesis, 
showing the annealing of the Oligo dT18 (primer) followed by the reverse transcription to 
produce the cDNA. In this example the cDNA is dissociated from the RNA via raising the pH 
with an alkali solution as opposed to raising the temperature to merely terminate the 
transcription. Diagram sourced from DevBio website on the 22/02/2017 at 15:308.  
 
Figure 306: Representation of the sequence of events associated to PCR, depicting the 
separation of DNA (denaturation, 1), the binding of gene specific primers (annealing, 2), the 
construction of complementary DNA strands (elongation, 3) and finally, the repetition of 
termination and denaturation for X cycles until appropriate gene amplification is achieved. 
Diagram sourced from WikiMedia website on 14/03/2017 at 11:009. 
 
Whilst the cell lines used for the initial loading studies were assumed to be folate receptor 
positive or negative based on the literature, these cell lines could have changed quite 
significantly from their originating parent cell line. Therefore, these cells may not exhibit the 
same genetic traits of the respective parent cell lines10. Accordingly, PCR was employed to 
crudely indicate the levels of gene expression for folate receptors α, β and γ in A549, HeLa and 
A2780 cancer cell lines. Forward and reverse sequence primers were ordered freshly and as 
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per the specification of Matsushita et al, whilst the PCR protocol was adapted from that of Shen 
et al (protocol and primer selection are discussed in experimental section 3.8.2)11, 12.  
 
Whilst PCR studies were conducted for these various cell lines, a number of issues arose, with 
blurring of PCR product bands within the gels and in some instances, no measurable PCR gene 
amplification products at all (including the control band for β Actin, a gene which is 
omnipresent). From the experiments conducted, A549s showed the most promising response 
to PCR and the clearest representation via agarose gel electrophoresis. Therefore, whilst the 
literature indicated A549s are folate receptor positive for all sub-categories, it was important 
to explicitly ascertain expression within the A549 cell culture utilised in the present research. 
Moreover, whilst Mornet et al indicated that A549s were susceptible to folate receptor α 
manipulation, the present research looked to establish the level of gene expression 
manipulation that might be achievable. Accordingly, PCR was employed to crudely indicate 
the levels of gene expression for folate receptors α, β and γ in the A549 cell line cultured in 
high folate media as well as low folate media. Agarose gel electrophoresis images of said PCR 





Figure 307: Agarose gel image of PCR products for A549 cells cultured in high and low folic 
acid containing medium (DMEM and RPMI respectively). Cells were cultured in T25 flasks 
for 4 weeks and were split every 3-4 days at around 90% confluency. RNA isolation, cDNA 
synthesis and PCR were conducted as per section 3.8.2. Red circles indicate the apparent 
suppression of the folate receptor alpha gene in the low folate cultured A549s (RPMI media) 
vs the high folate cultured A549s (DMEM).  
 
As aforementioned, the principle of this technique resides in the amplification of the gene / 
genes of interest via the PCR. More specifically, due to a lack of sensitivity, only the genes that 
are amplified are typically observed as a strong band within the agarose gel. Figure 307 shows 
a total of 6 channels, three per A549 cell culture (DMEM vs RPMI), with successive channels 
representing attempted amplification of folate receptors α, β or γ respectively.  
 
With regards to the α channel (lane 1 – DMEM cultured A549s and lane 4 – RPMI cultured 
A549s), there is clear presence of a band centred at 787bp for the DMEM culture (lane 1), 
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whilst there is no observable band at 787bp for the RPMI culture (lane 4). It is therefore evident 
from Figure 308, in contrast to the works of the literature (Mornet et al), the high folic acid 
media cultured A549s displayed a high level of folate receptor α gene expression, whilst the 
low folic acid media cultured A549s displayed an effective folate receptor α gene suppression5. 
That is to say, the present research contradicts the literature, which displayed that culturing 
A549s in low folate medium significantly increased surface folate receptor expression.  
 
It is noteworthy however, that in line with the literature, no folate receptor β gene expression, 
nor amplification, was observable regardless of the media manipulation of the A549 cultures. 
Moreover, there is a measurable presence of folate receptor γ in both samples (332bp), with 
arguably a slightly stronger band represented in the high folate cultured A549s than that of the 
low folate cultured cells (lanes 3 and 6 respectively). To the best of our knowledge, this has 
not been discussed within the literature to any great extent. However, the persistent expression 
of folate receptor γ, regardless of α and β expression, is perhaps to be expected, on account of 
its primary function as a folate efflux protein. That being said, whilst a slight decrease is 
observed in the expression of γ protein for the low folate cultured A549s, on account of the 
apparent lack thereof of any folate receptor uptake proteins, one might expect that the efflux 
protein gene should also be equally suppressed. The effective maintenance of the efflux protein 
γ may therefore indicate that whilst the cells have effectively turned off the expression of α and 
β genes (in the zero folate culture), the cells may still comprise the corresponding receptor 
proteins on their surface and therefore, maintain a need for said efflux protein expression. 
Moreover, it is established within the literature that folate uptake is not exclusive to the active 
uptake via the aforementioned receptors, therefore, the cells may still take up folate via passive 
mechanisms, potentially further maintaining the need for folate efflux proteins.  
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The experiment was repeated in triplicate, with all agarose gels displaying the same down 
regulation of α in low folate media, zero expression of β in both and a maintained expression 
of γ in both. It is noteworthy that these experiments were conducted using two different types 
of media as opposed to using zero folate RPMI & a supplemented RPMI. Accordingly, the 
expressions observed cannot be directly compared. Later efforts for cellular utilisation used 
such zero and supplemented media and is discussed in greater depth later. Accordingly, to 
verify the PCR results, a commercial antibody system was used to visualise folate receptor 
alpha in the A549s that were cultured in the two different media via immunocytochemistry, in 
both confocal microscopy and FACS.  
 
3.4. Immunocytochemistry Studies 
Immunocytochemistry is the process of staining for a specific protein or antigen of 
interest via the employment of antibodies. The folate receptor primary antibody employed in 
the present research was raised in rabbits, was polyclonal, and displayed activity in human cell 
lines for folate receptor α (see experimental section 3.8.3). The secondary antibody of the 
present research was appropriately paired with the primary and comprised an Alexa Fluor dye, 
emissive within the green channel. Immunocytochemistry can be carried out on live or fixed 
cells dependent on the localisation of the target protein. In the present study, folate receptor α 
is a surface localised protein and therefore live cell studies were conducted as the antibody is 
not required to penetrate the cell. In the case of an internal target, live cell studies are not 
possible as the cells need to be permeabilised in order for the antibodies to reach their intended 
target. 
 
Live cell immunocytochemistry gives the added advantage that the cells do not require a 
permeabilisation stage in order for the utilised antibody to reach its intended target. 
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Subsequently, this live cell technique obviates substantial chemical alteration of the cells 
permeability and thus represents a more biologically unaltered experiment. A Hodges group 
routine protocol was implemented, with adjustments being made to incubation times and 
antibody concentrations in line with manufacturer instructions (see experimental section 3.8.3).  
 
In brief, A549s from low and high folate cultures were seeded into separate MatTek dishes and 
allowed to adhere overnight (typically 12 hours). The cells were then washed with PBS and 
incubated with primary antibody (Folate Receptor Alpha Polyclonal Antibody, 2µg/mL in 2mL 
media (DMEM or RPMI dependent on which culture the cells were from)) for 45 minutes. 
Cells were then washed three times with PBS and incubated with secondary antibody (Goat 
anti-rabbit Secondary Antibody, Alexa Fluor 488, 2µg/mL in 2mL media) for 30 minutes. The 
cells were then washed three times with PBS and immersed in 1mL imaging media before 
being imaged via live confocal microscopy within a pseudo incubation chamber. Images 





Figure 308: Blank A549s taken from supplemented folate RPMI media culture. Cells were 
seeded overnight onto MatTek dishes and subsequently treated with folate receptor alpha 
polyclonal antibody (2µg/mL in 2mL supplemented RPMI) for 45 minutes. Cultures were 
washed, immersed in imaging media and immediately transferred to a live cell imaging 
chamber for confocal microscopy studies. A) in focus brightfield plane of the collected z stack 
profile, B) averaged fluorescence signal over the z stack and C) overlay of the average antibody 
fluorescence signal over the respective in focus brightfield image. High folate cultured A549s 
show a relatively low emission intensity and distribution in comparison to the low folate 







Figure 309: Blank A549s taken from zero folate RPMI media culture. Cells were seeded 
overnight onto MatTek dishes and subsequently treated with folate receptor alpha polyclonal 
antibody (2µg/mL in 2mL supplemented RPMI) for 45 minutes. Cultures were washed, 
immersed in imaging media and immediately transferred to a live cell imaging chamber for 
confocal microscopy studies. D) in focus brightfield plane of the collected z stack profile, E) 
averaged fluorescence signal over the z stack and F) overlay of the average antibody 
fluorescence signal over the respective in focus brightfield image. Low folate cultured A549s 
show a relatively high emission intensity and distribution in comparison to the high folate 






The confocal images of Figures 308 and 309 evidence that, in line with the literature, when 
A549s are cultured in low folate media there is a marked increase in the expression of folate 
receptor α on the surface of the cells. That is to say, upon review of the compressed z stack 
fluorescence images b) and e) of Figures 308 and 309 respectively, it is evident that there is 
significantly more measurable fluorescence in the low folate media cultured A549’s (e) than in 
the high folate media cultured A549’s (b). As aforementioned, immunocytochemistry is 
receptor dependent cellular staining. Therefore, greater emission is indicative of greater 
primary and secondary antibody binding, which is in turn indicative of greater surface protein 
expression. It is noteworthy that some degree of internalisation of the fluorophore was 
recorded, most likely due to internalisation of what were originally surface receptors which 
had bound the fluorescently tagged antibody during staining, thus some strong fluorescence 
signal was observed within the cells (observable via numerous z-stack slices). This signal was 
ruled out as auto-fluorescence on account of no such signal observable within the blank 
samples (no antibody loading) under the same microscope conditions. Such internalisation is 
to be expected on account of routine cellular folate receptor internalisation and recycling 
cycles13. Further research could look to confirm this hypothesis by conducting the staining 
using a fixed cell sample and no permeabilisation.  
 
Moreover, given the substantially convex longitudinal cross section of the cell surface, each 
slice of the z stack image is representative of the signal measured at a portion of the cell. 
Therefore, whilst the overlay images of c) and f) are somewhat indicative of surface localised 
fluorescence, it does not exclusively represent the progression of fluorescence from the lowest 
point of the cell to the top, which would signify the fluorescence progressing from the periphery 
of the cell to the centre. Instead, some of the signal of internalised fluorescence is averaged 
into the final data observable in images b) and e). It would be excessive to represent each slice 
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of the corresponding z-stacks within Figures 308 and 309, however, the general progression of 
this fluorescence may be observed for the low folate cultured z stack in Appendix Section 7.1, 
so as to evidence the surface localisation over internalisation.   
 
Summary of Findings 
It is therefore evident from the above, and in agreement with the literature, that low folate 
cultured A549s do indeed exhibit upregulated surface expression of folate receptor α. This 
would therefore appear to contradict the earlier PCR data, which showed that culturing A549s 
in low folate media significantly reduced expression of the folate receptor α gene, which would 
subsequently imply a reduction in folate receptor α protein expression.  
 
The significant difference between the antibody signal observed in the confocal z stack data 
for the high and low folate cultured A549s served as sufficient evidence of an imposed 
modulation of folate receptor α expression, and therefore, high and low folate cultured A549s 
were carried forward for future cellular experimentations. All future high and low folate 
manipulations were conducted using zero folate RPMI and a supplemented high folate RPMI 
(using a separate flask of zero folate RPMI with the addition of 20mg folic acid). Through 
supplementation of RPMI with folic acid it is ensured that the only difference in media 
formulation is that of the folate content, thus, any imparted differences in the A549 cultures 








3.5. Comparative Uptake Studies 
Proof of Concept 
Subsequent research sought to ascertain whether the presence of folate moieties on the 
surface of GNP-Fol does indeed lead to enhanced nanoparticular cellular uptake when 
compared to the citrate coated surface of GNP-Cit. Accordingly, initial research comprised 
confocal microscopy, qualitatively assessing ruthenium probe fluorescence in high and low 
folate media cultured A549s dosed with RuPhenSS loaded GNP-Fol and GNP-Cit separately. 
The results of these studies are represented in Figures 311 to 314. The principle being that for 
the high folate receptor expressing cells, more prominent FITC and RuPhen signals should be 
observable, on account of higher antibody staining and GNP-Fol-RuPhen uptake. In contrast, 
the low folate receptor A549s should display the opposite. This hypothesis is displayed 
grammatically in Figure 310 below.  
 
Figure 310: Diagrammatic representation of high and low folate receptor expressing A549 
cells with corresponding antibody / RuPhen dosing levels. 
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As noted, comparable size of the two nanoparticular systems is important so as to theoretically 
afford systems with comparable surface loading of RuPhenSS and featuring largely similar 
physical limitations in relation to cellular uptake. Accordingly, the GNP-Fol and GNP-Cit 
nanoparticular systems were made to be within ±5nm of each other, with the typical size of 
GNP-Fol being ~15nm and GNP-Cit ~13nm, so as to give theoretically equivalent surface 
loading potential and geometric uptake limitations. The cell samples were loaded with identical 
concentrations and volumes of GNP-Fol-RuPhenSS or GNP-Cit-RuPhenSS (10µL of 1mM 
solution per 1mL of ~1nM GNP), with identical dosing times (3 hours) and cell seeding 
densities (800,000) employed (see Experimental section 3.8.4).  
 
Sephadex filtration is the means typically employed within the literature for removal of non-
nanoparticular bound molecules within GNP-Cit solutions. However, sephadex purification 
was unsuitable for GNP-Fol as the resulting filtered system would become unstable and 
aggregate (typically within one hour). On review of the literature, no protocol was found for 
the filtration of GNP-Fol by sephadex. It is hypothesised herein that the instability of the GNP-
Fol system post sephadex filtration stems from the removal of excess folate from the system. 
Therefore, through sephadex filtration, it is hypothesised that the pH of the system is 
dramatically altered through removal of unreacted sodium folate, as well as potential removal 
of loosely associated folate moieties to the surface of the nanoparticles. As an alternative, GNP-
Fol-RuPhenSS and GNP-Cit-RuPhenSS systems were subjected to 24 hour dialysis in 
deionised water to remove the majority of unbound RuPhenSS whilst preserving an appropriate 










Figure 311: Live cell confocal microscopy images of A549s that have been cultured in high 
folate RPMI (lower folate receptor α expression) and subsequently dosed with antibodies and 
GNP-Fol-RuPhen. Cells were dosed with 1mL of ~1nM GNP-Fol loaded with 12µL RuPhen 
(1mM) for 3 hours. a) in focus plane of the brightfield z stack; b) average antibody fluorescence 
signal across the z stack; c) average RuPhen fluorescence signal across the z stack; d) overlay 
of the average antibody and RuPhen signals, e) overlay of all channels, f) and g) are orthogonal 
representations of the RuPhen fluorescence signal collected across the z stack profile for the 






Figure 312: Live cell confocal microscopy images of A549s that have been cultured in high 
folate RPMI (lower folate receptor α expression) and subsequently dosed with antibodies and 
GNP-Cit-RuPhen. Cells were dosed with 1mL of ~1nM GNP-Cit loaded with 12µL RuPhen 
(1mM) for 3 hours. a) in focus plane of the brightfield z stack; b) average antibody fluorescence 
signal across the z stack; c) average RuPhen fluorescence signal across the z stack; d) overlay 







Figure 313: Live cell confocal microscopy images of A549s that have been cultured in low 
folate RPMI (higher folate receptor α expression) and subsequently dosed with antibodies and 
GNP-Fol-RuPhen. Cells were dosed with 1mL of ~1nM GNP-Fol loaded with 12µL RuPhen 
(1mM) for 3 hours. a) in focus plane of the brightfield z stack; b) average antibody fluorescence 
signal across the z stack; c) average RuPhen fluorescence signal across the z stack; d) overlay 







Figure 314: Live cell confocal microscopy images of A549s that have been cultured in low 
folate RPMI (higher folate receptor α expression) and subsequently dosed with antibodies and 
GNP-Cit-RuPhen. Cells were dosed with 1mL of ~1nM GNP-Cit loaded with 12µL RuPhen 
(1mM) for 3 hours. a) in focus plane of the brightfield z stack; b) average antibody fluorescence 
signal across the z stack; c) average RuPhen fluorescence signal across the z stack; d) overlay 







From the above confocal studies it is evident that there is significantly greater ruthenium probe 
fluorescence intensity and signal prevalence in the high folate receptor expressing A549s dosed 
with GNP-Fol-RuPhenSS (Figure 311) by comparison to GNP-Cit-RuPhenSS (Figure 312). In 
contrast however, in the low folate receptor expressing A549s, a largely comparable level of 
fluorescence is observed for the two nanoparticular systems (Figures 313 and 314). The 
RuPhenSS signal (red) can be seen permeating throughout the cells, with varying intensities 
and localisations within individual cells. Furthermore, there are small, intense, localised spots 
or clusters of signal, which may be as a result of vesicles or endosomes carrying bulk materials. 
It is noteworthy that no signal was observed in the nucleus of the cells, which may serve as 
proof that the fluorescent probe remains attached to the surface of the nanoparticles and / or 
free fluorophore is not released from the endosomes. Some signal is observable within the 
nuclear region of the cells as an artefact stemming from surface signal which has been collapsed 
into a single plane from the z stack. To evidence this, images f) & g) of Figure 311 represent 
orthogonal signal profiles of a single cell, showing fluorescence intensity throughout a cell 
from bottom to top. Image f) represents the orthogonal profile unedited whilst image g) shows 
the same profile with the additional of manual fluorescent periphery marking. The markings in 
image h) are to help represent the convex nature of the cell and localisation of the RuPhen 
fluorescence signal across the cell.  
 
As a final note, there was a marked difference in uptake between GNP-Fol-RuPhen and GNP-
Cit-RuPhen in the high folate receptor expressing A549s and a marginal difference in uptake 
in the low folate receptor expressing A549s. This is of particular significance, given the 
continuity of all other experimental and environmental conditions, as it evidences the 
considerable impact that the surface functionalisation of the nanoparticular systems plays in 
the mediated uptake of said system.  
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3.6. Competitive Uptake Studies 
3.6.1. Combined Cell Cultures 
Moving on from comparison of uptake in isolated systems, it is important to 
fundamentally evidence that the increased cellular uptake of GNP-Fol is not just merely 
because of a more rapid uptake system or a more prevalent one. Instead, it must be evidenced 
that this is as a result of a targeted system that has a preference for the folate receptor mediated 
uptake over other pathways. In order to address this, a co-culture of the two A549 cell systems 
was established, comprising the high folate receptor expressing and low folate receptor 
expressing A549s. For tracking purposes, the low folate receptor expressing A549s had their 
nuclei stained with Hoechst and washed five (5) times prior to tripsination, mixing with a 
suspension of non-stained high folate receptor expressing A549s and seeding onto 6 well 
plates. Once this co-culture cell system had then adhered to the culture dish (~4 hours) they 
were treated with GNP-Fol-RuPhenSS and their uptake compared qualitatively by confocal 
microscopy. Dosing procedures and loading times mimicked that of the previous experiments. 





Figure 315: Live cell confocal microscopy images of a co-culture high and low receptor 
expressing A549 cultures. High folate receptor α expressing A549s had their nuclei stained and 
were washed prior to being mixed with low folate receptor α expressing A549s. After 4 hours, 
the co-culture was dosed with 1mL of ~1nM GNP-Fol loaded with 6µL RuPhen for 3 hours: 
a) in focus brightfield plane of the z stack; b) average Hoechst fluorescence across the z stack; 
c) average RuPhen fluorescence across the z stack; d) overlay b and c; and e) an overlay of all 






A number of issues were apparent from these confocal studies. Firstly, it is evident from the 
images of Figure 315, that there was a degree of Hoechst bleed through from the high folate 
receptor expressing A549s into the low folate receptor expressing A549s. More specifically, 
images b) - d) show a number of cells with a strong blue channel signal for the nuclei and a 
weak red channel signal for the RuPhen probe. However, the same images also show a number 
of cells with a weak blue channel signal for the nuclei with a strong red channel signal for the 
RuPhen probe. One possibility in this regard is that there is a mixture of high and low folate 
receptor expressing A549s within the low folate receptor cell culture, and that there was 
inconsistent nuclei staining within the preparation. Alternatively, and in line with the prior 
imaging studies, there is a consistent degree of folate receptor expression in both cultures, albeit 
at alternative extremities, and the inconsistency arises through bleed-through of Hoechst dye 
within the co-culture. This bleed-through may be as a result of insufficient washes prior to 
lysing and mixing of the two cell cultures, or perhaps, during the plating procedure, some of 
the Hoechst dyed cells die or rupture, releasing Hoechst dye which subsequently stains cells 
from the other originating culture (low folate receptor expressing). This issue prevents any 
degree of certainty in the qualitative analysis of the difference in nanoparticular uptake, and 
effectively nullifies the possibility of quantitative analysis / comparison. Accordingly, co-
culture studies were not further investigated.  
 
Subsequently, it was hypothesised that the lack of differential uptake within the cell co-culture 
may be as a result of the nanoparticles settling within the culture dish. Moreover, it was 
hypothesised that the settled nanoparticles were merely being taken up by any viable uptake 
mechanism, of any particular cell they may happen to fall within the vicinity of. It was further 
apparent that were the present nanoparticular system to be employed in any later in vivo studies, 
said system would be required to exhibit a preferential uptake whilst being constantly subjected 
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to flow. Therefore, in order to crudely model this need for selective uptake whilst being 
subjected to flow, ruthenium probe based loading studies were repeated with the samples being 
dosed and incubated on a plate rocker.  
 
3.6.2. Subjected Flow Uptake Studies 
Theoretically, incubating the cells on a plate rocker would prevent the nanoparticles 
within the media from settling onto the MatTek dish. Instead, the nanoparticles would 
hypothetically gently pass over the cell surface, thus presenting an opportunity for the folate 
moieties on the surface of the GNP-Fol system to bind to the receptors of the cells. In contrast, 
the GNP-Cit system should pass over the cell surfaces, exhibiting some uptake (be it passive 
or active), but theoretically exhibiting significantly less folate receptor mediated uptake. 
Therefore, there should be less uptake within the high folate receptor expressing A549s of 
GNP-Cit-RuPhen vs GNP-Fol-RuPhen; no apparent difference in uptake of GNP-Cit-RuPhen 
across high and low folate receptor expressing A549s; and, significant difference in uptake of 
GNP-Fol-RuPhen in going from high to low folate receptor expressing A549 cultures. Confocal 
images for said studies are represented in Figures 316 to 319 and full experimental details are 





Figure 316: Confocal microscopy images of high folate receptor α expressing A549s dosed 
for 24 hours on a plate rocker with GNP-Fol-RuPhen (1mL of ~1nM GNP-Fol loaded with 
12µL 1mM RuPhen). Folate receptors were subsequently stained with Folate Receptor Alpha 
Polyclonal Antibody (2µg/mL in 2mL media), washed three times with PBS and incubated 
with secondary antibody (Goat anti-rabbit, Alexa Fluor 488, 2.5µg/mL in 2mL media). a) in 
focus brightfield plane of z stack; b) average antibody fluorescence across z stack; c) average 







Figure 317: Confocal microscopy images of high folate receptor α expressing A549s dosed 
for 24 hours on a plate rocker with GNP-Cit-RuPhen (1mL of ~1nM GNP-Cit loaded with 
12µL 1mM RuPhen). Folate receptors were subsequently stained with Folate Receptor Alpha 
Polyclonal Antibody (2µg/mL in 2mL media), washed three times with PBS and incubated 
with secondary antibody (Goat anti-rabbit, Alexa Fluor 488, 2.5µg/mL in 2mL media). a) in 
focus brightfield plane of z stack; b) antibody fluorescence across z stack; c) RuPhen 







Figure 318: Confocal microscopy images of low folate receptor α expressing A549s dosed for 
24 hours on a plate rocker with GNP-Fol-RuPhen (1mL of ~1nM GNP-Fol loaded with 12µL 
1mM RuPhen). Folate receptors were subsequently stained with Folate Receptor Alpha 
Polyclonal Antibody (2µg/mL in 2mL media), washed three times with PBS and incubated 
with secondary antibody (Goat anti-rabbit, Alexa Fluor 488, 2.5µg/mL in 2mL media). a) in 
focus brightfield plane of z stack; b) antibody fluorescence across z stack; c) RuPhen 







Figure 319: Confocal microscopy images of low folate receptor α expressing A549s dosed for 
24 hours on a plate rocker with GNP-Cit-RuPhen (1mL of ~1nM GNP-Cit loaded with 12µL 
1mM RuPhen). Folate receptors were subsequently stained with Folate Receptor Alpha 
Polyclonal Antibody (2µg/mL in 2mL media), washed three times with PBS and incubated 
with secondary antibody (Goat anti-rabbit, Alexa Fluor 488, 2.5µg/mL in 2mL media). a) in 
focus brightfield plane of z stack; b) antibody fluorescence across z stack; c) RuPhen 






From the images of Figures 316 to 319 it is evident that there is a difference in the level of 
GNP-Fol-RuPhen and GNP-Cit-RuPhen uptake within A549 cells irrespective of the number 
of folate receptors present. Specifically, it is evident that in both the high folate receptor α 
expressing (Figure 316, 317) and low folate receptor α expressing (Figure 318, 319) A549 
cultures there was a greater level of RuPhen signal present for the GNP-Fol system (Figures 
316 and 318) vs the GNP-Cit system (Figures 317 and 319). This is in support of the theory 
that the GNP-Fol system should present a greater level of uptake than GNP-Cit in the presence 
of flow due to surface folate receptor binding.  
 
However, it is not readily discernible from the confocal data whether there is indeed any 
difference in levels of uptake of GNP-Fol-RuPhen between the high receptor (Figure 316) and 
low receptor samples (Figure 318). A number of potential conclusions could be drawn, which 
include: there is a negligible level of difference in uptake between the samples, irrespective of 
level of receptors available; there is not a significant difference in the level of receptors between 
the samples; or, there is a significant difference in receptor levels, but there are alternative 
means of uptake available to the GNP-Fol system that are not present for the GNP-Cit system. 
It is also evident that there was little observable difference between the level of uptake 
displayed across the high and low folate receptor expressing A549s for the GNP-Cit system 
(Figures 317 and 319). However, given the lack of difference in the GNP-Fol system samples, 
this result could merely be coincidental for the GNP-Cit system.  
 
In order to further polarise the different levels of folate receptors available for nanoparticular 
uptake, receptor blocking studies were conducted via utilisation of primary antibody. 
Additionally, differences in uptake were quantitatively assessed through utilisation of 
Fluorescence Activated Cell Sorting (FACS) microscopy.  
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3.7. Folate Receptor Blocking Studies 
Subsequent research focussed on the more readily comparable difference in uptake 
stemming solely from the availability of folate receptor mediated uptake (levels of receptors 
available). To achieve this, folate receptor blocking was utilised, with folate receptors actively 
blocked through dosing high folate receptor α expressing A549 cultures with the folate receptor 
α primary antibody before subsequently dosing the cells with the appropriate nanoparticular 
solutions.  
 
In brief, the high folate receptor α expressing A549s were plated onto MatTek dishes and half 
the samples had had their α folate receptors blocked via incubation with α primary antibody 
(2µg / mL in 2mL media) for 1 hour. Subsequently, samples were incubated with either GNP-
Fol-RuPhen or GNP-Cit-RuPhen on a plate rocker for 24 hours. The premise of this experiment 
being that if the majority of cellular uptake of the GNP-Fol system originates from folate 
receptor α mediated endocytosis, any blocking of the receptors should have a marked effect on 
the extent of uptake. Furthermore, the extent of the effect of blocking should be more evident 
in the high folate receptor α A549 culture by comparison to the low receptor α A549 culture 
given that there are more receptors available for blocking. Inversely, there should be little to 
no effect observed in the cellular uptake of the GNP-Cit based system as it is hypothesised that 
these nanoparticles should not be targeting the folate receptor uptake system and instead are 
being taken up via other means.   
 
Cellular uptake of the two systems (GNP-Fol-RuPhen and GNP-Cit-RuPhen) was investigated 
in the high folate receptor bearing A549s via confocal microscopy (Figures 320 to 323) and 
FACS analysis (Figures 324 to 328). See experimental section 3.8.6 for full details. The 
samples of the present confocal and FACS studies are represented in Table 301.  
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HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 
No Blocking With Receptor α Blocking 
Sample a) Blank - 
Sample b) GNP-Fol-RuPhen Sample d) GNP-Fol-RuPhen 
Sample c) GNP-Cit-RuPhen Sample e) GNP-Cit-RuPhen 
Table 301: Overview of confocal microscopy and flow cytometry samples.   
3.7.1. Confocal Microscopy Studies 
 
Figure 320: Confocal microscopy images collected for high folate receptor α expressing A549s 
that have been dosed for 24 hours on a plate rocker with GNP-Fol-RuPhen (1mL of ~1nM 






a) brightfield in focus plane of the z stack; b) average RuPhen fluorescence signal across z 
stack and c) overlay of channels.   
 
 
Figure 321: Confocal microscopy images collected for high folate receptor α expressing A549s 
that have been dosed for 24 hours on a plate rocker with GNP-Cit-RuPhen (1mL of ~1nM 
GNP-Fol loaded with 12µL 1mM RuPhen). NO RECEPTOR BLOCKING.  
a) brightfield in focus plane of the z stack; b) average RuPhen fluorescence signal across z 









Figure 322: Folate Receptors Pre-Blocked - Confocal microscopy images collected for high 
folate receptor α expressing A549s that have been pre-dosed with Folate Receptor Alpha 
Polyclonal Antibody (2µg/mL in 2mL media) for one hour before being co-dosed for 24 hours 
on a plate rocker with GNP-Fol-RuPhen (1mL of ~1nM GNP-Fol loaded with 12µL 1mM 
RuPhen). a) brightfield in focus plane of the z stack; b) average RuPhen fluorescence signal 









Figure 323: Folate Receptors Pre-Blocked - Confocal microscopy images collected for high 
folate receptor α expressing A549s that have been pre-dosed with Folate Receptor Alpha 
Polyclonal Antibody (2µg/mL in 2mL media) for one hour before being co-dosed for 24 hours 
on a plate rocker with GNP-Cit-RuPhen (1mL of ~1nM GNP-Cit loaded with 12µL 1mM 
RuPhen). a) brightfield in focus plane of the z stack; b) average RuPhen fluorescence signal 
across z stack and c) overlay of channels.   
 
Discussion 
The results indicate that upon blocking folate receptor α with primary antibody there is a 
significant decrease in RuPhen probe signal for the GNP-Fol-RuPhen samples (see Figures 320 
& 322). Through qualitative comparison of images b) and c) of Figure 320 (unblocked A549s 








to be less distribution of signal, although the signal intensity seems comparable across the 
samples. This would therefore indicate that less nanoparticles are taken up by the blocked 
system as a whole, leading to less distribution, but when the particles are in, they display a 
comparable intensity as they are evenly loaded with the RuPhen probe. This therefore 
potentially indicates that folate receptor α plays a key role in the uptake of GNP-Fol-RuPhen 
into the high folate receptor α expressing A549 cells.  
 
It also appears that folate receptor α blocking does not lead to any significant change in RuPhen 
signal intensity or distribution when A549 cells are dosed with GNP-Cit-RuPhen (Figures 321 
and 323). This is evident through qualitative comparison of images b) and c) of Figure 321 
(unblocked A549s with GNP-Cit-RuPhen) and Figure 323 (blocked A549s with GNP-Cit-
RuPhen). This would therefore indicate that there is no significant difference in the amount of 
GNP-Cit-RuPhen taken up by the high folate receptor α expressing A549 cells irrespective of 
receptor blocking, which is in turn potentially indicative of the utilisation of alternative 
receptors for the uptake of GNP-Cit into the cells.  
 
Lastly, through comparison of the GNP-Fol sample images (Figures 320 and 322) and the 
GNP-Cit sample images (Figures 321 and 323) that both the blocked and unblocked GNP-Fol-
RuPhen samples presented greater levels of RuPhen emission than the GNP-Cit-RuPhen 
samples. This is to be expected and is in alignment with the above findings, as it is evident that 
the GNP-Fol system displays a high dependency on the levels of folate receptor α for cellular 
uptake. Accordingly, in a cell line displaying high levels of folate receptor α, the GNP-Fol 





3.7.2. Flow Cytometry Studies 
 
 
Figure 324: FACS dot-plot data of forward scatter (particle size) vs side scatter (particle 
granularity) for the samples of Table 301 in high folate receptor α expressing A549 cells. a) 
Blank untreated cells, b) GNP-Fol-RuPhen, c) GNP-Fol-RuPhen + receptor blocking, d) GNP-
Cit-RuPhen and e) GNP-Cit-RuPhen + receptor blocking. The circled population represents 
gating of fragments, with the cited number representing the percentage of the population 
corresponding to healthy cells.  
 
a)     b)        c)  




Figure 325: FACS dot-plot data of forward scatter (particle size) vs Propidium Iodide channel 
signal intensity (red channel, RuPhen emission intensity) for the samples of Table 301 in high 
folate receptor α expressing A549 cells. a) Blank untreated cells, b) GNP-Fol-RuPhen, c) GNP-
Fol-RuPhen + receptor blocking, d) GNP-Cit-RuPhen and e) GNP-Cit-RuPhen + receptor 
blocking. “Blank Calibrated” represents cells with RuPhen channel fluorescence equal to or 
greater than the strongest emission of the blank sample (upper limit of auto-fluorescence). Any 





a)    b)       c) 




Figure 326: FACS Histogram data of RuPhen channel signal for the Blank calibrated sub-
population of the samples of Table 301 in high folate receptor α expressing A549 cells. a) 
Blank untreated cells, b) GNP-Fol-RuPhen, c) GNP-Fol-RuPhen + receptor blocking, d) GNP-
Cit-RuPhen and e) GNP-Cit-RuPhen + receptor blocking. The associated table provides the 






a)    b)       c) 




Figure 327: FACS Overlay histogram data of RuPhen channel signal for the  Blank calibrated 
sub-population of the samples of Table 301 in high folate receptor α expressing A549 cells. a) 
Overlay of GNP-Fol-RuPhen and GNP-Fol-RuPhen + Blocking; b) overlay of GNP-Cit-
RuPhen and GNP-Cit-RuPhen + Blocking; c) overlay of GNP-Fol-RuPhen and GNP-Cit-





a)           b)  




RUPHEN SIGNAL  
(RUPHEN LOADED CELLS SUB-CULTURE) 
SAMPLES EVENTS MEAN MEDIAN 
Blank 30 88.9 69 
GNP-Fol-RuPhen 515 359 290 
GNP-Fol-RuPhen + Block 103 346 259 
GNP-Cit-RuPhen 356 296 231 
GNP-Cit-RuPhen + Block 316 212 192 
Table 302: Statistical data from the FACS histogram plots of samples b)-e) of Table 301 and 
Figure 326, corresponding to the red channel measurements (RuPhen Signal) from the Blank 
calibrated sub culture.  
 
Discussion 
Encouragingly, the FACS data supports the findings of the confocal studies in that the use of 
folate receptor α blocking has aneffect on the uptake on GNP-Fol-RuPhen in the high folate 
receptor bearing A549s and a negligible effect on the uptake of GNP-Cit-RuPhen.  
 
In particular, it is evident that there is a considerable decrease in the number of events above 
the RuPhen signal threshold upon blocking the receptors in the GNP-Fol-RuPhen samples 
(Table 302, 80% reduction in events), with a modest reduction in fluorescence intensity (5% 
reduction in mean intensity). By comparison, there is a reasonable reduction in events for the 
GNP-Cit system (Table 302, 11% reduction in events) and a larger shift in fluorescence 
intensity (29% reduction in intensity). As per the findings of the confocal microscopy studies, 
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the GNP-Fol-RuPhen system displayed greater events and fluorescence intensity over the 
GNP-Cit-RuPhen system (31% more events and 18% greater mean fluorescence).  
 
From the above confocal and FACS microscopy studies it is hypothesised that folate receptor 
α blocking has a reasonably strong impact on the cellular uptake of GNP-Fol-RuPhen, 
especially when combined with the plate-rocker dosing protocol. Accordingly, this formed the 
primary protocol for cellular uptake comparison studies for all subsequent experiments, 
allowing for meaningful comparison of the folate receptor targeted GNP-Fol system over the 
GNP-Cit system for delivery of theranostic agents to folate receptor positive cancer cell lines.  
 
3.8. Conclusions 
The folate receptor targeting capabilities of folate capped gold nanoparticles was 
investigated in the present research. The ruthenium probe functionalised folate and citrate 
capped gold nanoparticle systems of chapter 2 were utilised in a variety of cells in order to 
observe differences in the rate and specificity of their cellular uptake in folate receptor positive 
and negative cell lines. It was not possible to draw accurate comparisons between the uptake 
of the two systems when utilising different cell lines for receptor positive and negative studies 
on account of different cellular properties. 
 
Various methods were investigated for control of the levels of folate receptors observed within 
A549 cells. These cells were chosen as they only presented with folate receptor α, and the 
levels of this expression can be modulated with use of folate deficient / supplemented medias. 
Through manipulation of the levels of receptor, combined with receptor blocking utilising a 
folate receptor α polyclonal antibody and simulating flow within the samples, significant 
differences in cellular uptake of the folate and citrate capped gold nanoparticle systems were 
133 
 
observed. In particular, it was found via confocal microscopy and flow cytometry that the folate 
capped gold nanoparticle system displayed greater uptake and emission than the citrate capped 




3.9.1. General Cell Culture 
Media Preparation 
Human carcinoma cells were routinely cultured in either Dulbecco’s Modified Eagles 
Medium (DMEM) or Gibco 1640 Roswell Park Memorial Institute (RPMI) medium, 
supplemented with 10% foetal calf serum, 100 units/mL penicillin and 0.1 mg/mL 
streptomycin, within an incubator (37°C, 95% relative humidity and 5 % CO2). Cells were 




Cells were passaged approximately twice weekly. Appropriate media, phosphate buffered 
saline (PBS) and trypsin were warmed to 37 °C in a water bath. Media was removed from the 
culture flask and the cells washed with PBS (10 mL) to remove dead cells and old media. 
Trypsin (5 mL) was added and the flak incubated at 37 °C for 5 minutes. Flasks were gently 
tapped and visualised under light microscope to confirm detachment. Fresh media (10 mL) was 
then added to prevent further cellular digestion by the trypsin and the solution pipetted oer the 
bottom of the flask to ensure full cellular detachment. The cellular suspension was transferred 
to a 15 mL falcon tube and centrifuged (Rotofix 32, Hettich Zentrifugen) at 1500 rpm for 5 
minutes at room temperature. The supernatant was discarded and the cell pellet re-suspended 
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in 5 mL appropriate media ready for counting and seeding into new culture flasks, or to be used 
for experiments accordingly.  
 
Cell Counting 
Cells were counted using a Neubauer haemocytometer. 10 µL of the 5mL cellular suspension 
was pipetted underneath each side of the coverslip of the haemocytometer. The grid was viewed 
under a microscope (10× objective lens) and cells present in two of the grids were counted and 
averaged (‘N’x104 cells/mL). Then, (1x105/’N’x104) x volume wanted = volume needed to be 
added in order to give ‘x’ mL at 1x105 cells/mL concentration. Cells were carried forward as 
appropriate.  
 
3.9.2. Principle Uptake Confocal Microscopy Studies 
T75 flasks of Mesenchymal Stem Cells (MSCs), HeLa cells and A549 cells were each 
maintained via the general cellular practice as outlined in section 3.8.1. These cells were split 
and plated onto 35mm MatTek imaging dishes with a density of 0.3 x 106 cells per well for 
A549s and HeLa cells and 0.2 x 106 cells per well for MSCs. The cells were suspended in 2mL 
of DMEM and cultured for 24 hours in an incubation chamber to allow them to adhere and 
stabilise. Old media was removed via pipetting and the cells washed with PBS solution three 
times to remove dead cells and residual media. The remaining cells were immersed with a 
solution of GNP-Fol (900uL of ~1nM GNP) loaded with RuPhenSS (12uL of 1mM solution) 
suspended in 2mL of DMEM and returned to the incubator for a further 24hours. Old media 
was removed via pipetting and the samples washed with PBS three times to remove dead cells, 
unbound particles and old media. The cells were re-suspended in imaging media 
(ThermoFisher, Invitrogen, Live Cell Imaging Solution, A14291DJ) and immediately analysed 
in a live cell chamber of a confocal microscope. The samples were excited using a 488nm laser 
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and emission was collected across a 580-680nm range. The laser strength and signal gain of 
the microscope were calibrated using untreated MSCs as these cells displayed the most 
prominent auto-fluorescence within the collection range.  
 
3.9.3. PCR Studies 
RNA Isolation 
T25 culture flasks of the appropriate cell lines were cultured until confluent in appropriate 
media (RPMI, supplemented RPMI or DMEM). Cells were subsequently washed, lysed and 
pelted as per the general methods section 3.8.1. RNA was extracted from the cell pellets via 
utilisation of Qaigen RNA isolation kit (Qaigen RNeasy Mini Kit) according to the 
manufacturer’s instructions.  
 
First, the cell pellet is suspended in 350µL Buffer RLT and vortexed for 10 seconds. 350µL of 
ethanol (~70%) was added to the lysate and the resulting mixture mixed via pipetting. The 
sample was then transferred to an RNEasy spin column, the column placed within a 2mL 
eppendorf and then subsequently centrifuged for 15 seconds at 8000RCF. Through-flow was 
discarded and the column returned to the eppendorf. 700µL of buffer RW1 was added to the 
column and the column centrifuged for a further 15 seconds at 8000RCF. Through-flow was 
discarded, column returned to the eppendorf. 500µL buffer RPE was added to the column and 
the column centrifuged for a further 15 seconds at 8000RCF. Through-flow was discarded, 
column returned to the eppendorf. This step was repeated. The spin column was then 
transferred to a new eppendorf and centrifuged at the maximum speed for one minute to dry 
the membrane. The spin column was then inserted in a fresh 1.5mL eppendorf, was loaded with 
50µL RNAse free water and centrifuged for one minute at 8000RCF to elute RNA. Purity and 
concentration were ascertained via analysis of 260/280nm ratio of UV-Vis spectrum.  
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cDNA Synthesis from total RNA 
First strand cDNA synthesis was performed using BioLine Tetro cDNA Synthesis Kit (BioLine 
Reagents Ltd, UK) according to the manufacturer’s instructions.  
Total RNA (4µg) in RNAse free water was added to sterile RNAse free micro-centrifuge tubes 
containing a mixture of 1µL Oligo (dT)18 Primer Mix, 1µL of 10mM dNTP mix, 4µL 5xRT 
Buffer, 1µL RiboSafe RNAse Inhibitor, 1µL Tetro-Reverse-Transcriptase (200µg/µL) and 
20µL DEPC-treated water. This solution forms a priming pre-mix, which was alliquated into 
the micro-centrifuge tubes in ice. The solutions were mixed gently by pipetting before being 
incubated at 45°C for 30 minutes within a pcr chamber. The reaction was terminated by 
incubation at 85°C for 5 minutes before being chilled on ice. Solutions were either carried 
forward immediately for PCR or stored at -20°C. 
 
PCR 
PCR studies were carried out utilising a protocol adapted from that of Shen et al12. Forward 
and reverse primers were freshly ordered and matched the sequences set forth by Matsushita et 
al11.  
 
10pM / µL stock solutions of the folate receptor α, β and γ forward and reverse primers were 
prepared separately in DEPC treated water, as well as β Actin control primers. PCR mixtures 
were prepared in micro-centrifuge tubes, comprising 10x NH4 Reaction Buffer (5µL), MgCl2 
(4µL of a 50mM solution), dNTP Mix (1µL of a 100mM solution), BioTaq Polymerase (1µL), 
cDNA, appropriate Primer (1µL of 10pM/µL stock soltion) and DEPC water (up to 50µL total 
volume). The micro-centrifuge tubes were placed in a PCR incubation chamber and subjected 
to the following amended PCR cycle: 5 minutes at 94°C, 35 cycles of (45 seconds at 94°C, 60 
seconds at 59°C and 90 seconds at 72°C) befoe terminating the reaction at 72°C for 10 minutes. 
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PCR products then purified with a Qaigen PCR Purification Kit and had their concentrations 
analysed via UV-Vis.  
 
PCR Purification 
PCR products were purified via utilisation of Qaigen PCR Purification Kit according to the 
manufacturer’s instructions.  
5 volumes of Buffer PB were added to 1 volume PCR Mix and 10µL of a 3M sodium acetate 
solution added. The resulting solution was transferred to a spin column within a centrifuge tube 
and centrifuged at 13000rpm form 60 seconds, with any flow-through discarded. 750µL Buffer 
PE was added to the spin column and the column centrifuged for a further 60 seconds at 
13000rpm, flow-through was discarded. The membrane was dried by a further round of 
centrifugation as above, and the dried column placed in a fresh centrifuge tube. 30µL Buffer 
EB was added and the purified PCR product eluted by centrifugation at 13000rpm for 60 
seconds. Purified PCR products were either carried directly forward for agarose gel 
electrophoresis or stored at -80°C.  
 
Agarose Gel Electrophoresis 
Agarose gel electrophoresis was conducted as per the protocol of fellow Hannon group doctoral 
researcher Peter Cail.  
100mL of a 3% agarose gel was freshly prepared via heating 2.7g agarose stock in 97mL of 
TEA buffer. Fresh agarose gel solution was poured into a gel column and had lane inserts were 
placed at the top of the gel column. The solution was allowed to cool to room temperature and 
set for one hour. Once set, the lane inserts were removed and the gel column transferred to an 
electrophoresis tank and submerged in fresh TEA solution. 50bp ladder stock was placed within 
the first lane (1µL of a 1µg/10µL fresh stock solution) followed by the appropriate PCR 
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products, which had been diluted to give a unified concentration with the weakest PCR product 
solution and (10µL of appropriate PCR stock, mixed with 2µL Loading Dye). A current was 
applied across the agarose gel and the solutions allowed to migrate across the gel for two hours 
to give appropriate separation. The gel was removed, TEA solution drained and el replaced 
back in the chamber. The gel was then submerged in a fresh TEA solution containing a DNA 
stain stock. The gel was covered with foil and allowed to stain for 40 minutes. Stain solution 
was removed and the gel immediately analysed within a photo-illuminator.  
 
3.9.4. Immunocytochemistry Studies 
Cell Plating 
A549 cells were cultured as two separate cultures for 2 months, the first in zero folate RPMI 
medium (ThermoFisher, Gibco RPMI) and the second in supplemented folate RPMI medium 
(zero folate RPMI media supplemented with 20mg folic acid). Cells were maintained as per 
the general cellular practice as outlined in section 3.8.1, with mere supplementation of 
appropriate media. Cells were then washed, lysed, pelleted, re-suspended and counted. 0.8x106 
cells were then seeded onto MatTek dishes in appropriate medium and allowed to adhere 
overnight (~12 hours).  
 
Antibody Staining 
Old media was removed from the MatTek dishes and each dish washed with PBS (2mL x 3) 
via pipetting. The cells were then incubated with primary antibody (Folate Receptor Alpha 
Polyclonal Antibody, 2µg/mL in 2mL media (zero folate RPMI or supplemented RPMI 
dependent on cell culture used)) for 45 minutes. Cells were then washed with PBS (2mL x 3) 
and incubated with secondary antibody (Goat anti-rabbit Secondary Antibody, Alexa Fluor 
488, 2µg/mL in 2mL media) for 30 minutes. The cells were then washed with PBS (2mL x 3), 
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immersed in 1mL imaging media and immediately imaged via live confocal microscopy within 
a pseudo incubation chamber.  
 
Confocal Microscope Settings 
Green Channel: Excitation, 514nm Emission, 490-570nm 
 
3.9.5. Comparative Uptake Studies 
Nanoparticle Purification 
GNP-Fol and GNP-Cit were freshly prepared as per section 2.3.2. Each system was dialysed 
overnight in a semi permeable membrane (Spectra-Por® Float-A-Lyzer® G2, 5 mL, MWCO 
8-10 kDa) in deionised water to remove unreacted reagents and excess folate. The systems then 
had their concentrations roughly calculated via UV-Vis and the stronger system diluted to the 
same concentration as the weaker system (~1nM). 24µL of a 1mM RuPhen stock was then 
titrated into 2mL of GNP-Fol in increments of 6µL under magnetic stirring to afford GNP-Fol-
RuPhen. The same was carried out for GNP-Cit to afford GNP-Cit-RuPhen. The systems were 
stirred at room temperature for ~30 minutes and were subsequently dialysed in a semi 
permeable membrane overnight (~12 hours) to remove unbound RuPhen and excess folate / 











Cells were cultured and plated onto MatTek dishes as per section 3.8.3. The following samples 
were prepared as separate MatTek dish cultures: 
A549s (zero folate culture) A549s (supplemented folate culture) 
1. Blank 2. Blank 
3. Secondary Antibody Only 4. Secondary Antibody Only 
5. Pri + Sec Antibodies (AB) 6. Pri + Sec Antibodies (AB) 
7. GNP-Fol-RuPhen + AB 8. GNP-Fol-RuPhen + AB 
9. GNP-Cit-RuPhen + AB 10. GNP-Cit-RuPhen + AB 
 
After overnight culture in MatTek dishes, old media was removed from samples 1-10 and the 
dishes washed with PBS (2mL). 2mL of fresh media (zero folate samples 1, 3 and 5; 
supplemented folate samples 2, 4 and 6) was added to samples 1-6 and the samples returned to 
the incubation chamber. 1mL of GNP-Fol-RuPhen was mixed gently by pipetting into 1mL of 
zero folate RPMI and 1mL of GNP-Fol-RuPhen was mixed with 1mL of supplemented RPMI. 
The same was repeated for GNP-Cit-RuPhen. These nanoparticular-media suspensions were 
then pipetted into the appropriate MatTek dishes (7-10) and the dishes returned to the incubator. 
Samples were incubated for 3 hours, then old media was removed from samples 5-10 and the 
samples washed with PBS (3 x 2mL). 2mL of a 2µg/mL solution of folate receptor alpha 
polyclonal antibody (ThermoFisher, 548908) in RPMI was added to each sample and the 
samples incubated for a further 45 minutes. Old media was removed from samples 3-10 and 
the cells washed with PBS (3 x 2mL). 2mL of a 2.5µg/mL solution of secondary antibody (Goat 
anti-Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor 488) in RPMI was added to each 
sample and the samples incubated for a further 30 minutes. Old media was removed from all 
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samples and each sample washed with PBS (3 x 2mL). Imaging media (2mL) was added to 
each sample and the samples immediately imaged via confocal microscopy.  
 
Confocal Microscope Settings 
Green Channel: Excitation, 514nm Emission, 490-570nm 
Red Channel: Excitation, 488nm Emission, 580-680nm 
 
3.9.6. Subjected Flow Uptake Studies 
Cell Culture 




Fresh batches of GNP-Fol and GNP-Cit were synthesised as per section 2.3.2 and were 




Samples and antibodies were prepared as per section 3.8.4, dosing times and protocols are 
equally identical. The only modification to this dosing protocol was the utilisation of a plate 
rocker. Said plate rocker weas pseudo sterilised through extensive washes with 70% ethanol. 
Cells were only subjected to plate rocking on its lowest setting within an incubator at the point 
of nanoparticular dosing (12 hours post plating onto MatTek dishes). All samples were 
subjected to plate rocking, not just those being dosed with nanoparticles. The plate rocker was 
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removed and samples stained with appropriate antibodies statically within the incubation 
chamber.  
 
3.9.7. Folate Receptor Blocking Studies 
Cell Culture 
High folate receptor α expressing A549s were cultured and maintained as per section 3.8.5.  
 
Nanoparticle Preparation 
Fresh batches of GNP-Fol and GNP-Cit were synthesised as per section 2.3.2 and were 




Cells were cultured and plated onto MatTek dishes as per section 3.8.5. The following samples 
were prepared as separate MatTek dish cultures (for confocal studies) and 6 well plates (for 
FACS studies): 
A549s - No Blocking A549s – With Folate α Blocking 
1. Blank - 
2. GNP-Fol-RuPhen 3. GNP-Fol-RuPhen  
4. GNP-Cit-RuPhen  5. GNP-Cit-RuPhen 
 
Samples and antibodies were prepared as per section 3.8.5, dosing times and protocols are 
equally identical. The only modification to this dosing protocol was the pre-dosing of samples 
3 and 5 with folate receptor alpha primary antibody prior to nanoparticular dosing (as per 
section 3.8.5). Accordingly, prior to nanoparticular dosing the media was removed from 
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samples 3 and 5 and the samples washed with PBS (3 x 2mL). The samples were stained with 
appropriate antibodies statically within the incubation chamber. 1mL of a 4µg/mL solution of 
folate receptor alpha polyclonal antibody (ThermoFisher, 548908) in RPMI was added to each 
sample and the samples incubated for 30 minutes on a plate rocker. Subsequently, 1mL of 
either GNP-Fol-RuPhen or GNP-Cit-RuPhen was added to samples 3 and 5 respectively. 
Samples 1, 2 and 4 had their old media removed, were washed with PBS (3 x 2mL) and 
supplemented with fresh RPMI (2mL per sample). All samples were returned to the incubator 
and were incubated / worked up as per the remainder of the protocol for section 3.8.5 for 
confocal microscopy samples. 
 
Confocal Microscope Settings 
Green Channel: Excitation, 514nm Emission, 490-570nm 
Red Channel: Excitation, 488nm Emission, 580-680nm 
 
FACS 
High folate receptor α expressing A549 cells were seeded onto 6 well plates (300,000 cells per 
well) and supplemented with 2mL supplemented RPMI. The cells were incubated for 24 hours 
before treatment with appropriate solutions to allow cell adhesion to the well base. Old media 
was removed from the plates and each well washed with PBS (2mL) to remove residual media 
and dead cells. Each well was subsequently dosed with the same protocol as above for confocal 
studies, one well for each sample condition, no replicates. The cells were washed with 2 mL 
PBS before being lysed, pelleted and re-suspsended as per section 3.8.1. Samples were 
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Chapter 4 – Platinum(IV) Anticancer Agents and Cellular Uptake 
4.1. Platinum(IV) Pro Drug Design and Synthesis 
In tandem with the research of chapter 3 into the development and utilisation of 
nanoparticle bound ruthenium imaging agents, and as previously discussed, it was a further 
objective of the present research to design, develop and utilise a platinum(IV) pro drug. In this 
regard, a number of platinum(IV) compounds with potential pro-drug capabilities were 
investigated in the present research, with early efforts utilising compounds of the literature and 
latter efforts focussing on a number of novel compounds being conceptualised and synthesised. 
Two compounds of the literature (Pelosi et al1. and Lippard et al.2) as well as two novel 
platinum(IV) species (Trial Compounds 1 and 2) were investigated in early efforts of the 
present research and are outlined in Figure 401. However, the primary novel platinum(IV) 
species conceptualised and utilised throughout the research and reported herein is represented 




Figure 401: Pt(IV) compounds investigated during preliminary nanoparticle loading, stability 
and cytotoxicity studies. Pelosi and Lippard compounds have been reported to exhibit 
antiproliferative and cytotoxic properties respectively, whilst novel Trial Compounds 1 and 2 
were based on those compounds but with added thiol anchoring groups in the pursuit of 





Figure 402: The novel Pt(IV) compound (Pt(IV)LipA) conceptualised and utilised throughout 
the presently reported research along with its corresponding synthetic protocol.  
 
The lack of specificity of traditional platinum based chemotherapeutic agents such as cisplatin, 
and the ability of cancer cells to build resistance to such agents are key aspects for consideration 
when designing new chemotherapeutic agents3, 4. In this regard, platinum(IV) agents afford the 
opportunity to incorporate additional moieties to the platinum centre through the addition of 
two axial binding sites (the compounds are octahedral, bearing 6 ligands – an improvement 
over the four of square planar or tetrahedral platinum(II) compounds)5.  
 
In this vein, the Pelosi and Lippard Pt(IV) compounds were developed so as to provide 
chemotherapeutic Pt based agents which present increased solubility whilst theoretically 
maintaining a level of cytotoxicity that would be therapeutically beneficial, or indeed, 
enhancing said cytotoxicity1. The present research employed these two compounds for initial 
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nanoparticle loading studies so as to establish key concepts such as the ability to load gold 
nanoparticles (both GNP-Fol and GNP-Cit systems) with Pt(IV) agents bearing an axially 
bound carboxylic acid motif and subsequently, explore what affect this has on the system’s 
ability to deliver said agents and induce DNA-cisplatin adduct formation.  
 
Nanoparticle loading studies were conducted using the same protocol as the Ruthenium based 
loading studies in section 2.2.2, loading 1mL of ~1nM GNP-Fol or GNP-Cit (as separate 
systems) with a stock solution (1mg/mL) of either the Pelosi or Lippard Pt(IV) agents (as 
separate systems). However, these nanoparticle loading studies were unsuccessful, with both 
GNP-Fol and GNP-Cit systems seemingly unable to support even 1µg of either of the Pelosi 
or Lippard compounds. Specifically, the nanoparticle systems either showed no shift in the 
SPR band in the subsequent UV-Vis spectrum post titrations (which would have been 
indicative of surface binding of reagents) or the SPR band broadened significantly and the 
solution became polydisperse and purple (indicative of agglomeration/aggregation). 
 
It was therefore hypothesised that the unsuccessful nanoparticle loading of these compounds 
was likely the result of instability in the resulting solution post titration (circa 99% water) or 
because of unfavourable surface coordination conditions between the nanoparticles and the 
carboxylic acid motifs (the former being associate with the Lippard compound and the latter 
with the Pelosi compound). Accordingly, subsequent efforts sought to design and synthesise a 
novel Pt(IV) agent that demonstrated improved solubility over Lippard and loading capabilities 
over Pelosi.  
 
In order to address nanoparticle loading, the incorporation of lipoic acid was investigated. As 
reported herein, transition metal probes of varying nature have been synthesised within the 
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Pikramenou group, the majority of which feature at least one lipoic acid unit. These probes 
present quite significant loading capabilities within the nanoparticle systems employed (as per 
chapter 2 of the present research) and this is believed to be partly as a result of the di-sulphur 
containing 5 membered ring of lipoic acid. Of course, many other factors contribute to the 
stability of a system and the capability of a compound to be successfully loaded onto a 
nanoparticle surface, however, the utilisation of lipoic acid was a logical succession for the 
present drug design studies.  
 
Trial compound 1 was a first attempt at a novel Pt(IV) agent, based on the synthetic protocol 
of the Lippard compound2, but replacing the use of succinic anhydride with lipoic acid 
anhydride. This Pt(IV) complex incorporates axially coordinated lipoic acid ligands via the 
oxygen atoms of the terminal hydroxyl group. This design was the most simplistic of those 
considered as it resembled a straight adaptation of the common Pt(IV) pro drug intermediate 
c,c,t-[Pt(NH3)2(Cl)2(OH)2] (compound 401, see experimental section 4.6.1). This complex was 
more soluble than the Lippard complex, yet it was found to still lack sufficient solubility for 
application in subsequent nanoparticle studies. Moreover, the reaction was not clean, with a 
number of unidentifiable and inseparable by-product peaks observable within the mass and 
NMR spectra. 
 
Trial compound 2 was based on the aforementioned Pelosi compound and sought to incorporate 
lipoic acid by way of an amine linker to the axially coordinated carboxylic acid motif. Trial 
compound 2 was also associated with a number of impurities and it was again not possible to 
separate out the target compound to a sufficiently pure solution. It was hypothesised that this 
crude reaction mixture was as a result of non-uniform mono-protection of the di-amine. More 
particularly, despite stoichiometric control of the amine and protecting groups, there would 
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inherently be irregularities in the protective step, with a mixture of mono-protection, di-
protection and no protection. The result would in turn give a mixture of lipoic-amine 
intermediates. Poor purification at this stage would lead to impurities being carried over and 
inherently lead to further irregularities. Accordingly, due to the expense of platinum reagents 
and difficulties in post-reaction purification, amine linkages were subsequently abandoned as 
a route to future lipoic acid incorporation. 
 
Subsequent research efforts sought to simply amend the Pelosi complex through replacement 
of the axial succinic anhydride ligand with a lipoic acid ligand, leading to the formation of the 
Pt(IV)LipA complex (Figure 402). 
 
4.2. Pt(IV)LipA Complex Synthesis and Characterisation 
The principal concept behind the design of the Pt(IV)LipA complex was the 
incorporation of a lipoic acid ligand to facilitate nanoparticle loading, whilst preserving the 
acetylamido ligand of the Pelosi complex, which is thought to be responsible for the increased 
solubility of the Pelosi complex1. The Pt(IV)LipA complex was synthesised through amending 
the second stage of the Pelosi synthesis (see Experimental section 4.6.1) replacing succinic 
anhydride with lipoic acid anhydride. A 10 times molar excess of a lipoic acid anhydride 
solution was utilised so as to help increase product yield, with no effect on the purification 
stage of the synthesis due to polar differences in solubility of reactants and the target complex. 
The Pt(IV)LipA complex was easily separated by trituration with diethyl ether. The complex 
was subsequently washed several times with diethyl ether and dried under high vacuum 
overnight. No further purification was required and the overall yield of the complex was 70% 
(for full details, see Experimental Section 4.6.1). The characterisation of the Pt(IV)LipA 










   
Figure 403: MS and NMR studies of the Pt(IV)LipA complex and associated characterisation. 
a) MALDI-TOF showing product [M+H]+ peak at 564.0g/mol along with corresponding 
isotope peaks; b) 1H NMR spectrum; c) COSY spectrum with signals ranging ≈1.4-3.7ppm, 
showing close range couplings of different proton environments, facilitating allocation of 7, 7’, 
9, 9’, 10 and 10’; d) Chemical structure and numerical allocations for Pt(IV)LipA, i) Proton 
environments (1-10’) and ii) Carbon environments (A-J). Full corresponding analytical data is 
available in Appendix section 7.2.  
 














Proton peaks 1-5 and carbon peaks A-E were readily assigned by comparison with the Pelosi 
and Lippard complex assignments in the literature, with only small shifts in relative peaks of 
circa 0.1-0.3ppm. Proton peak 6 and carbon peaks F-J were again somewhat readily assigned 
through comparison to the literature of lipoic acid NMR data, which in turn helped to 
appropriately assign proton peaks 7-10’ within the COSY and HSQC spectra.  
 
The Pt(IV)LipA complex incorporates the solubility prospects of the Pelosi complex (through 
the acetylamido ligand) with the loading potential of lipoic acid by way of the two axial 
positions. It was hypothesised that upon reduction, either by reductive species within 
endosomes of target tumour cells or within the hypoxic environment of the tumour / cells, these 
axial ligands would dissociate, leaving the active Pt(II) complex cisplatin6. Accordingly, it was 
envisaged that the Pt(IV)LipA complex would present a viable Pt(IV) pro-drug candidate with 
enhanced solubility over typical complexes of such nature and with the ability to coordinate to 
the surface of gold nanoparticles. Attractively, Pt(IV)LipA is readily synthesised via a two-
stage one-pot protocol with a high overall yield (≈70%).  
 
4.3. Testing Reduction Capabilities 
Prior to nanoparticle loading studies, the potential for the Pt(IV)LipA complex to be 
reduced to the active anticancer agent cisplatin was investigated. Whilst there is a wealth of 
research into the cellular application and reduction of Pt(IV) pro-drugs, there is still some 
debate surrounding the proposed mechanism of reduction of the Pt(IV) centre to Pt(II) at the 
target location. At present, it is largely believed that it is as a result of either the hypoxic 
environment of a tumour and/or the presence of reductive agents within endosomes that may 




As a crude test of reductive capabilities and subsequently induced cytotoxicity (prior to 
implementation in more representative cellular studies) Circular Dichroism (CD) Spectroscopy 
was employed. The CD spectrum of Calf Thymus (ct) DNA possesses a characteristic signal 
in the region of 300-200nm, displaying a peak at 275nm, a trough at 245nm and another peak 
at 220nm8. This region is essentially the fingerprint of the calf thymus DNA, highlighting its 
varying absorption of left and right circularly polarized light. It has been shown in the literature 
that when Pt agents bind to CT DNA its fingerprint region is altered, giving shifts in the 
characteristic peaks and troughs, thus forming a means of detection of DNA binding9. 
Accordingly, titration experiments were conducted utilising CT DNA and the Pt(IV)LipA 
complex, with results represented in Figure 404 (see experimental section 4.6.2).  
 
Figure 404: Circular Dichroism Spectrum data for titrations of Pt(IV)LipA complex (145µL, 
300µM) and a reductive agent (20µL, 1mM ascorbic acid) into a CT DNA stock solution 
(comprising 98µM of CT DNA in NaCl, Na cacodylate and Milli Q water). The solution was 
stirred at room temperature for 5 minutes after each titration and its CD spectrum recorded 
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Figure 405: Circular Dichroism Spectrum data for titrations of cisplatin (145µL, 300µM) into 
a CT DNA stock solution (comprising 98µM of CT DNA in NaCl, Na cacodylate and Milli Q 
water).  
 
It was hypothesised that upon titration of a solution of Pt(IV)LipA alone into a CT DNA stock 
solution there would be minimal change to the spectrum as a result of the compound being 
theoretically unable to interact with the DNA in the same way as cisplatin. That is to say, the 
Pt(IV)LipA complex should not display the ability to form intra-strand covalent bonds to 
adjacent Guanine residues of the DNA helix, therefore no “kink” should be formed and 
subsequently, there should be a relatively insignificant shift in the spectrum, unless the complex 
presents another method of binding10. Whilst Pt(IV)LipA has a chiral centre (indicated with * 
in Figure 402) and displays absorption within the 200-220nm region of the CD spectrum, only 
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It was further anticipated that upon titration of the reducing agent into the solution (ascorbic 
acid), the Pt(IV) centre would be reduced to Pt(II), thus facilitating binding with the CT DNA 
and in turn altering the fingerprint region of the spectrum11. Unfortunately, ascorbic acid 
displays an absorption within the fingerprint region of CT DNA (220-280nm). However, due 
to its weak absorption at its severely diluted titration state, along with its use within the 
literature for reduction tests of Pt(IV)11, its use was maintained. A 1mM solution of ascorbic 
acid was utilised so as to give a greater probability that the Pt(IV) complex would be reduced 
and thus give the potential for binding.  
 
Upon titration of the Pt(IV)LipA complex into the CT DNA solution (in the absence of a 
reducing agent) shifts can be observed in the fingerprint region of the spectrum (Figure 404), 
with a reduction in the peaks at 275nm and 220nm (circa 16% and 20% reduction respectively) 
and an increase in the trough signal at 245nm (circa 200% increase). Whilst the Pt(IV) complex 
is optically active, it is unlikely that its activity and individual CD signal alone would induce 
such a significant shift in the fingerprint region of the spectrum. It was therefore subsequently 
hypothesised that either; the complex was reduced in the solution upon titration, perhaps as a 
result of the other agents present, generating cisplatin and thus inducing cisplatin-DNA adduct 
formation; the axial ligands dissociated in solution due to poor stability / solubility, or: the 
Pt(IV)LipA complex has another mechanism of interaction with the DNA helix, aside from the 
intended cisplatin mimicking methodology. Accordingly, further research in this area should 
look at the specifics of the Pt structure pre and post titration, perhaps utilising NMR studies to 
ascertain any structural differences, as well as monitoring the stability of the complex in 




Rather unexpectedly, upon titration of the ascorbic acid solution into the CT DNA / Pt(IV) 
solution an increase was observed across each of the peaks / troughs of the fingerprint region 
(220nm – 34%, 245nm – 65% and 275nm – 4%). This may be as a result of reduction of the 
Pt(IV) complex as expected and thus induced cisplatin activity. Subsequent cellular studies 
were employed to investigate the potential of Pt(IV)LipA to act as an anticancer agent as well 
as its specific mode of action.   
 
For completeness, the mirror titration experiment utilising cisplatin was conducted and is 
represented in Figure 405 (see experimental section 4.6.2). As reported in the literature, there 
is a shift in the trough of the CT DNA fingerprint spectrum at 275nm, most likely as a result 
of the binding and subsequent DNA alteration imparted by cisplatin. Interestingly, this shift is 
relatively small by comparison to that demonstrated by the Pt(IV)LipA complex and only the 
single trough of the spectrum was affected, as opposed to the entire fingerprint region.  
 
4.4. Nanoparticle Loading Studies 
Having confirmed the structure of the Pt(IV)LipA complex and crudely ascertained its 
ability to bind to ct DNA, subsequent efforts were made into the nanoparticle loading of the 
complex onto the GNP-Fol and GNP-Cit systems. The same loading protocol was employed 
for the Pt(IV) complex titrations into GNP solutions as utilised for the ruthenium probe loading 
studies (see section 2.2.2), with constant stirring and subsequent sonication of samples prior to 
running UV-Vis and DLS scans to confirm binding and ascertain solution stability (see 
experimental section 4.6.3). The collated data from these loading studies are represented in 





Figure 406: UV-Vis absorption spectrum data for titration of a 1mg/mL Pt(IV)LipA stock 
solution into 1mL of 1nM GNP-Fol. Titration volumes of Pt(IV)LipA were varied to give 
incrementally increases in µg Pt(IV) added as opposed to traditional mmol added. Only minor 
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nm and the SPR band broadening from 478-630nm to 478-634nm. Shift and broadening of the 
SPR band are indicative of surface binding in the nanoparticle system.  
 
 
Figure 407: UV-Vis absorption spectrum data for titration of a 1mg/mL Pt(IV)LipA stock 
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incrementally increases in µg Pt(IV) added as opposed to traditional mmol added. The SPR 
band λmax shifted by 2nm from 516nm to 518 nm and the SPR band also shifted and narrowed 
from 436-551nm to 443-556nm. Shift and narrowing of the SPR band are also indicative of 
surface binding in the nanoparticle system. 
 
The UV-Vis titration data (Figures 406 and 407) for the GNP-Fol and GNP-Cit systems showed 
some minor differences in the effect of Pt(IV) loading. In the case of the GNP-Fol system, the 
SPR band λmax shifted by 2nm and the band broadened, which is a typical response expected 
in nanoparticle loading experimental data. However, for the GNP-Cit system, the SPR band 
λmax also shifted, but the SPR band actually narrowed by 2nm and the entire band shifted by 
5nm with respect to its minima at 551nm v 556nm. It is not understood why one system would 
show broadening of the SPR band and the other narrowing, however, it is understood in the 
literature that any such alteration to the SPR band is indicative of surface binding12. More 
particularly, it is believed that whilst alteration of the SPR band is indicative of nanoparticle 
binding, the specific change that is imparted is more dependent on the polarity and degree of 
interaction of the respective titrated compound with the SPR of the nanoparticle system itself.  
 
Much the same as the ruthenium probe loading studies, the nanoparticle systems were not able 
to be filtered by sephadex on account of loss of stability of the system (most likely through 
removal of too much environmentally stabilising folate / citrate in solution). Accordingly, the 
systems were dialysed for 24 hours in appropriately pH balanced deionised water (circa pH 9 
for GNP-Fol and pH 7 for GNP-Cit) within microporous dialysis tubing to remove the majority 
of any unbound Pt(IV) agent (see experimental section 4.6.3). The solutions were subsequently 
sonicated for 10 minutes and filtered through a rudimental cotton plug to remove any 
precipitated material. Solutions were monitored via DLS at 24 hour intervals to ascertain 
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stability and it was found that the systems remained disperse and non-agglomerated for up to 
96 hours, irrespective of sonification.  
 
4.5. Cellular Activity Studies 
Subsequent research efforts sought to ascertain the cytotoxic capabilities of the 
Pt(IV)LipA complex within cancer cell systems. For continuity, high folate receptor α 
expressing A549 cells were utilised for these cytotoxicity experiments going forwards. 
Particular objectives of this research were to ascertain the degree of cytotoxic activity of 
Pt(IV)LipA, provide  an indication of the method of action of the cytotoxic agent and the 
cellular localisation of said agent.  
 
4.5.1. MTT Assays 
To investigate the cytotoxic activity of the Pt(IV)LipA agent, MTT assays were 
conducted for high folate receptor α expressing A549s dosed with the agent. MTT assays are a 
form of colorimetric measurement of cellular metabolic activity13 & 14. More particularly, it is 
a means of measuring a cell culture’s ability to reduce MTT (a tetrazolium dye, 3-[4,5-
dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide) to the insoluble MTT-Formazan by-
product. This process of reduction of MTT is governed by the activity of oxido-reductase 
enzymes which in-turn is governed by cellular viability. Accordingly, the more surviving cells 
within a cell culture, the better the collective ability to process the MTT dye to MTT-Formazan. 
This MTT-Formazan is subsequently solubilised and gives a strong purple solution with 
absorption within the UV-Vis spectrum. Therefore, the UV-Vis spectrum of the sample in 




MTT assays were utilised to ascertain the cytotoxicity of Pt(IV)LipA on its own as well as 
when loaded onto GNP-Fol (GNP-Fol-Pt(IV)) and GNP-Cit (GNP-Cit-Pt(IV)) systems in 
comparison to cisplatin. The results of these studies are graphically represented in Figure 408. 
See experimental section 4.6.4 for full details.  
 
 
Figure 408: Normalised MTT data recorded for A549 cell cultures dosed with anti-cancer 
compounds in varying doses. Normalised absorbance reflects % cell viability, with the control 
data resembling 100% viability. 12.5µM, 25µM and 50µM solutions of cisplatin and 
Pt(IV)LipA were investigated, along with the Pt(IV)LipA compound when loaded onto GNP-
Fol and Cit nanoparticle systems.  
 
The MTT data of Figure 408 shows that at low to medium concentrations the Pt(IV)LipA 
complex displays significantly greater cytotoxicity than cisplatin in A549 cells, with 70% vs 
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93% cell viability respectively at 12.5µM and 53% vs 85% cell viability respectively at 25µM. 
However, in contrast to the trend, the Pt(IV)LipA complex displays no significant increase in 
cytotoxicity in going from medium to high dose (53% to 51% viability going from 25µM to 
50µM respectively) whereas cisplatin displays a considerable increase in toxicity across this 
range (85% to 60% viability respectively). It is believed that the small difference in cytotoxic 
affect in going from 25µM to 50µM of Pt(IV)LipA is likely due to limited solubility of the 
complex at high concentrations. In this regard, it was noted that some degree of precipitation 
was observed during the loading studies at high concentrations. A similar hypothesis is put 
forwards for cisplatin, albeit with a reduced impact on the resulting incremental increase in 
cytotoxicity.  
 
Higher concentrations were not investigated within these studies on account of the limitations 
on nanoparticle loading and the solubility of the complexes, which would artificially skew the 
effective IC50 values for the complexes. It should also be noted that, as per introduction section 
1.3.1, cisplatin resistant A549 cells are available to purchase, displaying typically much higher 
levels of resistance to cisplatin than the parent cell line. As previously discussed, this formed 
an additional incentive for the utilisation of A549s over other folate receptor positive cell lines, 
as it might afford the opportunity to subsequently investigate and compare the efficacy of the 
Pt(IV) agents ability to deliver cisplatin in alternative forms to resistant cells in later research.  
 
The MTT results also show that the impact of Pt(IV)LipA is typically enhanced when loaded 
onto nanoparticle systems. For the GNP-Fol-Pt(IV) system, the lowest concentration of Pt(IV) 
gave significantly less cytotoxicity than the Pt(IV) agent alone, with 86% vs 70% respectively. 
However, at 25µM there was comparable cytotoxicity (59% vs 53% viability respectively) and 
at 50µM GNP-Fol-Pt(IV) displayed a significant increase in cytotoxicity over Pt(IV) alone 
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(38% vs 52% respectively). It is hypothesised that the reduced efficacy at lower concentrations 
within the GNP-Fol-Pt(IV) system may be as a result of the effective amount of free Pt(IV) 
agent delivered. That is to say, it is assumed that there will be an effective percentage range of 
the Pt(IV) complexes present that actually dissociate from the nanoparticle surface, thus, 
forming an effective concentration of Pt(IV) agent that may actually be delivered relative to 
the overall concentration present. Accordingly, at lower concentrations, more Pt(IV) complex 
may reach the cells as part of the GNP-Fol-Pt(IV) system over the free Pt(IV) system, but less 
dissociated Pt(IV) is available vs the free Pt(IV) system. Carrying this effect over, the greater 
the number of Pt(IV) complexes there are relative to nanoparticle carriers, the greater the 
number of complexes that are likely to dissociate, skewing the effective percentage and 
improving efficacy.  
 
Unlike the GNP-Fol-Pt(IV) system, the GNP-Cit-Pt(IV) system displayed increased 
cytotoxicity over the free Pt(IV) agent at all concentrations. However, it is noteworthy that the 
nanoparticles themselves displayed a high level of toxicity to the cells which may be associated 
with the surface surfactant zonyl. In order to obviate the toxic effect of zonyl as much as 
possible, the nanoparticles were subjected to extra rounds of sonification and centrifugation 
prior to being loaded with the Pt(IV)LipA complex. Despite these efforts however, the 
nanoparticle system itself displayed a cell viability of 77%, which therefore means that the 
nanoparticles alone are more cytotoxic than cisplatin at 25µM.  
 
Whilst GNP-Cit-Pt(IV) displays significantly higher cytotoxicity at each concentration 
increment than all of the other systems (63%, 49% and 28% for 12.5µM, 25µM and 50µM 
respectively), these effects are likely also as a result of the toxicity of the particles themselves. 
Accordingly, these statistics are likely not indicative of the number of Pt(IV) complexes 
165 
 
delivered to the cells or even the number of nanoparticles taken up by cells, given that free 
zonyl may diffuse through the culture and damage cells which have not taken up any GNP-Cit-
Pt(IV).  
 
The GNP-Fol system also displayed some small level of cellular toxicity (viability of 89%) and 
this may result from the basic pH of the system. Whilst the present studies utilised 1mL of 
~1nM GNP-Fol and GNP-Cit for continuity from earlier studies, future studies could look to 
vary the concentration or volume of nanoparticles with concentration of Pt(IV)LipA loading, 
to give optimal dose delivery vs system toxicity.  
 
The MTT studies therefore indicate that the GNP-Fol system likely delivers more Pt(IV) 
complex than the free Pt(IV) agent alone and that the Pt(IV) agent is more cytotoxic to cisplatin 
resistant A549 cells than cisplatin. No conclusion can be drawn from the MTT studies as to the 
implied level of nanoparticle uptake or imparted platinum based cytotoxicity of the GNP-Fol-
Pt(IV) and GNP-Cit-Pt(IV) systems on account of GNP-Cit cellular toxicity. In order to 
ascertain levels of nanoparticle uptake and effective Pt(IV) agent delivery, 
immunonocytochemical and ICPMS studies were conducted.  
 
4.5.2. Confocal Microscopy Studies 
4.5.2.1. Cisplatin-DNA Adduct Imaging Principle 
Whilst the MTT data of section 4.5.1 provided a cellular means of ascertaining 
the extent of cytotoxicity of the Pt(IV)LipA agent with respect to cisplatin, this does not give 
an indication of its specific method of action. In particular, these studies do not help to prove 
nor disprove whether cisplatin-DNA adducts are indeed formed. Moreover, whilst these studies 
support the theory that GNP-Fol-Pt(IV) is more cytotoxic than Pt(IV) alone, it does not indicate 
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that this increase in cytotoxicity is purely from increased levels of uptake of the GNP-Fol 
system and subsequently, nanoparticle bound Pt(IV)LipA. These raised levels of cytotoxicity 
could merely be due to the highly basic nature of the GNP-Fol system and similarly, in the case 
of the GNP-Cit system, on account of the surface surfactant Zonyl FSA.  
 
Accordingly, it was an object of subsequent studies to investigate the formation of cisplatin-
DNA adducts when the Pt(IV)LipA complex is administered to A549s. It was a further object 
of the research to ascertain the levels of any such cisplatin-DNA adduct formation in an attempt 
to give an indication of the level of successful Pt(IV) drug delivery in the different systems.  
 
Through the use of immunocytochemistry, these cisplatin-DNA adducts were investigated both 
qualitatively (confocal microscopy) and quantitatively (FACS analysis). In this regard, a 
commercial antibody was purchased (Anti-Cisplatin modified DNA antibody [CP9/19], see 
experimental section 4.6.5). This primary antibody displays selective binding to kinks in DNA 
formed by cisplatin-DNA adducts. A secondary antibody was selected with an Alexa Fluor 488 
dye, displaying fluorescence in the green channel. Alexa Fluor 488 dye was selected as it 
presented an emissions profile which fell outside of both the ruthenium based molecular probe 
employed in nanoparticle tracking studies as well as the blue channel emission of the nuclear 
stain Hoechst. Accordingly, through utilisation of the CP9/19 antibody system, the DNA-
damage antibody signal was measured in combination with nuclear staining with minimal 
signal bleed-through, utilising confocal microscopy and FACS analysis. The present studies 
did not include the use of the ruthenium probe, these results are discussed in Chapter 5 as the 




The dosing protocol of the present Pt(IV) immunocytochemistry confocal cellular studies was 
adapted from the protocol employed in the folate receptor α immunocytochemistry confocal 
studies (see Experimental section 4.6.5). As before, high folate receptor α expressing A549s 
were used to present a more polar difference in nanoparticle uptake in the GNP-Fol system 
upon cellular blocking with folate receptor α primary antibody (as previously discussed in 
Chapter 3). In principle, upon blocking the A549 cells with a folate receptor α primary antibody 
prior to and during cellular dosing with GNP-Fol-Pt(IV), a large shift should be observed in 
cisplatin based adduct formation, which should in turn lead to significant reduction in FITC 
based fluorescence (green channel fluorescence). Such significant spectral shifts should not be 
observed within the GNP-Cit-Pt(IV) samples.  
 
High folate receptor α expressing A549 cells were seeded onto coverslips within 6 well plates 
and cultured for 24 hours; samples were then either incubated with appropriate solutions for 24 
hours or had their media changed and incubated for a further 24 hours (as represented in Table 
401) on a plate rocker; samples were subsequently washed, fixed and permeabilised, prior to 
staining with appropriate CP9/19 antibodies and Hoechst stains. With regard to cell staining, 
unlike the previous folate receptor immunocytochemistry studies, the target of interest was 
within the cell membrane. Due to the size of the antibodies employed in such studies it was 
therefore not possible to conduct live cell studies targeting the cisplatin-DNA adducts. 
Accordingly, and as briefly noted above, the present immunocytochemistry studies were 
conducted on fixed cells that had been subsequently permeabilised to allow influx of the 
appropriate antibody (see experimental section 4.6.5 for full details on fixed cell 





4.5.2.2. Fixed Cell Confocal Immunocytochemistry Images 
The fixed cell confocal microscopy images for the samples of Table 401 are 
represented in Figures 409-416. All confocal images were collected within a single scan as a 
z-stack profile, utilising the brightfield, blue and green channels simultaneously, ensuring 
complete signal overlap and homogeneity. So as to ensure localisation of green channel signal 
with respect to blue (Cisplatin-DNA adduct signal vs Hoechst nuclei signal) the blue channel 
signal was used to set the bottom and top of the z stack profile range to be collected. Therefore, 
the z stack profiles collected across Figures 409 – 416 represent the range across the samples 
corresponding from the bottom of the nuclei to the top of the nuclei. It shall be appreciated that 
the entire range from bottom of the cell to the top of the cell was also collected for each sample 
so as to evidence the entirety of the localisation of the antibody signal. These results are omitted 
here as no such signal was observable after the microscope had been calibrated to account for 
and obviate recording false-positive signal and non-selective biding signal (discussed further 
in section 4.4.2.3).  
 
HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 
No Blocking With Receptor α Blocking 
Blank (not shown) - 
Figure 409 - Secondary Antibody Only - 
Figure 410 – Pri + Sec Antibodies (AB) - 
Figure 411 - Cisplatin + AB - 
Figure 412 - Pt(IV)LipA + AB - 
Figure 413 - GNP-Fol-Pt(IV) + AB Figure 415 - GNP-Fol-Pt(IV) + AB 
Figure 414 - GNP-Cit-Pt(IV) + AB Figure 416 - GNP-Cit-Pt(IV) + AB 




Figure 409: Fixed cell immunocytochemistry confocal studies of high folate receptor α 
expressing A549 cells stained with secondary antibody bearing Alexa-Fluor 488, illustrating 
non-selective binding of antibody or artificial signal. A) in focus plane of brightfield channel; 
B) Hoechst signal across Z stack; C) Antibody fluorescence across Z stack; D) Overlay of B 







Figure 410: Fixed cell immunocytochemistry confocal studies of high folate receptor α 
expressing A549 cells stained with primary antibody CP9/19 and secondary antibody bearing 
Alexa-Flour 488, illustrating non-selective binding of antibody pair. A) in focus plane of 
brightfield channel; B) Hoechst signal across Z stack; C) Antibody fluorescence across Z stack; 







Figure 411: Fixed cell immunocytochemistry confocal studies of high folate receptor α 
expressing A549 cells dosed with 25µM cisplatin for 24 hours before being fixed, 
permeabilised and stained with CP9/19 and secondary antibody. A) in focus plane of brightfield 
channel; B) Hoechst signal across Z stack; C) Antibody fluorescence across Z stack; D) 







Figure 412: Fixed cell immunocytochemistry confocal studies of high folate receptor α 
expressing A549 cells dosed with 25µM Pt(IV)LipA for 24 hours before being fixed, 
permeabilised and stained with CP9/19 and secondary antibody. A) in focus plane of brightfield 
channel; B) Hoechst signal across Z stack; C) Antibody fluorescence across Z stack; D) 







Figure 413: Fixed cell immunocytochemistry confocal studies of high folate receptor α 
expressing A549 cells dosed GNP-Fol-Pt(IV) (1ml 1nM GNP-Fol 25µM + Pt(IV)LipA) for 24 
hours before being fixed, permeabilised and stained with CP9/19 and secondary antibody. A) 
in focus plane of brightfield channel; B) Hoechst signal across Z stack; C) Antibody 







Figure 414: Fixed cell immunocytochemistry confocal studies of high folate receptor α 
expressing A549 cells dosed GNP-Cit-Pt(IV) (1ml 1nM GNP-Cit + 25µM Pt(IV)LipA) for 24 
hours before being fixed, permeabilised and stained with CP9/19 and secondary antibody. A) 
in focus plane of brightfield channel; B) Hoechst signal across Z stack; C) Antibody 








Figure 415: Fixed cell immunocytochemistry confocal studies of high folate receptor α 
expressing A549 cells dosed with GNP-Fol-Pt(IV) (1ml 1nM GNP-Fol + 25µM Pt(IV)LipA) 
in the presence of folate receptor α blocking for 24 hours before being fixed, permeabilised and 
stained with CP9/19 and secondary antibody. A) in focus plane of brightfield channel; B) 
Hoechst signal across Z stack; C) Antibody fluorescence across Z stack; D) Overlay of B and 







Figure 416: Fixed cell immunocytochemistry confocal studies of high folate receptor α 
expressing A549 cells dosed with GNP-Cit-Pt(IV) (1ml 1nM GNP-Cit + 25µM Pt(IV)LipA) 
in the presence of folate receptor α blocking for 24 hours before being fixed, permeabilised and 
stained with CP9/19 and secondary antibody. A) in focus plane of brightfield channel; B) 
Hoechst signal across Z stack; C) Antibody fluorescence across Z stack; D) Overlay of B and 







4.5.2.3. Fixed Cell Confocal Immunocytochemistry Results Discussion 
A number of control samples were analysed via confocal microscopy in order 
to appropriately threshold the lasers and respective channels of the microscope prior to 
collecting images of the samples that were treated with appropriate solutions (see Table 401 
and corresponding Figure 409 – 416). Firstly, a blank sample of clean, untreated A549s that 
had merely been stained with nuclear dye (Hoechst) were imaged. These blank cells were 
imaged to threshold the blue channel laser so as to ensure there was no Hoechst fluorescence 
signal noise observable within the green channel. Secondly, blank A549s were fixed and 
subsequently treated with the secondary antibody and Hoechst only (Figure 409). This provided 
a means of ascertaining non-selective binding of the secondary antibody within the cells / the 
degree of signal remaining post washing. In this regard, there will inevitably be some secondary 
antibody remaining within the cells, either non-selectively bound or completely unbound, post 
washing. Accordingly, the green channel signal was calibrated through lowering laser power 
and signal gain to nullify any such signal. Lastly, blank A549s were fixed and subsequently 
treated with primary and secondary antibodies as well as Hoechst (Figure 410). The signal 
within the green channel in this sample therefore represents false positives, where the primary 
antibody is likely inadvertently binding to healthy or slightly defective DNA as opposed to 
DNA kinks caused by cisplatin adducts. Again, the green channel signal was calibrated to 
nullify any such signal.  
 
All images collected across the samples (Figures 409-416) were obtained through use of a 60x 
magnification oil lens.  However, the sample images of Figure 411 have been artificially 
magnified through image processing software, showing a smaller section of the sample that 
was imaged. This is so as to obviate presentation of artefacts produced by non-homogeneous 
coating of the fixative across the focal plane of the sample. All other samples (Figures 409, 410 
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and 412-416) were homogeneously coated in fixative and accordingly, the entirety of their 
respective images are shown.  
 
Upon review of the cisplatin studies (Figure 411) and Pt(IV)LipA studies (Figures 412) it 
appears that the majority of the antibody fluorescence signal appears to be localised to the 
nuclei of the cells, with said signal overlapping with that of the Hoechst nuclei stain. This is 
particularly clear from review of Image D of Figures 411 and 412, which shows overlap of the 
average antibody and Hoechst signals from across the collated z stacks for the respective 
samples. It is hypothesised that the green antibody signal situated outside the nuclear regions 
of the samples is likely as a result of damage to mitochondrial DNA.  
 
It is also evident from a comparison of Images B-E of Figures 411 and 412 that there is a 
difference in the prominence of antibody signal between the samples. More particularly, that 
the Pt(IV)LipA complex gives greater antibody signal than cisplatin, which is potentially 
indicative of greater platinum induced DNA damage to the nuclei of the cells. Whilst this would 
imply that the Pt(IV)LipA complex on its own imparts greater cisplatin-DNA adducts than 
cisplatin alone, likely through obviating the cisplatin resistance pathways of the cells (see 
introduction section 1.3.1), further investigations into the exclusivity of the antibody binding 
shall be required. In this regard, further investigations shall be required into whether platinum 
based anti-cancer agents that are known to be effective in the field but possessing substantially 
different methods of effect than cisplatin must be tested with the  CP9/19 antibody to establish 
whether the antibody still binds / represents adducts. Comparison of Figures 411 and 412 makes 
a promising case for the efficacy of the Pt(IV)LipA agent over cisplatin, which also aligns with 
the MTT data collected at the respective concentrations and as reported in section 4.4.1.   
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Subsequent samples (Figures 413 – 416) sought to compare the imparted DNA damage of 
GNP-Fol-Pt(IV) and GNP-Cit-Pt(IV) systems on the cells both with folate receptor α blocking 
(Figures 415 and 416 respectively) and without folate receptor α blocking (Figures 413 and 
414 respectively). The principle being that the GNP-Fol-Pt(IV) system should demonstrate 
greater platinum induced DNA adducts than the GNP-Cit-Pt(IV) system and that upon blocking 
the α folate receptors, the imparted damage of the GNP-Fol-Pt(IV) system should be 
significantly reduced and the imparted GNP-Cit-Pt(IV) system damage should be largely 
unaffected.  
 
Comparison of the images collected for the GNP-Fol-Pt(IV) and GNP-Cit-Pt(IV) samples 
(images A-E, Figures 413 and 414) show a substantially similar localisation and prevalence of 
antibody induced signal. Therefore, there appears to be minimal qualitative difference in DNA 
damage antibody signal across the systems. In comparison to the free Pt agent studies of 
Figures 411 and 412, there appears to be a more diffuse localisation of the antibody signal with 
respect to the nuclei of the cells, which is potentially indicative of more non-target delivery of 
therapeutic agents in the nanoparticlely delivered systems. Accordingly, it is possible that there 
is a greater amount of mitochondrial DNA damage rather than nuclear DNA damage for the 
nanoparticle systems.  
 
Encouragingly, and in line with the hypothesis, through blocking of the α folate receptors there 
appears to be a substantial decrease in the antibody signal of the GNP-Fol-Pt(IV) sample 
(Figure 415, Images A-E). By contrast, the antibody signal of the GNP-Cit-Pt(IV) sample with 
blocking appears largely unaffected (Figure 416, A-E). In this regard, qualitative comparison 
of Figures 413 and 415 shows a significant decrease in antibody signal (thus indicative of less 
platinum induced DNA-adducts / damage) for the GNP-Fol-Pt(IV) system, whereas 
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comparison of Figures 414 and 416 show largely unchanged antibody signal for the GNP-Cit-
Pt(IV) system. Lastly, the localisation of the induced antibody signal across Figures 413 – 416 
appears largely unchanged, which implies that the blocking merely affects uptake of the GNP-
Fol-Pt(IV) system and thus the quantity of Pt(IV)LipA agent that is delivered to the cell. It 
would appear that the localisation of the Pt(IV)LipA agent is unchanged, implying that the 
method of uptake is independent on the subsequent production of active agents and induced 
cytotoxicity.  
 
4.5.3. Flow Cytometry (Fluorescence Assisted Cell Sorting) 
Subsequent research sought to quantitatively assess the induced antibody signal of the 
GNP-Fol-Pt(IV) and GNP-Cit-Pt(IV) systems so as to accurately assess the impact of the 
systems across the cellular population, as opposed to qualitative assessment of isolated 
quadrants. Accordingly, FACS studies were conducted. For continuity, the same sample 
conditions employed for the confocal microscopy studies of section 4.5.2 were carried over.  
The samples of the present FACS studies are represented in Table 402.  
HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 
No Blocking With Receptor α Blocking 
Blank (not shown) - 
Pri + Sec Antibodies (AB) - 
Cisplatin + AB - 
Pt(IV)LipA + AB - 
GNP-Fol-Pt(IV) + AB GNP-Fol-Pt(IV) + AB 
GNP-Cit-Pt(IV) + AB GNP-Cit-Pt(IV) + AB 




The cell samples were identical to those of the previous confocal studies, with high folate 
receptor α expressing A549s seeded within 6 well plates and allowed to adhere overnight before 
being subjected to the appropriate conditions of table 402. The cells were subsequently washed 
with PBS before being tripsinised and fixed in suspension ready for permeabilisation and 
immunocytochemical staining (see experimental section 4.6.5 for full details). In order to 
preserve as much data as possible, the PBS washes of each sample were retained, pelleted and 
also subjected to immunocytochemical analysis, so as to allow for an analysis of the most 
severely damaged A549 cells and give an overall indication of population damage. Post 
sample-staining, the samples were washed and re-suspended multiple times to remove free 
reagents and subsequently analysed by FACS microscopy.  
 
Figure 417: FACS dot-plot data of forward scatter (particle size) vs side scatter (particle 
granularity) for the samples of Table 402 in high folate receptor α expressing A549 cells. A) 
Blank sample, b) Antibody control, c) Cisplatin, d) Pt(IV)LipA, e) GNP-Fol-Pt(IV), f) GNP-
Fol-PtIV)-Block, g) GNP-Cit-Pt(IV) and h) GNP-Cit-Pt(IV)-Block. The circled population 
represents gating of fragments, with the cited number representing the percentage of the 
population corresponding to healthy cells.  
a) b) c) d) 






Figure 418: FACS dot-plot data of forward scatter (particle size) vs FITC channel signal 
intensity (antibody emission intensity) for the samples of Table 402 in high folate receptor α 
expressing A549 cells. A) Blank sample, b) Antibody control, c) Cisplatin, d) Pt(IV)LipA, e) 
GNP-Fol-Pt(IV), f) GNP-Fol-PtIV)-Block, g) GNP-Cit-Pt(IV) and h) GNP-Cit-Pt(IV)-Block. 
“Antibody Calibrated” represents cells with FITC channel fluorescence equal to or greater than 
the strongest emission of the antibody control sample (upper limit of non selective binding). 
Any signal therefore should represent cisplatin-DNA conjugate FITC fluorescence signal. 
Associated statistics are tabulated beneath within the FACS analysis software and are 
represented again later in Table 403. 
 
a) b) c) d) 




Figure 419: FACS Histogram data of FITC channel signal for the “Antibody Calibrated” sub-
population of the samples of Table 402 in high folate receptor α expressing A549 cells. A) 
Blank sample, b) Antibody control, c) Cisplatin, d) Pt(IV)LipA, e) GNP-Fol-Pt(IV), f) GNP-
Fol-PtIV)-Block, g) GNP-Cit-Pt(IV) and h) GNP-Cit-Pt(IV)-Block.  
 
 
a) b) c) d) 




Figure 420: FACS Overlay histogram data of FITC channel signal for the “Antibody 
calibrated” sub-population of the samples of Table 402 in high folate receptor α expressing 
A549 cells. A) Overlay of GNP-Fol-Pt(IV) and GNP-Fol-Pt(IV)-Block; b) Overlay of GNP-
Cit-Pt(IV) and GNP-Cit-Pt(IV)-Block; c) Overlay of GNP-Fol-Pt(IV) and GNP-Cit-Pt(IV); 














SAMPLES EVENTS % OF SAMPLE MEAN MEDIAN 
Blank 1 0.01 45.6 45.6 
Antibodies Control 41 0.41 55.0 46.9 
Cisplatin 142 1.42 51.2 42.5 
Pt(IV)LipA 180 1.8 49.6 42.6 
GNP-Fol-Pt(IV) 8254 82.5 129.0 119.1 
GNP-Fol-Pt(IV)-Block 7210 72.1 107.0 102.1 
GNP-Cit-Pt(IV) 7573 75.7 81.8 77.2 
GNP-Cit-Pt(IV)-Block 7129 71.3 77.8 73.3 
Table 403: Statistical data drawn from FACS histogram plots of samples a)-h) of Figure 419.  
 
A number of potential observations can be drawn from the FACS data collected for the above 
A549 immunocytochemical studies. Upon review of Figures 417 and 418 there appears to be 
an increase in DNA damage induced FITC signal within the nanoparticle samples (e – h) over 
cisplatin (c) and Pt(IV)LipA alone (d). More particularly, Figure 418 represents dot-plot data 
for the samples of Table 402, plotting FITC channel signal (antibody fluorescence intensity) 
against forward scatter (cell size), having already been gated to remove fragments (as 
represented in Figure 417). The “Antibody Calibrated” sub-population of the dot-plots 
represents the threshold for false positive fluorescence signal and therefore identifies the 
minimal fluorescence required for data points to be considered representative of DNA-
Cisplatin adduct induced antibody fluorescence signal. Accordingly, any particles displaying a 
FITC intensity above this threshold fall within the “Antibody Calibrated” sub-culture. 
Therefore, simple visual comparison of the plots shows that cisplatin (c) and Pt(IV)LipA (d) 
show significantly less particles beyond the DNA damage antibody signal threshold vs all of 
the nanoparticle samples (e – h, ~70-80% total sample difference). As noted, Figure 417 
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represents dot-plot data of forward scatter (particle size) vs side scatter (particle granularity) 
and therefore shows the standard distribution of the data cloud for samples a)-h).  
 
Figure 419 represents histogram plots of the data collected for samples a) – h), showing the 
distribution of particles displaying FITC channel fluorescence which exceeds the Antibody 
Calibrated threshold. This data, in combination with the histogram-overlay data of Figure 420 
and statistics of Table 403, better represents the relationship of the DNA damage with respect 
to the different samples. In this regard, from overlay-histogram A) (overlap of plots e) and f) 
of Figure 418) it appears that there is a decrease in the overall population displaying FITC 
fluorescence above the threshold for samples treated with GNP-Fol-Pt(IV) vs GNP-Fol-Pt(IV)-
Block. More particularly, when A549 cells are treated with GNP-Fol-Pt(IV) in the presence of 
folate receptor blocking there is a 13% decrease in the number of events (8254 vs 7210), a 17 
% reduction in the mean fluorescence intensity (129.0 vs 107.0) and a 14% reduction in the 
median fluorescence intensity (119.0 vs 102.0). This data therefore appears to agree with the 
hypothesis (and prior research detailed herein) that blocking the folate receptors leads to a 
reduction in the uptake of GNP-Fol within high folate receptor α expressing A549s, which in 
turn, leads to a reduction in cytotoxic events.  
 
 Upon review of overlay-histogram B) (overlap of plots g) and h) of Figure 418) it also appears 
that there is no clear relationship between nanoparticle loading with the GNP-Cit-Pt(IV) system 
in the presence of folate receptor α blocking in A549s. More particularly, when A549 cells are 
treated with GNP-Cit-Pt(IV) in the presence of folate receptor blocking there is a 4% decrease 
in the number of events (7573 vs 7129), a 3% reduction in the mean fluorescence intensity 
(81.8 vs 77.8) and a 5% reduction in the median fluorescence intensity (77.2 vs 73.3). This data 
therefore appears to agree with the hypothesis (and prior research detailed herein) that blocking 
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the folate receptors leads to no significant change in the uptake of GNP-Cit within high folate 
receptor α expressing A549s.  
 
Overlay histogram C) compares the particle distribution for GNP-Fol-Pt(IV) vs GNP-Cit-
Pt(IV) within the FITC channel beyond the threshold (plots e) and g) of Figure 418). From this 
overlay histogram and the accompanying statistics it is shown that the GNP-Fol-Pt(IV) system 
displays 10% more events (8254 events vs 7573 respectively), 37% higher mean fluorescence 
intensity (129.0 vs 81.8 respectively) and 35% higher median fluorescence intensity (119.0 vs 
77.2 respectively) over the GNP-Cit-Pt(IV) system within the high folate receptor α expressing 
A549 cells. The same trend (albeit with different statistics) is observable for the blocked GNP-
Fol-Pt(IV) system over the blocked GNP-Cit-Pt(IV) system.  
 
Accordingly, from the above FACS studies it is further hypothesised that the GNP-Fol-Pt(IV) 
system displays increased cisplatin-DNA adduct formation over cisplatin, Pt(IV)LipA alone 
and the GNP-Cit-Pt(IV) system in high folate receptor α expressing A549 cells. Through 
comparing the above data, as well as the confocal data or earlier studies, it appears that folate 
receptor blocking has an affect on GNP-Fol system uptake, thus indicating that folate receptor 
mediated uptake plays a key role in uptake of the system. The GNP-Cit system appears to either 
operate independently of folate receptor α or with a lesser dependence on said receptor 
mediated uptake.  
 
4.5.4. ICPMS 
Following the immunocytochemical confocal and FACS microscopy studies detailed 
herein, subsequent research sought to identify and quantitatively assess the cellular localisation 
of the sample components within A549 cells. In particular, it was an objective of the research 
188 
 
to quantify the localisation of gold salt and platinum species within the whole cell, cytosol and 
nucleus. Accordingly, Inductively Coupled Plasma Mass Spectrometry (ICPMS) was utilised, 
assessing the localisation of such components with high folate receptor α expressing A549 cells 
that have been dosed with the samples as per Table 404. For continuity, the same concentrations 
and dosing protocols were employed as per the previous studies (see experimental section 4.6.6 
for full details). ICPMS data for these samples is represented in Figures 421 to 424 below.  
 
HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 
No Blocking With Receptor α Blocking 
a) Blank  - 
b) Cisplatin  - 
c) Pt(IV)LipA  - 
d) GNP-Fol-Pt(IV) f) GNP-Fol-Pt(IV) 
e) GNP-Cit-Pt(IV) g) GNP-Cit-Pt(IV) 
Table 404: Overview of samples submitted for ICPMS. A549s were seeded onto 6 well plates 
and allowed to adhere overnight. Samples were then dosed with 25µM anti-cancer agent either 
alone (Cisplatin (b) and Pt(IV)LipA (c)) or as part of a nanoparticle system, loaded onto either 






Figure 421: Graphical representation of the total number of gold nanoparticles on average per 
whole cell of samples d) to g) of Table 404. Expectedly, significantly fewer GNP-Fol centres 
are present upon blocking the folate receptors (36 vs 12). Unexpectedly, more GNP-Cit cores 
were found on average in the presence of folate receptor blocking.  
 
Figure 422: Graphical representation of the total number of platinum centres on average per 







































































Figure 423: Graphical representation of the total number of platinum centres on average per 
cytosol of A549 cells dosed as per samples b) to g) of Table 404. 
 
Figure 424: Graphical representation of the total number of platinum centres on average per 


























































































Figure 425: Graph comparing the Pt uptake statistics represented across Figures 422-424.  
 
 Upon review of the above ICPMS studies, the data of Figure 421 suggests that, in line with 
prior data and present hypotheses, blocking of folate receptor α with primary antibody leads to 
reduced levels of GNP-Fol uptake. Statistically, 64% less GNP-Fol particles were delivered to 
each cell upon receptor blocking (36 GNPs per cell without blocking vs 13 GNPs with 
blocking). However, in contrast to prior studies, the ICPMS data of Figure 421 shows an 
increased level of cellular uptake of GNP-Cit upon blocking of folate receptor α. Prior studies 
implied comparable levels of uptake, with comparable fluorescent probe emission and 
cytotoxic effects. It is hypothesised that this may be as a result of folate receptor blocking, 
forcing an alternative mechanism of uptake to be exaggerated for GNP-Cit particles.  
Alternatively, this may be a mere anomaly and may not be apparent upon experimental repeats. 
Further studies shall therefore be required in order to ascertain the appropriate conclusion in 






























ICPMS Comparison of Pt Distribution
N.O Pt centres per Cell
N.O Pt centres per Cytosol
N.O Pt centres per Nuclei
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Figure 422 represents the Pt centre data recorded by ICPMS for the average whole cell for 
samples b) to g) of Table 404. In line with prior cytotoxicity and immunocytochemical studies, 
there is less Pt present for the cisplatin sample (b) vs the Pt(IV)LipA sample (c) in the whole 
A549s, displaying 81% less Pt respectively (250,000 vs 1,300,000 centres). The level of Pt 
delivered to the cell is higher for each of the GNP-Fol and GNP-Cit systems over the 
Pt(IV)LipA system, with the unblocked GNP-Fol-Pt(IV) system displaying the most Pt 
(1,800,000) and the blocked GNP-Fol-Pt(IV) system forming the minimum (1,450,000). 
Accordingly, the blocked A549 cell sample dosed with GNP-Fol-Pt(IV) shows 19% less Pt 
present within the whole cell than the unblocked sample. In line with prior studies, levels of Pt 
present for the blocked and unblocked GNP-Cit samples are comparable, ranging by 9% 
(1,700,000 and 1,500,000 respectively). 
 
The data of Figure 423 represents some unexpected results in relation to the levels of Pt in the 
cytosol of the A549 cells corresponding to samples b) to g) of Table 404. As expected, the level 
of Pt present in cells dosed with Pt(IV)LipA is higher than that for cisplatin, displaying 48% 
more Pt centres (350,000 centres vs 190,000 centres respectively). Another aspect which is as 
expected is the higher level of Pt present for the unblocked GNP-Fol-Pt(IV) system vs blocked, 
displaying 29% more Pt centres (250,000 centres vs 180,000 centres  respectively). However, 
unexpectedly, the free Pt(IV)LipA system displayed  higher levels of Pt within the cytosol of 
the cells than all of the Nanoparticle based systems, with 21% more Pt than the closest NP 
system (GNP-Cit-Pt(IV)-Blocked, 280,000 centres). It is hypothesised that the figure for Pt 
present in the cytosol of the sample for the nanoparticle samples is inherently low due to the 
method of fractioning the cellular samples prior to ICPMS analysis. In this regard, a cellular 
fractioning kit was used to extract the appropriate components of the cell for analysis (see 
experimental section 4.6.6 for full details). In brief, the sample undergoes a centrifugation step 
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with an appropriate lysing agent to separate out the cytosol from the nucleus, which is 
subsequently re-suspended and decanted for digestion. However, it was noted at this point 
during the fractionation that the cellular pellet did re-suspend, but the nanoparticle pellet did 
not. Accordingly, it is highly likely that the Pt centre measurements for the nanoparticle 
samples of the cytosol are only representative of free Pt and not nanoparticlely bound Pt, which 
may have been removed with a proportion of the nanoparticles. Thus, a large proportion of the 
Pt present is not recorded. This theory is also supported by the inconsistency between the 
combination of nuclear and cytosolic quantities not correlating approximately to whole cell 
quantities.  
 
The data of Figure 424 displays a similar trend to the cytosolic data, with GNP-Fol-Pt(IV) 
displaying more nuclear Pt centres than the GNP-Cit-Pt(IV) system, but free Pt(IV)LipA 
displaying increased Pt than all other samples. The nanoparticle anomaly of the cytosolic Pt 
does not apply for this metric, as it would only ever be free Pt that is found within the nucleus. 
This statistic is therefore in contradiction to the quantitative antibody studies as per the FACS 
data herein, which suggests that free Pt(IV)LipA leads to less DNA damage than nanoparticle 
bound Pt(IV)LipA. It is therefore hypothesised that whilst the free Pt(IV)LipA system delivers 
more Pt to the nuclei of the cells, the nanoparticle systems still present with greater DNA 
damage as a result of their method of delivery. More particularly, it is assumed that the free 
Pt(IV)LipA complex is modified and digested by the cell, altering its structure and reducing its 
toxicity or method of interaction with the DNA. In comparison, the nanoparticle systems 
obviate these modifications and deliver the intended structure of the Pt(IV)LipA complex. 
Therefore, less Pt centres are delivered, but more Pt is delivered as the Pt(IV)LipA complex, 
thus leading to increased levels of DNA damage. This theory of course needs significant 
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experimental follow up in order to ascertain the structures that reach the nuclei of the cells, as 
well as repeats of the studies reported herein so as to enable statistical analysis of the data.  
 
4.6. Conclusions 
A novel Pt(IV) complex was synthesised and it’s potential as an anti-cancer agent 
investigated. The Pt(IV)LipA complex comprises a lipoic acid ligand and therefore features the 
ability to surface functionalise gold nanoparticle systems. Accordingly, the cytotoxicity of the 
novel Pt(IV) agent was investigated as free agent and when loaded onto folate capped and 
citrate capped gold nanoparticle systems. The levels of cisplatin-DNA adducts formed for the 
Pt(IV) agent (both as a free agent and as part of nanoparticle systems) were also compared to 
those formed for cisplatin in a dosing routine for cisplatin resistant A549 cells. 
 
MTT assays have identified that the Pt(IV)LipA complex presents with a greater cytotoxicity 
than cisplatin, both as a free agent and when loaded onto nanoparticles. The most potent form 
is when the agent is loaded onto folate capped gold nanoparticles, likely as a result of high 
levels of folate receptor mediated endocytosis. This latter point was proven through folate 
receptor positive and negative studies, via media manipulation and utilisation of folate receptor 
α blocking. DNA adduct formation was measured via immunocytochemistry, using a 
commercial antibody labelled with an alexa fluor 488 dye. The GNP-Fol-Pt(IV)LipA system 
displayed greater levels of uptake (ICPMS data) and levels of DNA-adduct formation 
(fluorescence in confocal microscopy and flow cytometry studies) over the GNP-Cit-
Pt(IV)LipA system and cisplatin free agent. Greatest levels of damage and uptake were 
afforded to the GNP-Fol-Pt(IV)LipA system in the unblocked folate receptor positive A549 






Compound 401:  cis,cis,trans[PtCl2(NH3)2(OH)2(CH3CONH)] 
 
Compound 401 was prepared as per the synthetic procedure of Pelosi et al.1.  
A mixture of acetonitrile (10 mL) and of 30% hydrogen peroxide (1.666 mL) was stirred for 
30 min at 25°C. Cisplatin (0.33 mmol, 100 mg) was added to this mixture and the resulting 
suspension was stirred for 5 min. Methanol (5 mL) was then added and the reaction mixture 
was stirred at room temperature for 24 h. The resulting pale yellow precipitate was separated 
by centrifugation (6000rpm, 30 minutes) and was washed with diethyl ether. Yield: 85% (106 
mg). Characterisation agrees with that of the literature. δH (300 MHz; CDCl3); 1.89 (1H, s, H-
4), 5.02 (2H, m, H-3,1), 3.81-6.25 (6H, m, NH3). m/z (ES); [M-H2O]
+ 358, [M+2Na-3H]+ 418.  
 
Compound 402:  cis,cis,trans[PtCl2(NH3)2(HOOC(CH2)2COO)(CH3CONH)] 
 
Compound 402 was prepared as per the synthetic procedure of Pelosi et al.1.  
cis,cis,trans[PtCl2(NH3)2(OH)2(CH3CONH)] (0.11 mmol, 40 mg) was suspended in DMF 
(4mL) at 50°C. After 5 min succinic anhydride (1.07 mmol, 107 mg) was added. The reaction 
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mixture was stirred at 50°C until complete dissolution of the suspended solid (about 3 h). The 
solution was then allowed to cool, the solvent removed under reduced pressure and the residue 
triturated with diethyl ether. Yield: 38mg, (73%). Characterisation agrees with that of the 
literature. δH (300 MHz; CDCl3); 1.96 (3H, s, H-1), 2.38-2.48 (2H, m, H-5), 2.49-2.58 (2H, m, 
H-4), 5.15 (1H, s, NH), 6.30-6.62 (6H, m, NH3). m/z (ES); [M-H]
- 473,474,476 (Isotope 
splitting pattern).  
 
Compound 403:  c,c,t-[Pt(NH3)2(Cl)2(OH)2] 
 
Various methods were attempted for the synthesis of compound 403, however the most 
successful was that of Huan Liu et al.15 with modifications.  
cis-Pt(NH3)2Cl2 (40 mg, 0.13 mmol) and H2O2 (30% wt/vol, 1.5 mL, 50.0 mmol) were 
dissolved in H2O (2 mL) and heated at 70°C, under nitrogen, with vigorous stirring for 5 h in 
the dark. After allowing the solution to cool to room temperature gradually, the solution was 
left in the fridge overnight to precipitate the insoluble product, c,c,t-Pt(NH3)2Cl2(OH)2 (40mg, 
92%) which was obtained from filtration. Characterisation agrees with that of the literature. δH 
(300 MHz; CDCl3); Solubility prevents clear characterisation (also noted in literature). m/z 




Compound 404:  Lipoic Anhydride 
 
Lipoic anhydride was prepared as per the synthetic procedure of Andrzej Sadownik, James 
Stefely and Steven L. Regen16. Characterisation agrees with that of the literature. 
A solution of α-lipoic acid (0.1g, 0.5mmol) and dicyclohexylcarbodiimide (0.065g, 0.3mmol) 
was stirred in 2 mL of dry DCM for 24 hours at room temperature under a nitrogen atmosphere. 
The product mixture was filtered in order to remove the urea which had formed. No yield 
determined as the product is an anhydride and should not be isolated. IR; 1735, 1805 
(Anhydride) and lack of 1701 (Acid). m/z (ES); [M+Na]+ 417.  
 
Compound 405:  c,c,t-[Pt(NH3)2(Cl)2(O2C(CH2)4C3H5S2)2] 
 
Compound 405 was prepared via a modification to a method outlined by Dhar et al.2.  
c,c,t-[Pt(NH3)2Cl2(OH)2] (5mg, 1.5x10
-5mol) in DMSO (2 mL) was heated to 50°C for 10 
minutes until all suspended material was in solution. Lipoic Anhydride (135µL of a 
0.0525gmL-1 solution, 1.8x10-5mol) was then added and the reaction mixture was stirred at 
50°C under N2 for 24 hours. Upon cooling to room temperature, the reaction mixture was 
centrifuged at 6000rpm for 30 minutes to pellet the insoluble product. The product was 
collected by suction filtration and washed with acetonitrile.  
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c,c,t-[Pt(NH3)2(Cl)2(O2C(CH2)4C3H5S2)2] was yielded as a pale yellow crystalline powder 
(0.5mg, 5%). δH (300 MHz; CDCl3); No data available (solubility issues). 
m/z (ES); [M+Na]+ 733. 
 
Compound 406:  cis,cis,trans[PtCl2(NH3)2(HOOC(CH2)4C3H5S2)(CH3CONH)] 
 
Pt(IV)LipA was prepared via a modification to a method outlined by Pelosi et al.1. 
cis,cis,trans[PtCl2(NH3)2(OH)2(CH3CONH)] (0.12mmol, 45 mg) was suspended in DMF 
(1.5mL) at 50°C. After 5 min Lipoic anhydride (~4 mmol) was added. The reaction mixture 
was stirred at 50°C for 72 hours. The solution was then allowed to cool, the solvent removed 
under reduced pressure and the residue triturated with diethyl ether. Yield: 46mg, (70%). 
δH (400 MHz; CDCl3); 1.43 (2H, m, H-6), 1.55 (2H, m, H-5), 1.59 (1H, m, H-7’), 1.70 (1H, m, 
H-7), 1.92 (1H, m, H-9’), 1.99 (3H, s, H-1), 2.23 (2H, m, H-4), 2.48 (1H, m, H-9), 3.16 (1H, 
m, H-10’), 3.19 (1H, m, H10), 3.61 (1H, m, H-8), 5.32 (1H, s, NH), 6.33-6.80 (6H, m, NH3). 
δc (100 MHz; CDCl3); 24.5 (a), 25.7 (e), 28.8 (f), 34.7 (g), 36.7 (d), 38.3 (j), 40.2 (i), 56.7 (h), 
176.4 (b) and 181.6 (c). m/z (ES); [M-H]+ 563,564,566 (Isotope splitting pattern).  
 
4.7.2. Reduction Capabilities – CD Spectroscopy 
CD Spectroscopy was utilised to ascertain the DNA binding capabilities of Pt(IV)LipA, 
employing a protocol adapted from Dr Lois Bright (former PhD member of the Hannon group). 
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Calf-thymus DNA (ct-DNA) was purchased from Sigma Aldrich. DNA stock solutions were 
made up in ultrapure water (18.2 MΩ). CD spectra were obtained for the solutions utilising a 
quartz cuvette with a 1 cm path-length. A 98µM solution of CT DNA in NaCl (20mM), Na 
cacodylate and Milli Q water (to 1mL) was employed. 145µL of a 300µM solution of either 
Pt(IV)LipA or cisplatin was added and the solution gently agitated for 10 minutes. The CD 
spectrum was subsequently recorded. Following this addition, Ascorbic Acid (20µL, 1mM) 
was added to the Pt(IV)LipA sample and the solution gently agitated for a further 10 minutes. 
Alterations to the fingerprint region of CT DNA are indicative of DNA binding.  
 
4.7.3. Nanoparticle Loading Studies 
The loading potential of Pt(IV)LipA onto the GNP-Fol and GNP-Cit systems was conducted 
as per the ruthenium probe titration experiments of section 2.3.2.  
Fresh solutions of GNP-Fol and GNP-Cit were prepared as per section 2.3.2 and UV-Vis 
absorption spectra were collected for titration of a 1mg/mL Pt(IV)LipA stock solution into 1mL 
of either 1nM GNP-Fol or 1mL of 1nM GNP-Cit. Titration volumes of Pt(IV)LipA were varied 
to give incremental increases in µg Pt(IV) added as opposed to traditional mmol added. Each 
system was dialysed overnight in a semi permeable membrane (Spectra-Por® Float-A-Lyzer® 
G2, 5 mL, MWCO 8-10 kDa) in deionised water to remove unreacted reagents. The systems 
then had their concentrations roughly calculated via UV-Vis and the stronger system diluted to 
the same concentration as the weaker system (~1nM) before being carried forward for cellular 
studies.  
 
4.7.4. MTT Assays 




High folate receptor α expressing A549 cells were seeded into 96 well plates (8000 cells per 
well in 200µL supplemented RPMI media) and allowed to adhere overnight. 12 sample wells 
were allocated to each condition. Fresh 1mg/mL stock solutions of Pt(IV)LipA (in 90:10 
ethanol and DMSO) and cisplatin (in water) were prepared, along with fresh solutions of GNP-
Fol, GNP-Cit and GNP-Fol-Pt(IV) and GNP-Cit-Pt(IV). Pt loaded nanoparticle systems were 
prepared as 12.5, 25 and 50µM Pt solutions in 100µL of ~1nM GNPs. Old media was removed 
from the 96 well plates using a multi-channel pipette and each well was washed with PBS 
(100µL) to remove dead cells and residual media. The wells were subsequently treated as per 






20µL of a 5 mg/mL MTT solution in PBS was added to each well, excluding one set of control 
wells, and incubated for two hours. The medium was carefully removed by aspiration from all 
wells and 200µL DMSO was subsequently added per well to dissolve the purple formazan. The 
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plates were incubated for a further 20 minutes before the absorbance was measured at 590 nm 
using a microplate reader (BioRad).  
 
4.7.5. Fixed Cell Immunocytochemistry 
Cell Culture 
High folate receptor α expressing A549s were cultured and maintained as per section 3.8.5.  
 
Nanoparticle Preparation 
Fresh batches of GNP-Fol and GNP-Cit were synthesised as per section 2.3.2 and were 
subsequently loaded with 25µM YoungPt(IV) (14µL of a 1mg/mL stock solution) and purified 




Cover slips were washed in 70% ethanol and rinsed with PBS before being stuck to the bottom 
of each well of 12 well plates. These dishes were allowed to dry for 1 hour before being seeded 
with high folate receptor α expressing A549s (400,000 cells per well) and incubated overnight 
to adhere. These coverslip samples were utilised for confocal microscopy studies, plain 6 well 
plates were utilised for flow cytometry studies. 
 
 The following samples were prepared: 
HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 




Secondary Antibody Only - 
Pri + Sec Antibodies (AB) - 
Cisplatin + AB - 
Pt(IV)LipA + AB - 
GNP-Fol-Pt(IV) + AB GNP-Fol-Pt(IV) + AB 
GNP-Cit-Pt(IV) + AB GNP-Cit-Pt(IV) + AB 
 
Fixed Cell Confocal Immunocytochemical Studies 
The fixation and mounting of samples was conducted via an adapted protocol provided by Dr 
Lucia Cardo on 29th March 2017.  
The 12 well plates were removed from the incubator and the old media aspirated from the wells. 
The wells were washed with PBS (1mL) to remove dead cells and residual media. Each well 
was then treated with either 500µL of ~1nM GNP-Fol / Cit loaded with 25µM Pt(IV)LipA, 
25µM Pt(IV)LipA alone or 25µM cisplatin alone, each of which made up to 1mL in fresh 
supplemented RPMI media. The folate receptor blocking samples were previously blocked for 
one hour with folate receptor α primary antibody as per section 3.8.7. The samples were 
subsequently returned to the incubator and incubated on a plate rocker for 18 hours. The plates 
were then removed, old media gently removed and the cells gently washed with PBS (2 x 1mL) 
to remove unbound reagents and free nanoparticles. The cells were subsequently fixed in 
formalin (500µL, 10% solution) for 10 minutes at room temperature. Formalin was removed 
and the cells washed with PBS (3 x 1mL), before being permeabilised with 0.1% Triton X-100 
(0.5mL) for 10 minutes at room temperature. Triton was removed and the cells washed with 
PBS (3 x 1mL), before being blocked with 10% normal goat serum (0.5mL) at room 
temperature for 1 hour. Goat serum was removed and the cells were dosed with anti-cispltin 
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modified antibody (CP9/19) at room temperature for two hours (500µL of a 2µg/mL solution 
in 10% normal goat serum). The primary antibody was removed and the coverslips washed 
with 1% goat serum (5 x 1mL). Cells were then dosed with secondary antibody (500µL of a 
2µg/mL solution in 10% goat serum) for 1 hour at room temperature in the dark. Cells were 
rinsed with 1% goat serum (5 x 1mL) and the nuclei stained with Hoechst (500µL of a 5µg/mL 
solution in 1% goat serum) for 10 minutes at room temperature. The coverslips were washed 
with 1% goat serum (1mL x 5), then dipped in PBS before being mounted onto microscope 
slides with a drop of mounting medium.  
 
Fixed Cell Flow Cytometry Studies 
The utilised fixed cell FACS protocol was adapted from the published protocol of Cell 
Signaling Technology17. 
Cells were dosed with the appropriate samples as per the above confocal studies. The 6 well 
plates were then removed from the incubator, old media removed and the cells washed with 
PBS (1mL). The cells were then tripsinised (1mL tripsin 1X for 5 mins in an incubator) and 
collected with fresh RPMI media (1mL), cells were collected into 2mL Eppendorf’s. The cells 
were pelleted at 1500rpm for 5 mins and the supernatant discarded. The cells were then re-
suspended in 1mL 10% formalin, vortexed and fixed at 37°C for 10 minutes. The samples were 
chilled on ice for 1 minute, then centrifuged at 1500rpm for 5 minutes to remove formalin. The 
pellets were re-suspended in 1mL of 90% ice cold methanol and kept on ice for 30 minutes to 
permeabilise them. 1mL incubation buffer (0.5g Bovine Serum Albumin (BSA) in 100mL 
PBS) was added and the cells centrifuged. The supernatant was removed and the cells re-
suspended in 1mL incubation buffer. This step was repeated three times. The cells were re-
suspended in primary antibody (500µL of a 2µg/mL solution in incubation buffer) and dosed 
for one hour at room temperature. The cells were centrifuged, the supernatant removed and the 
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pellets re-suspended in incubation buffer (1mL). This step was repeated three times. The cells 
were re-suspended in secondary antibody (500µL of a 2µg/mL solution in incubation buffer) 
for 30 minutes at room temperature in the dark. The cells were centrifuged, supernatant 
removed and re-suspended in incubation buffer (1mL). This step was repeated three times. The 
cells were then centrifuged, supernatant removed and re-suspended in 1mL PBS. The samples 
were then analysed by flow cytometry.  
 
Confocal Microscope Settings 
Blue Channel:  Excitation, 402nm Emission, 450-490 
Green Channel:  Excitation, 514nm Emission, 500-570nm 
Red Channel:   Excitation, 488nm Emission, 580-680nm 
 
4.7.6. ICPMS Studies 
The digestion stage of the below ICPMS protocol was adapted from protocols provided by Dr 
Lucia Cardo (Hannon research group, University of Birmingham) and Ms Siobhan King 
(Pikramenou research group, University of Birmingham), along with the recommended cell 
culture stage. No replicates were investigated in the present studies.  
 
Cell Culture 
High folate receptor alpha expressing A549 cells were seeded into seven T75 flasks (one flask 








The T75 flasks were dosed using the same protocol of 4.6.5, but with appropriately scaled 
reagents (approximately 7 x more cells present, therefore 7 x more nanoparticles / platinum 
agents used, maintaining 25µM final concentration) and alternative sample work up. 
HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 
No Blocking With Receptor α Blocking 
a) Blank  - 
b) Cisplatin  - 
c) Pt(IV)LipA  - 
d) GNP-Fol-Pt(IV) f) GNP-Fol-Pt(IV) 
e) GNP-Cit-Pt(IV) g) GNP-Cit-Pt(IV) 
 
Sample Work Up 
Old media / media containing the reagents of the above table was removed from the T75 flasks 
and the cells gently washed with PBS (5mL x 3) to remove unbound reagents / particles and 
residual media. The cells were tripsinised and pelleted as per section 3.8.5. The cells were then 
re-suspended in 2mL of PBS and counted using a haemocytometer. 1mL of each sample was 
pipetted into fresh 2mL falcon tubes, pelleted at 1500rpm for 5 minutes and supernatant 
removed. The whole cell pellet samples were immediately stored at -80°C ready for whole cell 
ICPMS analysis.  
 
Subsequent nuclear and cytosolic fractionation was conducted as per the protocol supplied with 
the BioVision Nuclear/Cytosol Fractionation Kit utilised.  
The remaining 1mL of suspended cells were chilled on ice for 1 minute and subsequently 
centrifuged at 4°C for 5 minutes at 600G. The PBS was removed and 0.2mL of Cytosol 
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Extraction Buffer A was added. The solutions were vortexed on the highest setting for 15 
seconds and were incubated on ice for 10 minutes. 11µL of ice cold Cytosol Extraction Buffer 
B was added and the solution vortexed for 5 seconds. The solutions were then centrifuged at 
4°C for 5 minutes at 16000G. The supernatant (cytoplasm fraction) was removed and 
immediately stored at -80°C ready for cytosolic ICPMS analysis.  
 
The remaining pellet was re-suspended in 100µL ice cold Nuclear Extraction Buffer mix and 
vortexed on the maximum setting for 15 seconds. The samples were stored on ice for 10 
minutes and this process was repeated four times. The samples were centrifuged at 16,000G, 
4°C for 10 minutes. The supernatant (nuclear fraction) was transferred to a fresh Eppendorf 
and immediately stored at -80°C, ready for ICPMS analysis.   
 
The resulting sample fractions (whole cell, nuclear and cytoplasm) were digested in a mixture 
of concentrated nitric acid (69%, 100µL) and freshly prepared aqua regia (3:1, HCl (32%) and 
HNO3 (69%) 100 µL). Samples were transferred to screw cap vials and incubated overnight at 
80 ºC in an oven to fully digest the metal particles and cells. Subsequently, the samples were 
diluted with milli-Q-water to a final acid concentration of ~2%. Samples were transferred to 
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Chapter 5 – Theranostic GNPs and Cellular Uptake 
5.1. Theranostic GNPs 
5.1.1. Theranostic GNP Concept  
It was a final objective of the present research to prepare and investigate the use of 
theranostic gold nanoparticle systems within high folate receptor α expressing cell lines. Two 
theranostic systems were conceptualised, synthesised and utilised, comprising; GNP-Fol, 
RuPhen imaging probe and Pt(IV)LipA (hereafter GNP-Fol-Theranos); and GNP-Cit, RuPhen 
imaging probe and Pt(IV)LipA (hereafter GNP-Cit-Theranos). The “thera”-peutic aspect of 
these two systems stems from the incorporation of the Pt(IV)LipA complex whilst the diag-
“nostic” aspect is fulfilled by incorporation of the ruthenium based RuPhen imaging probe. 
The general structure for these two theranostic systems is represented in Figure 501.  
 
Figure 501: Representation of the general structure of the two theranostic GNP systems of 
the present research; GNP-Fol-Theranos and GNP-Cit-Theranos. 
In principle, these particles should represent a class of cellular probes with active and passive 
targeting systems which facilitate fluorescence based cellular localisation studies in tandem 
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with cytotoxic activity studies. It was a continued objective of the present research to 
investigate the difference in cellular uptake of the folate capped GNP-Fol system in comparison 
to the citrate capped GNP-Cit system in high folate receptor α expressing A549s.  
 
5.1.2. Theranostic GNP Loading Studies 
Loading studies for the theranostic systems were conducted utilising the same protocol 
and reagent concentrations as employed in the prior RuPhen and Pt(IV)LipA loading studies 
(see experimental sections 2.2.2 and 4.4 respectively). In brief, 1mL each of ~1nM GNP-Fol 
and GNP-Cit were separately loaded with RuPhen (12µL of 1mM solution in titration 
increments of 4µL) and subsequently Pt(IV)LipA (28µL of a 1mg/mL solution in titration 
increments of 4µL) under constant stirring and with rounds of sonification post titration (5 
minutes each titration). The collective UV-Vis data for these loading studies is represented 




















GNP-Fol-Theranos Theranostic Loading Studies
GNP-Fol
GNP-Fol + 4uL RuPhen
GNP-Fol + 8uL RuPhen
GNP-Fol + 12uL RuPhen
GNP-Fol + 12uL RuPhen + 4uL Pt(IV)
GNP-Fol + 12uL RuPhen + 8uL Pt(IV)
GNP-Fol + 12uL RuPhen + 12uL Pt(IV)
GNP-Fol + 12uL RuPhen + 16uL Pt(IV)
GNP-Fol + 12uL RuPhen + 20uL Pt(IV)
GNP-Fol + 12uL RuPhen + 24uL Pt(IV)




Figure 502: UV-Vis absorption spectrum data for titration of a 1mM RuPhen stock solution 
and a 1mg/mL Pt(IV)LipA stock solution into 1mL of 1nM GNP-Fol, affording GNP-Fol-
Theranos. The RuPhen solution was titrated into the nanoparticle suspension prior to the 
Pt(IV)LipA solution. The SPR band λmax shifted by 2nm from 559nm to 561nm and the SPR 
band also shifted and narrowed from 477-621nm to 481-621nm. Shifting and narrowing of the 

























GNP-Fol-Theranos Theranostic Loading Studies
GNP-Fol
GNP-Fol + 4uL RuPhen
GNP-Fol + 8uL RuPhen
GNP-Fol + 12uL RuPhen
GNP-Fol + 12uL RuPhen + 4uL Pt(IV)
GNP-Fol + 12uL RuPhen + 8uL Pt(IV)
GNP-Fol + 12uL RuPhen + 12uL Pt(IV)
GNP-Fol + 12uL RuPhen + 16uL Pt(IV)
GNP-Fol + 12uL RuPhen + 20uL Pt(IV)
GNP-Fol + 12uL RuPhen + 24uL Pt(IV)





Figure 503: UV-Vis absorption spectrum data for titration of a 1mM RuPhen stock solution 
























GNP-Cit-Theranos Theranostic Loading Studies
GNP-Cit
GNP-Cit + 4uL RuPhen
GNP-Cit + 8uL RuPhen
GNP-Cit + 12uL RuPhen
GNP-Cit + 12uL RuPhen + 4uL Pt(IV)
GNP-Cit + 12uL RuPhen + 8uL Pt(IV)
GNP-Cit + 12uL RuPhen + 12uL Pt(IV)
GNP-Cit + 12uL RuPhen + 16uL Pt(IV)
GNP-Cit + 12uL RuPhen + 20uL Pt(IV)
GNP-Cit + 12uL RuPhen + 24uL Pt(IV)




















GNP-Cit-Theranos Theranostic Loading Studies
GNP-Cit
GNP-Cit + 4uL RuPhen
GNP-Cit + 8uL RuPhen
GNP-Cit + 12uL RuPhen
GNP-Cit + 12uL RuPhen + 4uL Pt(IV)
GNP-Cit + 12uL RuPhen + 8uL Pt(IV)
GNP-Cit + 12uL RuPhen + 12uL Pt(IV)
GNP-Cit + 12uL RuPhen + 16uL Pt(IV)
GNP-Cit + 12uL RuPhen + 20uL Pt(IV)
GNP-Cit + 12uL RuPhen + 24uL Pt(IV)
GNP-Cit + 12uL RuPhen + 28uL Pt(IV)
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Theranos. The RuPhen solution was titrated into the nanoparticle suspension prior to the 
Pt(IV)LipA solution. The SPR band λmax shifted by 2nm from 559nm to 561nm and the SPR 
band also shifted from 438-551nm to 439-552nm. Shifting of the SPR band is considered 
indicative of surface binding in the nanoparticle system. 
 
The UV-Vis titration data of Figures 502 and 503 (GNP-Fol and GNP-Cit systems respectively) 
show similar effects of nanoparticle loading with RuPhen and Pt(IV)LipA solutions across the 
systems. In each system, the SPR band λmax shifted by 2nm and the overall SPR band shifted 
upfield, which is typically representative of interaction of reagents with nanoparticle surfaces 
within the solutions. Unlike earlier loading studies, here the GNP-Fol system SPR band 
narrowed and the GNP-Cit system SPR band width was unchanged. These differences may be 
due to counteracting interactions of the two different reagents with the SPR band of the 
systems, but this shall require further research to ascertain.  
 
The concentration and titration limit of the Pt(IV)LipA stock solution employed in these 
nanoparticle loading studies was selected to give a final concentration of 25µM Pt(IV)LipA 
within the respective system (GNP-Fol-Theranos and GNP-Cit-Theranos). 25µM of the 
Pt(IV)LipA complex was selected to theoretically give the greatest cellular damage signal 
within the subsequent immunocytochemical studies whilst not inducing significant cell death 
i.e. balancing induced signal with lost signal. The concentration and titration limit of the 
RuPhen stock solution was selected to give theranostic nanoparticle systems that would 
theoretically present sufficient fluorescence for cellular tracking and imaging studies whilst not 




For continuity, the systems were dialysed for 24 hours in appropriately pH balanced deionised 
water (circa pH 9 for GNP-Fol and pH 7 for GNP-Cit) within microporous dialysis tubing to 
remove the majority of any unbound Pt(IV)LipA and RuPhen prior to investigating size and 
stability. Further research should be conducted following this stage of the particle preparation, 
using ICPMS to ascertain the quantities of the reagents which may now still be bounds to the 
particles. This data would also help to compliment the aforementioned surface loading studies 
conducted using UV-Vis spectroscopy.  
 
The solutions were subsequently sonicated for 10 minutes and filtered through a cotton plug to 
remove precipitated material. It was not possible to record accurate particle sizing data via DLS 
studies due to some precipitation of the Pt(IV)LipA complex within the solutions. DLS sizing 
data for the GNP-Cit-Theranos system was particularly non-representative due to the surface 
surfactant Zonyl FSA, which is known within the Pikramenou group to cause sizing artefacts. 
Accordingly, the samples were sized by Transmission Electron Microscopy (TEM), these 




Figure 504: TEM images collected for the GNP-Fol-Theranos system later utilised for cellular 
studies. Size calculated as ~17nm ±2nm. Sample images recorded by Theresa Morris,  




Figure 505: TEM images collected for the GNP-Cit-Theranos system later utilised for cellular 
studies. Size calculated as ~14nm ±2nm. Sample images recorded by Theresa Morris,  
Centre for Electron Microscopy, University of Birmingham.  
 
The TEM images of Figures 504 and 505 show that the average size of the GNP-Fol-Theranos 
and GNP-Cit-Theranos systems were ~17nm ±2nm and ~14nm ±2nm respectively, which 
correlates with an approximately equal increase in size going from the respective original 
nanoparticle systems. It was also evident from the TEM images that the GNP-Fol-Theranos 
system appeared to show greater agglomeration of particles than the GNP-Cit-Theranos 
system, although this may be an artefact resulting from the TEM sample preparation.  
 
After fresh formation of the above theranostic systems, the systems were qualitatively analysed 
for changes in stability over a 5 day period, observing changes in the colour of solution and 
presence of visible aggregates. It was noted that the systems displayed no visible change over 
four days, but on the fifth day the GNP-Fol-Theranos solution was starting to turn purple, which 
is considered to be an early indication of agglomeration / aggregation of the systems. These 
findings therefore suggest that the GNP-Fol-Theranos system is less stable than the GNP-Cit-
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Theranos system and that said systems should be utilised within 1-2 days of formation. 
Accordingly, the theranostic systems were prepared as above and utilised within subsequent 
cellular studies within 12 hours of their formation to obviate complications associated with 
particle stability.  
 
5.2. Fixed Cell Confocal Immunocytochemistry Studies 
The therapeutic and tracking capabilities of the GNP-Fol-Theranos and GNP-Cit-
Theranos systems were subsequently analysed by Immunocytochemical studies (qualitative 
analysis) and FACS analysis (quantitative). For continuity, the protocol employed for the 
immunocytochemical studies of the GNP-Fol-Pt(IV) and GNP-Cit-Pt(IV) systems was adapted 
and utilised (see experimental section 5.5.3).  
 
In brief: high folate receptor α expressing A549 cells were seeded onto coverslips within 6 well 
plates and cultured for 24 hours; samples were then either incubated with appropriate solutions 
for 24 hours or had their media changed and incubated for a further 24 hours (as represented in 
Table 501) on a plate rocker; samples were subsequently washed, fixed and permeabilised, 
prior to staining with appropriate CP9/19 antibodies and Hoechst. As before, these 
immunocytochemistry studies were conducted on fixed cells that had been subsequently 
permeabilised to allow influx of the appropriate antibody.  
 
The fixed cell confocal microscopy images for the samples of Table 501 are represented in 
Figures 506-511. Confocal images were collected as two separate z-stack profiles utilising the 
same z stack coordinates so as to ensure no bleed through of nuclear signal from the blue 
channel (Hoechst) into the green channel (DNA antibody). Accordingly, the brightfield, green 
(antibody signal, DNA adducts) and red (RuPhen signal, nanoparticle localisation) channels 
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were collected in one setting and the blue channel (Hoechst signal, nuclear stain) was collected 
in a separate setting, ensuring complete signal overlap and homogeneity across the z stack 
profile. The range of the z-stack profile was set using the brightfield channel, selecting the 
bottom and top of the cells within the focal field, ensuring collection of data across the entire 
cell. The blank and antibody only images were employed to calibrate the microscope to account 
for and obviate recording false-positive signal.  
 
HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 
No Blocking With Receptor α Blocking 
Blank (not shown) - 
Figure 506 - Secondary Antibody Only - 
Figure 507 – Pri + Sec Antibodies (AB) - 
Figure 508 - GNP-Fol-Theranos + AB Figure 510 - GNP-Fol-Theranos + AB 
Figure 509 - GNP-Cit-Theranos + AB Figure 511 - GNP-Cit-Theranos + AB 




Figure 506: Fixed cell immunocytochemistry confocal studies of high folate receptor α 
expressing A549 cells that have been stained with the secondary antibody bearing Alexa-Fluor 
488 only, illustrating false-positive fluorescence signal. A) in focus plane of the brightfield 
channel; B) average Hoechst signal across the Z stack; C) average DNA-damage antibody 
signal across the Z stack and D) overlay of all channels. No signal was observable within the 







Figure 507: Immunocytochemical confocal studies of high folate receptor α expressing A549 
cells that have been stained with primary and secondary antbodies, illustrating false-positive 
signal. A) in focus plane of brightfield channel; B) average Hoechst signal across Z stack; C) 
average DNA-damage antibody signal across Z stack, D) overlay of b and c and E) overlay of 








Figure 508: Immunocytochemistry confocal studies of high folate receptor α expressing A549 
cells dosed with GNP-Fol-Theranos (1ml of ~1nM GNP-Fol loaded with 25µM Pt(IV)LipA 
and 12µL of 1mM RuPhen) for 24 hours and stained with CP9/19 / secondary antibody. A) in 
focus plane of brightfield channel; B) average Hoechst signal across Z stack; C) average DNA-
damage signal across Z stack, D) average RuPhen signal across Z stack; E) overlay of b and c; 









Figure 509: Immunocytochemistry confocal studies of high folate receptor α expressing A549 
cells dosed with GNP-Cit-Theranos (1ml of ~1nM GNP-Cit loaded with 25µM Pt(IV)LipA 
and 12µL of 1mM RuPhen) for 24 hours and stained with CP9/19 / secondary antibody. A) in 
focus plane of brightfield channel; B) average Hoechst signal across Z stack; C) average DNA-
damage signal across Z stack, D) average RuPhen signal across Z stack; E) overlay of b and c; 









Figure 510: Immunocytochemistry confocal studies of high folate receptor α expressing A549 
cells pre-dosed with folate receptor α primary antibody for receptor blocking and subsequently 
dosed with GNP-Fol-Theranos (1ml of ~1nM GNP-Fol loaded with 25µM Pt(IV)LipA and 
12µL of 1mM RuPhen) for 24 hours and stained with CP9/19 / secondary antibody. A) in focus 
plane of brightfield channel; B) average Hoechst signal across Z stack; C) average DNA-
damage signal across Z stack, D) average RuPhen signal across Z stack; E) overlay of b and c; 









Figure 511: Immunocytochemistry confocal studies of high folate receptor α expressing A549 
cells pre-dosed with folate receptor α primary antibody for receptor blocking and subsequently 
dosed with GNP-Cit-Theranos (1ml of ~1nM GNP-Cit loaded with 25µM Pt(IV)LipA and 
12µL of 1mM RuPhen) for 24 hours and stained with CP9/19 / secondary antibody. A) in focus 
plane of brightfield channel; B) average Hoechst signal across Z stack; C) average DNA-
damage signal across Z stack, D) average RuPhen signal across Z stack; E) overlay of b and c; 









Confocal Microscopy Results Discussion 
A number of comparisons can be drawn from these fixed cell immunocytochemical confocal 
microscopy studies by qualitative analysis of Figures 506 to 511. Firstly, it appears that pre-
blocking folate receptors with folate receptor alpha monoclonal antibody leads to a decrease in 
RuPhen probe signal (red) and DNA-damage antibody signal (green) within high folate 
receptor α expressing A549 cells treated with GNP-Fol-Theranos (Figure 508 vs 510, 
unblocked vs blocked). For both signals (images c and d of the respective figures) there is a 
reduction in both fluorescence intensity and signal distribution. This agrees with the previous 
studies of sections 4.4.2. and 3.7, which indicate that pre-blocking folate receptors with the 
antibody leads to reduction in DNA damage and RuPhen signal respectively. Reduction in 
these signals is potentially indicative of reduced nanoparticle uptake and therefore reduced 
nanoparticle delivery of therapeutic (Pt(IV)LipA) and diagnostic (RuPhen) agents. 
Interestingly, the DNA-damage antibody signal of the GNP-Fol-Theranos system samples 
appears to be more localised to the nuclei of the cells than previous studies (GNP-Fol-Pt(IV), 
section 4.4.2.2), potentially with less mitochondrial DNA damage.  
 
By comparison, there is no readily observable difference in DNA-damage antibody signal or 
RuPhen signal across the GNP-Cit-Theranos samples, irrespective of folate receptor blocking 
(Figures 509 and 511). This is in agreement with previous studies (sections 4.4.2.2 and 3.7) 
and is potentially the result of the lack of uptake of the citrate based nanoparticle system by 
folate receptor α. Accordingly, if the GNP-Cit-Theranos system is taken up independently of 





A second observation is that it is not readily apparent whether the GNP-Fol-Theranos system 
(unblocked, Figure 508) gives increased nanoparticle uptake and cellular delivery of reagents 
over the GNP-Cit-Theranos system (unblocked, Figure 509). In particular, there is no readily 
observable difference between the signal intensity or distribution of the DNA-damage antibody 
signal (images c, e, g and h) or the RuPhen signal (images d, f, g and h) for the two samples. 
This might therefore indicate that the folate receptor system does not provide an increased level 
of uptake of GNP-Fol-Thernaos over the other pathways afforded to the GNP-Cit-Theranos 
system, or that the difference between the uptake of the two systems is negligible over a 
concentrated 24 hour dosing period. This result is in contrast to the findings of sections 4.4.2. 
and 3.7, and was investigated further by FACS and ICPMS for quantitative analysis and review.  
 
A third observation is that there appears to be a greater level of non-specific DNA-antibody 
binding within the GNP-Cit-Theranos samples (Figures 509 and 511) over the GNP-Fol-
Theranos samples (Figures 508 and 510). In particular, images c, e, g and h of Figures 509 and 
511 show that there is a lot of seemingly non-cellular based green fluorescence, which would 
imply that there was a greater amount of unbound fluorophore washed out of the cells or stuck 
to the cover slips. It is unknown why this would be more likely to happen for the GNP-Cit-
Theranos system samples over the GNP-Fol-Thernos system samples, however, it would 
appear that the same is observable within the receptor blocking study GNP-Fol sample (Figure 
510). This could be coincidental, and that it merely fortuitous that the non-receptor blocking 
GNP-Fol-Thernaos sample did not exhibit non-cellular based antibody signal. Alternatively, 
there could be a link between the folate receptor mediated endocytosis leading to more targeted 
delivery of reagents, which in turn leads to greater DNA damage, which increases the relative 
percentage of the antibodies used to stain the sample that bind appropriately, which therefore 
reduces the levels of free antibody available for non-specific binding. 
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A final observation is that there appears to be some nuclear localisation of the RuPhen probe 
across the theranostic particle samples. This is discussed further with respect to ICPMS studies 
later, however, RuPhen signal within the nuclei of the cells might indicate that the theranostic 
nanoparticular system is potentially unstable and might be releasing the probe within the cells 
upon uptake. This theory is somewhat reinforced by the studies of Chapter 3, wherein the cells 
were dosed with free RuPhen probe and no signal was readily apparent, indicating free probe 
does not get into the probe itself in sufficient concentrations to give a viewable signal. 
However, as part of a nanoparticular system, the probe may enter in larger quantities whilst 
bound and potentially subsequently dissociate from the particle surface. This theory shall of 
course require repeated studies of the above confocal microscopy experiments in collaboration 
with flow cytometry and ICPMS studies in order to fully ascertain the likelihood of particle 
degradation.  
 
5.3. Flow Cytometry Studies 
FACS analysis was utilised to quantitatively compare the induced antibody signal and 
associated RuPhen signal of the cell samples. For continuity, the same protocol and conditions 
were employed from the previously reported studies of Sections 3.7.2 and 4.5.3.  The samples 
of the present FACS studies are represented in Table 502.  
HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 
No Blocking With Receptor α Blocking 
Blank - 
Pri + Sec Antibodies (AB) - 
Cisplatin + AB - 
Pt(IV)LipA + AB - 
GNP-Fol-Theranos + AB GNP-Fol-Theranos + AB 
GNP-Cit-Theranos + AB GNP-Cit-Theranos + AB 
Table 502: Overview of fixed cell Fluorescence-Activated Cell Sorting (FACS) samples.   
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The cell samples were identical to those of the confocal studies (section 5.2), with high folate 
receptor α expressing A549 cells seeded within 6 well plates (400,000 cells per well, no cover 
slips) and allowed to adhere overnight before being subjected to the appropriate conditions of 
table 502 for 24 hours (Experimental section 5.5.3). The cells were subsequently washed with 
PBS before being tripsinised and fixed in suspension ready for permeabilisation and 
immunocytochemical staining (See Experimental section 5.5.3 for full details). Post sample-
staining, the samples were washed, centrifuged and re-suspended multiple times to remove free 
reagents and were subsequently analysed by FACS microscopy.  
 
 
Figure 515: FACS dot-plot data of forward scatter (particle size) vs side scatter (particle 
granularity) for the samples of Table 502 in high folate receptor α expressing A549 cells. A) 
Blank sample, b) Antibody control, c) Cisplatin, d) Pt(IV)LipA, e) GNP-Fol-Theranos, f) GNP-
Fol-Theranos-Block, g) GNP-Cit-Theranos and h) GNP-Cit-Theranos-Block. The circled 
population represents gating of fragments, with the cited number representing the percentage 
of the population corresponding to healthy cells.  
 
a)   b)       c)      d) 





Figure 516: FACS dot-plot data of forward scatter (particle size) vs FITC channel signal 
intensity (antibody emission intensity) for the samples of Table 502 in high folate receptor α 
expressing A549 cells. A) Blank sample, b) Antibody control, c) Cisplatin, d) Pt(IV)LipA, e) 
GNP-Fol-Theranos, f) GNP-Fol-Theranos-Block, g) GNP-Cit-Theranos and h) GNP-Cit-
Theranos-Block. “Antibody Calibrated FITC” represents cells with FITC channel fluorescence 
equal to or greater than the strongest emission of the antibody control sample (upper limit of 
non selective binding). Any signal therefore should represent cisplatin-DNA conjugate FITC 
fluorescence signal. Associated statistics are tabulated beneath within the FACS analysis 
software and are represented again later in Table 503. 
 
 
a)   b)       c)      d) 





Figure 517: FACS dot-plot data of forward scatter (particle size) vs red channel signal intensity 
(Ruphen emission intensity) for the samples of Table 502 in high folate receptor α expressing 
A549 cells. A) Blank sample, b) Antibody control, c) Cisplatin, d) Pt(IV)LipA, e) GNP-Fol-
Theranos, f) GNP-Fol-Theranos-Block, g) GNP-Cit-Theranos and h) GNP-Cit-Theranos-
Block. “Antibody Calibrated RuPhen” represents cells with RuPhen channel fluorescence 
equal to or greater than the strongest red channel emission of the antibody control sample 
(theoretically removing any potential signal bleedthrough). Any signal therefore should 
represent RuPhen induced fluorescence signal. Associated statistics are tabulated beneath 
within the FACS analysis software and are represented again later in Table 504. 
 
 
e)   f)       g)      h) 





Figure 518: FACS Histogram data of FITC channel signal for the “Antibody Calibrated FITC” 
sub-population of the samples of Table 502 in high folate receptor α expressing A549 cells. A) 
Blank sample, b) Antibody control, c) Cisplatin, d) Pt(IV)LipA, e) GNP-Fol-Theranos, f) GNP-
Fol-Theranos-Block, g) GNP-Cit-Theranos and h) GNP-Cit-Theranos-Block. The nanoparticle 
histograms (e-h) have been standardised to an intensity of 450 to allow for representative 
overlay. 
 
a)   b)       c)      d) 




Figure 519: FACS Overlay histogram data of FITC channel signal for the “Antibody 
Calibrated FITC” sub-population of the samples of Table 502 in high folate receptor α 
expressing A549 cells. a) Overlay of GNP-Fol-Theranos and GNP-Fol-Theranos-Block; b) 
Overlay of GNP-Cit-Theranos and GNP-Cit-Theranos-Block; c) Overlay of GNP-Fol-




a)      b)  
   
c)      d)  




Figure 520: FACS Histogram data of RuPhen channel signal for the “Antibody Calibrated 
RuPhen” sub-population of the samples of Table 502 in high folate receptor α expressing A549 
cells. A) Blank sample, b) Antibody control, c) Cisplatin, d) Pt(IV)LipA, e) GNP-Fol-
Theranos, f) GNP-Fol-Theranos-Block, g) GNP-Cit-Theranos and h) GNP-Cit-Theranos-
Block. The nanoparticle histograms (e-h) have been standardised to an intensity of 350 to allow 
for representative overlay. 
 
e)   f)       g)      h) 




Figure 521: FACS Overlay histogram data of RuPhen channel signal for the “Antibody 
Calibrated RuPhen” sub-population of the samples of Table 502 in high folate receptor α 
expressing A549 cells. a) Overlay of GNP-Fol-Theranos and GNP-Fol-Theranos-Block; b) 
Overlay of GNP-Cit-Theranos and GNP-Cit-Theranos-Block; c) Overlay of GNP-Fol-










a)      b)  
   
c)      d)  




PT(IV)LIPA SIGNAL  
(ANTIBODY CALIBRATED FITC SUB-CULTURE) 
SAMPLES EVENTS % OF SAMPLE MEAN MEDIAN 
Blank 1 0.01 45.6 45.6 
Antibodies Control 41 0.41 55.0 46.9 
Cisplatin 124 1.24 51.3 42.5 
Pt(IV)LipA 180 1.80 49.6 42.6 
GNP-Fol-Theranos 8028 80.3 76.6 72.7 
GNP-Fol-Theranos-Block 7412 74.1 78.6 74.3 
GNP-Cit-Theranos 7228 72.3 104 98.7 
GNP-Cit-Theranos-Block 7695 77.0 99.3 92.2 
Table 503: Statistical data from the FACS histogram plots of samples a)-h) of Figure 518, 
corresponding to the FITC channel measurements (Antibody Calibrated FITC signal).  
 
RUPHEN SIGNAL  
(ANTIBODY CALIBRATED RUPHEN SUB-CULTURE) 
SAMPLES EVENTS % OF SAMPLE MEAN MEDIAN 
Blank 351 3.51 13.4 11.2 
Antibodies Control 40 0.4 14.1 10.5 
Cisplatin 35 0.35 12.4 10.4 
Pt(IV)LipA 595 5.95 11.9 10.8 
GNP-Fol-Theranos 6746 67.5 15.8 13.5 
GNP-Fol-Theranos-Block 4950 49.5 15.8 12.6 
GNP-Cit-Theranos 5300 53.0 15.2 12.6 
GNP-Cit-Theranos-Block 2990 29.9 15.4 11.3 
Table 504: Statistical data from the FACS histogram plots of samples a)-h) of Figure 520, 
corresponding to the red channel measurements (RuPhen Signal) from the Antibody Calibrated 




DNA Damage Analysis (FITC Channel Data) 
A number of observations can be made from the FACS data of Figures 515 to 519 and Table 
503. In line with the Pt(IV) studies of Section 4.4.3, it appears upon review of Figures 515 and 
518 that there is an increase in DNA damage induced FITC signal within the theranostic 
nanoparticle samples (e – h) over cisplatin (c) and Pt(IV)LipA alone (d). More particularly, 
Figure 516 represents dot-plot data for the samples of Table 502, plotting FITC channel signal 
(antibody fluorescence intensity) against forward scatter (cell size). The “Antibody Calibrated 
FITC” sub-population of the dot-plots represents the threshold for false positive fluorescence 
signal and therefore identifies the minimal fluorescence required of the subsequent samples to 
be considered representative of DNA-Cisplatin adduct induced antibody fluorescence signal. 
Accordingly, any particles displaying FITC intensity above this threshold fall within the 
“Antibody Calibrated FITC” sub-culture. Comparison of the plots shows that cisplatin (c) and 
Pt(IV)LipA (d) show less particles beyond the DNA damage antibody signal threshold vs each 
of the theranostic nanoparticle samples (e – h).  
 
Figure 518 represents histogram plot data collected for samples a) – h), showing the distribution 
of particles displaying FITC channel fluorescence which exceeds the false-positive threshold 
(data points within the Antibody Calibrated FITC signal sub-culture). This data, in combination 
with the histogram-overlay data of Figure 519 and statistics of Table 503 better illustrate the 
relationship of DNA damage with the respective samples.  
 
From review of overlay-histogram A) (overlap of plots e) and f) of Figure 518) there appears 
to be no significant change in the severity of induced DNA damage for samples treated with 
GNP-Fol-Theranos irrespective of folate receptor α blocking. Numerically, when A549 cells 
are treated with GNP-Fol-Theranos in the presence of folate receptor blocking there is an 8% 
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decrease in the number of events (8028 vs 7412), a 2% increase in the mean fluorescence 
intensity (76.6 vs 78.6) and a 2% increase in the median fluorescence intensity (72.7 vs 74.3). 
This data therefore contradicts the present assumption (and prior research detailed herein) that 
blocking folate receptor α leads to a much larger reduction in cellular damage induced by the 
nanoparticle system. Interestingly, whilst this data shows that there is a reduction in the uptake 
of GNP-Fol-Theranos system upon blocking α folate receptors (~8%), there is no readily 
observable equivalent reduction in the severity of the cytotoxic events (corresponding to signal 
intensity, which actually increases for the blocked sample).  
 
One possible explanation for this observation is that the GNP-Fol-Theranos system might now 
be an unstable system (as previously discussed), and that the levels of Pt(IV)LipA bound to the 
particles within the system now vary. Accordingly, even if more particles are taken up, this 
may not subsequently lead to elevated levels of DNA adduct formation (FITC signal). 
  
Upon review of overlay-histogram B) (overlap of plots g) and h) of Figure 518) it would also 
appear that there is no clear relationship between nanoparticle loading with the GNP-Cit-
Theranos system irrespective of folate receptor α blocking in A549s. Numerically, when A549 
cells are treated with GNP-Cit-Theranos in the presence of folate receptor blocking there is a 
6% increase in the number of events (7228 vs 7695), a 5% reduction in the mean fluorescence 
intensity (104 vs 99.3) and a 7% reduction in the median fluorescence intensity (98.7 vs 92.2). 
This data therefore appears to agree with the hypothesis (and prior research detailed herein) 
that there is no induced trend in uptake of GNP-Cit-Theranos within high folate receptor α 
expressing A549s upon blocking the folate receptors. This might be because the citrate based 
system is more stable than the folate based system, or it might be a coincidence. Further 
experimental runs and repeats will therefore need to be performed across all of those reported 
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herein so as to appropriately explore whether these results are reproducible, especially with 
subsequent ICPMS studies to fully ascertain the stability of the folate and citrate systems.  
 
Overlay histogram C) compares the uptake of GNP-Fol-Theranos vs GNP-Cit-Theranos and 
the induced DNA damage severity (FITC channel) within the Antibody Calibrated FITC sub-
population (plots e) and g) of Figure 518). Upon review of this overlay histogram and the 
accompanying numerical data it would seem that the GNP-Fol-Theranos system displays 10% 
more events (8028 vs 7228 respectively), 35% lower mean fluorescence intensity (76.6 vs 104 
respectively) and 35% lower median fluorescence intensity (72.7 vs 98.7 respectively) than the 
GNP-Cit-Theranos system within the high folate receptor α expressing A549 cells. As 
represented in overlay histogram D) (overlay of plots f) and h) of Figure 118), the same trend 
is observable for the folate receptor α blocked samples of the respective systems, with all 
numerical data being lower for the GNP-Fol-Theranos system.  
 
It is proposed that this further potentially indicates a stability issue within the folate capped 
theranostic system over the citrate system. Again, this will need further research as triplicate 
experiments and sample replicates so as to allow for a more complete assessment of the results.   
 
RuPhen Distribution Analysis (Red Channel Data) 
Antibody Calibrated RuPhen Sub-Culture 
The red channel signal data of the above studies is represented in Figures 520 to 523, with 
associated statistics represented in Table 504. Figures 520 and 521 represent red channel 
fluorescence data for cells within samples a)-h) of Table 502 which exhibit a fluorescence 
intensity beyond that of the antibody control sample, these data points fall  within the 
“Antibody Calibrated RuPhen” sub-culture and the associated numerical data is recorded in 
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Table 504. This sub-culture was chosen for initial investigation so as to reduce the likelihood 
of signal bleed-through from the antibody fluorophore. It would appear upon review of the 
above data that there is little measurable signal within the red channel for samples a) to d) 
within this “Antibody Calibrated RuPhen” sub-culture (samples: blank, control, cisplatin and 
Pt(IV)LipA respectively). This result is anticipated, given that samples a) to d) contain no red 
channel emissive components. This data appears to confirm that the selection of the sub-culture 
was successful in minimising false positive recordings of cells that would display elevated red-
channel signal due to signal bleed-through from the primarily green channel emissive 
secondary antibody, as opposed to elevated uptake of RuPhen bearing nanoparticles.  
 
The overlay histogram data of Figure 521 and statistics of Table 504 for samples e) to h) are 
more comparable to the results reported for the FITC channel data as above. When A549 cells 
are treated with GNP-Fol-Theranos in the presence of folate receptor blocking, there is a 27% 
decrease in the number of events (6746 vs 4950), no change is observable in the mean 
fluorescence intensity (both 15.8) and a 7% reduction in the median fluorescence intensity 
(13.5 vs 12.6). This data therefore shows that the number of particles with fluorescence signal 
above the threshold is reduced upon blocking (indicative of less uptake), whilst the intensity is 
comparable. It would therefore appear that this data suggests that upon blocking, fewer 
particles do get taken up by the majority of the cells, but for the cells which do still take the 
particles up, there is a comparable RuPhen signal. This is somewhat different to the earlier 
studies, where reduction in events also lead to a reduction in signal intensity. This might then 
support the hypothesis that the folate based system is unstable. 
 
Overlay-histogram B) (overlap of plots g) and h) of Figure 520) appears to show that a similar 
relationship exists for nanoparticle loading with the GNP-Cit-Theranos system. When A549 
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cells are treated with GNP-Cit-Theranos in the presence of folate receptor blocking there is a 
43% decrease in the number of events (5300 vs 2990), a 1% increase in the mean fluorescence 
intensity (15.2 vs 15.4) and an 11% reduction in the median fluorescence intensity (12.6 vs 
11.3). This data therefore appears to contradict the present hypothesis that folate receptor 
blocking has no significant effect on uptake of the citrate based nanoparticle system.  
 
Moreover, overlay histogram C) compares the uptake of GNP-Fol-Theranos vs GNP-Cit-
Theranos and the induced RuPhen signal (plots e) and g) of Figure 520). From this overlay 
histogram data and the accompanying  numerical data, it appears that the GNP-Fol-Theranos 
system displays 22% more events (6746 vs 5300 respectively) than the GNP-Cit-Theranos 
system, with 4% higher mean fluorescence intensity (15.8 vs 15.2 respectively) and 7% higher 
median fluorescence intensity (13.5 vs 12.6 respectively), within the high folate receptor α 
expressing A549 cells. As represented in overlay histogram D) (overlay of plots f) and h) of 
Figure 520), the same trend is observable for the folate receptor α blocked samples of the 
respective systems.   
 
This data therefore suggests that the GNP-Fol-Theranos system is more widely taken up by the 
A549 cells than the GNP-Cit-Theranos system, thus why there is a greater number of events 
(particles displaying fluorescence above the threshold). However, given that the intensity of 
the fluorescence within those cells is comparable, this would suggest a comparable level of 
uptake of the two systems within those cells which do display appropriate levels of probe 
emission. Alternatively, there could be different levels of uptake and therefore different levels 
of RuPhen probe present between the two samples / cultures, but this signal is not conveyed as 
there is no measurable difference in afforded signal intensity and number of RuPhen complexes 
present. Lastly, as hypothesised above, these results might come as a consequence of the GNP-
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Fol system now being relatively unstable. As noted, further experiments will need conducting 
so as to fully explore this area of research.  
 
 Overview of Studies and Findings 
From the above FACS studies it is hypothesised that the GNP-Fol-Theranos system displays 
increased cisplatin-DNA adduct formation over cisplatin and Pt(IV)LipA alone, but with 
comparable levels to the GNP-Cit-Theranos system in high folate receptor α expressing A549 
cells. Contradicting data was retrieved for the RuPhen signal studies of the present FACS 
analysis. The data of this FACS analysis therefore contradicts the previous hypothesis and 
evidence set forth in confocal and cytotoxicity studies. The contradictory data might therefore 
indicate some inconsistencies with nanoparticle loading with reagents or that the folate capped 
theranostic system is now unstable. For more reliable quantitative data, ICPMS was conducted 
for the present theranostic systems to ascertain trends in nanoparticle uptake and cellular 
delivery of reagents. As noted, further experiments are essential within these studies so as to 





5.4. ICPMS Studies 
Following the immunocytochemical confocal and FACS microscopy studies detailed 
herein, subsequent research sought to quantify and assess the localisation of gold salt, 
ruthenium probe and platinum species within the whole cell, cytosol and nucleus of the A549 
cells dosed with the GNP-Fol-Theranos and GNP-Cit-Theranos systems. Accordingly, ICPMS 
was conducted for samples of high folate receptor α expressing A549 cells that have been dosed 
as per Table 506 (for continuity, the same concentrations and dosing protocols were employed 
as per section 5.5.4). ICPMS data for these samples is represented in Figures 525 to 531 below.  
 
HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 
No Blocking With Receptor α Blocking 
a) Blank  - 
b) Cisplatin  - 
c) Pt(IV)LipA  - 
d) GNP-Fol-Theranos f) GNP-Fol-Theranos 
e) GNP-Cit-Theranos g) GNP-Cit-Theranos 
Table 506: Overview of samples submitted for ICPMS. A549s were seeded onto 12 well plates 
(0.1 x 106 cells) and allowed to adhere overnight. Samples were then dosed with 25µM anti-
cancer agent either alone (Cisplatin (b) and Pt(IV)LipA (c)) or with the theranostic  
nanoparticle systems, either 0.5mL of ~1nM GNP-Fol (samples d and f) loaded with 
Pt(IV)LipA (28µL of a 1mg/mL stock) and RuPhen (12µL of a 1mM stock) or 0.5mL of ~1nM 





Figure 525: Graphical representation of the total number of gold nanoparticles on average per 
whole cell of samples d) to g) of Table 506. Expectedly, fewer GNP-Fol centres are present 
upon blocking the folate receptors (47 vs 13). Comparable levels of GNP-Cit cores were found 
































Figure 526: Graphical representation of the total number of platinum centres on average per 
whole cell of samples b) to g) of Table 506. 
 
Figure 527: Graphical representation of the total number of platinum centres on average per 









































































Figure 528: Graphical representation of the total number of platinum centres on average per 



























































ICPMS Comparison of Pt Distribution
N.O Pt centres per Cell
N.O Pt centres per Cytosol




Figure 530: Graphical representation of the total number of ruthenium centres on average per 
whole cell of samples b) to g) of Table 506. 
 
Figure 531: Graphical representation of the total number of ruthenium centres on average per 



































































Figure 532: Graph comparing the Ru uptake statistics represented across Figures 530-531.  
 
ICPMS Results Discussion 
The data of Figure 525 suggests that, in line with prior data and present hypotheses, the 
blocking of folate receptor α with primary antibody leads to reduced levels of GNP-Fol uptake, 
with 73% less GNPs being delivered to the cell (47 GNPs per cell vs 13). In contradiction to 
the ICPMS studies of section 4.4.4, and in line with the present hypothesis, there appears to be 
no significant effect on uptake of GNP-Cit with receptor blocking (23 and 24 particles on 
average respectively). This supports the previous conclusion that the contradictory nanoparticle 
data of section 4.4.4 was likely as a result of a handling error.  
 
Figure 526 represents the Pt centre data recorded by ICPMS for the average whole cell for 





























ICPMS Comparison of Ru Distribution
N.O Ru centres per Cell
N.O Ru centres per Cytosol
248 
 
there is less Pt present per cell for the cisplatin sample (b) vs the Pt(IV)LipA sample (c) in the 
whole A549s, displaying 81% less Pt respectively. The unblocked GNP-Fol system was the 
only nanoparticle system to deliver more Pt to the whole cell than the free Pt(IV)LipA sample. 
The blocked GNP-Cit system displayed comparable levels of Pt within each cell, irrespective 
of blocking (varying by just 1%), which is in alignment with the nanoparticle uptake data. The 
blocked A549 cell sample dosed with GNP-Fol-Theranos shows 30% less Pt present within the 
whole cell than the unblocked sample.  
 
The data of Figure 527 shows the same trend across the nanoparticle samples, with reduction 
in cytosolic Pt upon blocking for the GNP-Fol-Theranos system (19%) and comparable levels 
for the GNP-Cit-Theranos system (ranging by 8%). However, much the same as the ICPMS 
studies of 4.4.4, there is more cytosolic Pt for the free Pt(IV)LipA sample than for the 
nanoparticle samples (73% more in comparison to the closest nanoparticle system). As per 
section 4.4.4, it is hypothesised that the figure for Pt present in the cytosol of the sample for 
the nanoparticle samples is inherently low due to the method of fractioning the cellular samples 
prior to ICPMS analysis. In brief, it is likely that the Pt centre measurements for the 
nanoparticle samples of the cytosol are only representative of free Pt and not nanoparticlely 
bound Pt, thus, a large proportion of the Pt present is not recorded. The same can be said in this 
regard for the Ruthenium statistics of Figure 531.  
 
The data of Figure 528 displays the same trend as the cytosolic data, with GNP-Fol-Theranos 
displaying more nuclear Pt centres than all other systems, but free Pt(IV)LipA displaying 
increased Pt than the remaining nanoparticular systems. The nanoparticle anomaly of the 
cytosolic Pt does not apply for this metric, as it would only ever be free Pt that is found within 
the nucleus. Thus, it is evident from the studies that there is more Pt delivered to the nuclei of 
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the cells via the unblocked GNP-Fol-Theranos system over all other systems. As per section 
4.4.4, it is hypothesised that whilst the free Pt(IV)LipA system delivers more Pt to the nuclei 
of the cells, the nanoparticle systems still present with greater DNA damage as a result of their 
method of delivery. More particularly, it is assumed that the free Pt(IV)LipA complex has been 
modified and digested by the cell, reducing its toxicity or method of interaction with the DNA. 
In comparison, the nanoparticle systems might obviate these modifications and therefore 
potentially present less Pt as a whole, but more as effective complexes.  
 
In contrast to the above Pt based studies, the Ru ICPMS data present with contradictory data. 
Figure 530 represents the Ru centre data recorded by ICPMS for the average whole cell for 
samples b) to g) of Table 506.  In line with prior confocal and flow cytometry studies, there is 
less Ru present per cell for the blocked GNP-Fol-Theranos sample (f) in comparison to the 
unblocked GNP-Fol-Theranos syample (d) in A549s, displaying 18% less Ru respectively. 
This difference is however more marginal than for all other studies. Whilst the GNP-Fol-
Theranos samples (d) did present with greater levels of Ru than the GNP-Cit-Theranos samples 
(e), this was again a smaller difference than observed across other studies, showing a 22% 
reduction. Another curious point is that the Ru data of the GNP-Cit-Theranos system appears 
to have been impacted by receptor blocking, with the blocked sample (g) giving 22% less Ru 
than the unblocked sample (e).  
 
Moving on from this whole cell data, Figure 531 represents the Ru centre data recorded by 
ICPMS for the average cytosol for samples b) to g) of Table 506.  Here, there is less Ru present 
for the GNP-Fol-Theranos samples (d) than all others. Moreover, the GNP-Cit-Theranos 
samples present with the greatest amount of Ru. Both systems display greater levels of Ru upon 
receptor blocking. This data therefore contradicts all hypothesis and the above data for the 
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whole cell Ru. Two theories are put forward in this regard. Firstly, this data might be erroneous 
and simply require repeats. Secondly, it might be possible that much the same as the Pt studies, 
the process of fractioning the cellular samples into the cytosolic and nuclear components could 
have played a role in this data. More particularly, as noted, it was observed that during 
centrifugation of the cellular components to give the suspended cytosolic fractions there was a 
nanoparticle pellet formed. This pellet likely comprised of nanoparticles that were still surface 
functionalised with Pt and Ru. Accordingly, the cytosolic measures for Ru might be a more 
accurate representation of dissociated Ru, as opposed to the number of nanoparticles that are 
present and have Ru bound. This second proposition would then account for the contradictory 
levels of Ru measured in the cytosol vs the whole cell for the samples. Moreover, this would 
then agree with the confocal and flow cytometry data, as well as the ICPMS data which 
indicates the greater presence of GNPs for the folate based system over the citrate system in 
the whole cell A549 samples. Lastly, as previously noted, it is possible that the folate capped 
nanoparticles are no longer stable as a theranostic system. This might then lead to differences 
in Ru and Pt in the fractionations depending upon the levels of the nanoparticle system 
degradation across the samples. Repeats shall be required across these studies to fully 
investigate this further, whilst also allowing for a statistical analysis of the data.  
 
5.5. Conclusions 
Theranostic folate capped and citrate capped gold nanoparticle systems were produced 
in the present studies by surface functionalisation with Pt(IV)LipA and RuPhenSS. These two 
theranostic systems were proven to be stable over a 5-day period in isolation and were carried 




Confocal microscopy and flow cytometry studies showed that the GNP-Fol-Theranos system 
displayed comparable levels of induced cisplatin-DNA adducts than the GNP-Cit-Theranos 
system through immunocytochemistry studies. The folate capped gold nanoparticles also 
presented with comparable or less ruthenium probe emissions and a greater spread of the probe 
throughout the samples over the citrate capped gold nanoparticles. This trend was not readily 
apparent upon folate receptor competition / blocking with a folate receptor α polyclonal 
antibody within the GNP-Cit-Theranos samples. This is therefore potentially indicative of 
greater levels of GNP-Fol uptake over the GNP-Cit system as a result of folate receptor 
mediated endocytosis within A549 cells. Contradictory findings were therefore found and 
further experimentation is required, with triplicate experimental repeats as well as triplicate 
sample repeats.  
 
ICPMS studies of these theranostic nanoparticle systems presented with some contradicting 
data. In agreement with previous studies, there was greater levels of Au found for the GNP-
Fol-Theranos samples over GNP-Cit-Theranos, with this difference being reduced upon folate 
receptor blocking. The same trend was carried over for Pt studies, showing greater levels of Pt 
present in the whole cell, cytoplasm and nucleus for the GNP-Fol-Theranos system over the 
GNP-Cit-Theranos system. This data suggests that the GNP-Fol-Theranos system presents 
with greater levels of cellular uptake than the GNP-Cit-Theranos system in the absence of 
folate receptor blocking in A549s. However, there was no trend observable for Ru centres, with 








5.6.1. Nanoparticle Loading Studies 
The loading potential of RuPhen and Pt(IV)LipA onto the GNP-Fol and GNP-Cit 
systems was conducted as per the ruthenium probe titration experiments of section 2.3.2 and 
platinum agent loading experiments of section 4.6.3.  
Fresh solutions of GNP-Fol and GNP-Cit were prepared as per section 2.3.2 and UV-Vis 
absorption spectra were collected for titration of a 1mM RuPhen solution followed by a 
1mg/mL Pt(IV)LipA stock solution into 1mL of either ~1nM GNP-Fol or 1mL of ~1nM GNP-
Cit. Each nanoparticle system was loaded with the RuPhen probe first in incrementl titrations, 
followed by the Pt(IV)LipA agent. Each system was dialysed overnight in a semi permeable 
membrane (Spectra-Por® Float-A-Lyzer® G2, 5 mL, MWCO 8-10 kDa) in deionised water to 
remove unbound reagents. The systems then had their concentrations roughly calculated via 
UV-Vis and the stronger system diluted to the same concentration as the weaker system (~1nM) 
before being carried forward for cellular studies.  
 
5.6.2. TEM Sample Preparation 
TEM samples were prepared via pipetting 10-20µL of the appropriate nanoparticle 
sample onto TEM grids and allowing to dry at room temperature underneath a glass petri dish 
to prevent dust accumulation. Care was taken not to touch the grids via utilisation of tweezers. 
Sample grids were transferred to a grid holder and immediately submitted to Theresa Morris 
of the Centre for Electron Microscopy, University of Birmingham, for storage and or imaging.  
 
5.6.3. Fixed Cell Immunocytochemistry Studies 
Cell Culture 





Fresh batches of GNP-Fol and GNP-Cit were synthesised as per section 2.3.2, loaded with 
RuPhen (12µL of a 1mM solution) and 25µM YoungPt(IV) (14µL of a 1mg/mL stock solution) 
and were subsequently purified ready for cell culture experiments as per section 5.5.1. 
 
Dosing Protocol 
Cover slips were washed in 70% ethanol and rinsed with PBS before being stuck to the bottom 
of each well of 12 well plates. These dishes were allowed to dry for 1 hour before being seeded 
with high folate receptor α expressing A549s (400,000 cells per well) and incubated overnight 
to adhere. These coverslip samples were utilised for confocal microscopy studies, plain 6 well 
plates were utilised for flow cytometry studies. 
 
The following samples were prepared: 
HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 
No Blocking With Receptor α Blocking 
Blank - 
Secondary Antibody Only - 
Pri + Sec Antibodies (AB) - 
Cisplatin + AB - 
Pt(IV)LipA + AB - 
GNP-Fol-Theranos + AB GNP-Fol-Theranos + AB 






Fixed Cell Confocal Immunocytochemical Studies 
The fixation and mounting of samples was conducted via an adapted protocol provided by Dr 
Lucia Cardo on 29th March 2017 and as carried over from section 4.6.5.  
 
The 12 well plates were removed from the incubator and the old media aspirated from the wells. 
The wells were washed with PBS (1mL) to remove dead cells and residual media. Each well 
was then treated with either 500µL of ~1nM GNP-Fol-Theranos or GNP-Cit-Theranos, 25µM 
Pt(IV)LipA alone or 25µM cisplatin alone, each of which made up to 1mL in fresh 
supplemented RPMI media. The folate receptor blocking samples were previously blocked for 
one hour with folate receptor α primary antibody as per section 3.8.7. The samples were 
subsequently returned to the incubator and incubated on a plate rocker for 18 hours. The plates 
were then removed, old media gently removed and the cells gently washed with PBS (2 x 1mL) 
to remove unbound reagents and free nanoparticles. The cells were subsequently fixed in 
formalin (500µL, 10% solution) for 10 minutes at room temperature. Formalin was removed 
and the cells washed with PBS (3 x 1mL), before being permeabilised with 0.1% Triton X-100 
(0.5mL) for 10 minutes at room temperature. Triton was removed and the cells washed with 
PBS (3 x 1mL), before being blocked with 10% normal goat serum (0.5mL) at room 
temperature for 1 hour. Goat serum was removed and the cells were dosed with anti-cispltin 
modified antibody (CP9/19) at room temperature for two hours (500µL of a 2µg/mL solution 
in 10% normal goat serum). The primary antibody was removed and the coverslips washed 
with 1% goat serum (5 x 1mL). Cells were then dosed with secondary antibody (500µL of a 
2µg/mL solution in 10% goat serum) for 1 hour at room temperature in the dark. Cells were 
rinsed with 1% goat serum (5 x 1mL) and the nuclei stained with Hoechst (500µL of a 5µg/mL 
solution in 1% goat serum) for 10 minutes at room temperature. The coverslips were washed 
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with 1% goat serum (1mL x 5), then dipped in PBS before being mounted onto microscope 
slides with a drop of mounting medium.  
 
Fixed Cell Flow Cytometry Studies 
The utilised fixed cell FACS protocol was adapted from the published protocol of Cell 
Signaling TechnologyR417 and as carried over from section 4.6.5. 
Cells were dosed with the appropriate samples as per the above confocal studies. The 6 well 
plates were then removed from the incubator, old media removed and the cells washed with 
PBS (1mL). The cells were then tripsinised (1mL tripsin 1X for 5 mins in an incubator) and 
collected with fresh RPMI media (1mL), cells were collected into 2mL Eppendorf’s. The cells 
were pelleted at 1500rpm for 5 mins and the supernatant discarded. The cells were then re-
suspended in 1mL 10% formalin, vortexed and fixed at 37°C for 10 minutes. The samples were 
chilled on ice for 1 minute, then centrifuged at 1500rpm for 5 minutes to remove formalin. The 
pellets were re-suspended in 1mL of 90% ice cold methanol and kept on ice for 30 minutes to 
permeabilise them. 1mL incubation buffer (0.5g Bovine Serum Albumin (BSA) in 100mL 
PBS) was added and the cells centrifuged. The supernatant was removed and the cells re-
suspended in 1mL incubation buffer. This step was repeated three times. The cells were re-
suspended in primary antibody (500µL of a 2µg/mL solution in incubation buffer) and dosed 
for one hour at room temperature. The cells were centrifuged, the supernatant removed and the 
pellets re-suspended in incubation buffer (1mL). This step was repeated three times. The cells 
were re-suspended in secondary antibody (500µL of a 2µg/mL solution in incubation buffer) 
for 30 minutes at room temperature in the dark. The cells were centrifuged, supernatant 
removed and re-suspended in incubation buffer (1mL). This step was repeated three times. The 
cells were then centrifuged, supernatant removed and re-suspended in 1mL PBS. The samples 




Confocal Microscope Settings 
Blue Channel:  Excitation, 402nm Emission, 450-490 
Green Channel:  Excitation, 514nm Emission, 500-570nm 
Red Channel:   Excitation, 488nm Emission, 580-680nm 
 
5.6.4. ICPMS Studies 
The below ICPMS protocol was adapted from protocols provided by Dr Lucia Cardo (Hannon 
research group, University of Birmingham) and Ms Siobhan King (Pikramenou research group, 
University of Birmingham) and carried over from section 4.6.6.  
Cell Culture 
High folate receptor alpha expressing A549 cells were seeded into seven T75 flasks (one flask 
per condition as per the below table) and cultured to 80% confluency as per section 3.8.5. 
 
Dosing 
The T75 flasks were dosed using the same protocol of 5.5.3, but with appropriately scaled 
reagents (approximately 7 x more cells present, therefore 7 x more nanoparticles / platinum 
agents used) and alternative sample work up. 
HIGH FOLATE RECEPTOR α EXPRESSING A549S DOSED WITH: 
No Blocking With Receptor α Blocking 
a) Blank  - 
b) Cisplatin  - 
c) Pt(IV)LipA  - 
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d) GNP-Fol-Theranos f) GNP-Fol-Theranos 
e) GNP-Cit-Theranos g) GNP-Cit-Theranos 
 
Sample Work Up 
Old media / media containing the reagents of the above table was removed from the T75 flasks 
and the cells gently washed with PBS (5mL x 3) to remove unbound reagents / particles and 
residual media. The cells were tripsinised and pelleted as per section 3.8.5. The cells were then 
re-suspended in 2mL of PBS and counted using a haemocytometer. 1mL of each sample was 
pipetted into fresh 2mL falcon tubes, pelleted at 1500rpm for 5 minutes and supernatant 
removed. The whole cell pellet samples were immediately stored at -80°C ready for whole cell 
ICPMS analysis.  
 
Subsequent nuclear and cytosolic fractionation was conducted as per the protocol supplied with 
the BioVision Nuclear/Cytosol Fractionation Kit utilised.  
The remaining 1mL of suspended cells were chilled on ice for 1 minute and subsequently 
centrifuged at 4°C for 5 minutes at 600G. The PBS was removed and 0.2mL of Cytosol 
Extraction Buffer A was added. The solutions were vortexed on the highest setting for 15 
seconds and were incubated on ice for 10 minutes. 11µL of ice cold Cytosol Extraction Buffer 
B was added and the solution vortexed for 5 seconds. The solutions were then centrifuged at 
4°C for 5 minutes at 16000G. The supernatant (cytoplasm fraction) was removed and 
immediately stored at -80°C ready for cytosolic ICPMS analysis.  
 
The remaining pellet was re-suspended in 100µL ice cold Nuclear Extraction Buffer mix and 
vortexed on the maximum setting for 15 seconds. The samples were stored on ice for 10 
minutes and this process was repeated four times. The samples were centrifuged at 16,000G, 
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4°C for 10 minutes. The supernatant (nuclear fraction) was transferred to a fresh Eppendorf 
and immediately stored at -80°C, ready for ICPMS analysis.   
 
The resulting sample fractions (whole cell, nuclear and cytoplasm) were digested in a mixture 
of concentrated nitric acid (69%, 100µL) and freshly prepared aqua regia (3:1, HCl (32%) and 
HNO3 (69%) 100 µL). Samples were transferred to screw cap vials and incubated overnight at 
80 ºC in an oven to fully digest the metal particles and cells. Subsequently, the samples were 
diluted with milli-Q-water to a final acid concentration of ~2%. Samples were transferred to 





Chapter 6 – Conclusions & Future Work 
The utilisation of folate receptor overexpression as a means for targeted delivery of therapeutic 
and diagnostic agents to select cancer cells was investigated in the research reported herein.  
 
A novel synthetic protocol was developed for a more reliable and reproducible method of 
forming folate capped gold nanoparticles with comparable size and polydispersity to typical 
citrate capped gold nanoparticle systems that have been routinely developed and utilised within 
the field. As previously noted, further research must be done with regard to this novel protocol 
so as to better establish the intermediate species that is subsequerntly believed to be responsible 
for gold salt reduction and ultimately nanoparticle growth. This species might also have an 
impact on the specific folate moieties that are subsequently tethered to the outer surface of the 
nanoparticles and might ultimately play a key role in their ability to interact with folate 
receptors.  
 
Subsequently, the potential for both folate and citrate capped gold nanoparticles to act as 
targeted imaging agents was investigated. More specifically, separate nanoparticular systems 
were surface functionalised with a ruthenium based polypyridyl probe (RuPhenSS) and their 
ability to be taken up into folate receptor positive A549s investigated. Efforts went beyond this 
to compare their uptake when the cells had been subjected to a folate receptor antibody solution 
so as to block folate receptor α and theoretically exacerbate the importance of the folate 
moieties on the outer surface of the folate capped nanoparticle system. Through confocal 
microscopy and flow cytometry studies it was found that folate receptors might indeed play a 
key role in the particle uptake, with the folate system displaying greater levels of uptake over 
the citrate system. This effect was further proven through folate receptor blocking leading to a 
much lesser extent of particle uptake.  
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Further research then developed a novel Pt(IV) complex (Pt(IV)LipA) that was fully 
characterised and possessed the potential to bind to the surface of nanoparticles via a thiol 
moiety of one of the axial ligands. Much the same as the ruthenium studies, the surface 
functionalisation was investigated and the subsequently Pt(IV) loaded folate and citrate capped 
systems were subjected to cellular studies. Through confocal microscopy, flow cytometry and 
ICPMS studies it was found that folate receptors might indeed play a key role in the particle 
uptake, with the folate system displaying greater levels of uptake over the citrate system. This 
effect was further proven through folate receptor blocking leading to a much lesser extent of 
particle uptake. Further research must be conducted in this area through experimental repeats 
so as to facilitate statistical analysis of the results.  
 
Lastly, two theranostic gold nanoparticle systems were developed; a first utilising folate capped 
gold nanoparticles (for a folate receptor targeting system, GNP-Fol-Theranos) and a second 
utilising citrate capped gold nanoparticles (non-targeted system, GNP-Cit-Theranos). The gold 
nanoparticles of these respective systems were surface functionalised with the ruthenium based 
polypyridyl probe (RuPhenSS) and the novel Pt(IV) complex (Pt(IV)LipA), each utilising a 
lipoic acid based ligand for tethering means.  
 
The uptake of these two theranostic nanoparticle systems was investigated in folate receptor 
positive A549 cells that had their levels of receptor modulated through media supplementation 
with excess folate. Folate receptor positive and negative uptake studies were conducted 
utilising A549s with and without folate receptor blocking with a polyclonal antibody. Confocal 
microscopy, flow cytometry and ICPMS studies all showed enhanced levels of Ru probe based 
emissions for the GNP-Fol-Theranos system over the GNP-Cit-Theranos system. The level of 
probe emission and particle uptake was  decreased for GNP-Fol-Theranos upon folate receptor 
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blocking, whilst these parameters appeared relatively unchanged for the GNP-Cit-Theranos 
system, indicating a potentially high dependency and efficacy of folate receptor mediated 
endocytosis for the folate based particles.  
 
The cytotoxicity and degree of DNA damage induced by Pt(IV)LipA was investigated through 
MTT studies as well as confocal and flow cytometry studies utilising a commercial antibody 
for cisplatin-DNA adducts. Pt(IV)LipA showed enhanced cytotoxicity over cisplatin in A549 
cells both as a free agent and as part of the theranostic nanoparticle system. The GNP-Fol-
Theranos system presented with the greatest cytotoxicity, closely followed by the GNP-Cit 
system. Confocal microscopy, flow cytometry and ICPMS studies all indicated an enhanced 
level of uptake of Pt for the GNP-Fol-Theranos system samples over GNP-Cit-Theranos 
system. These results again indicate a greater level of uptake as a result of folate receptor 
mediated endocytosis.  
 
The confocal microscopy and ICP mass spectrometry results of the present research were not 
(and can not be) statistically analysed as only a single sample was analysed for each condition 
reported. This single sample experimental design was adopted since the synthetic experimental 
conditions were still being optimised in parallel, and repeat experiments require a larger batch 
of material. Now that the conditions for the experiment have been refined and the synthetic 
protocol finalised, future research efforts should look to repeat the experiments with triplicate 
samples per condition, as well as triplicate experimental runs as a whole, to allow for a full 
statistical analysis of the findings enabling quantitative rather than just qualitative conclusions. 
 
Further studies should also re-visit cellular studies into competition for the GNP-Fol-Theranos 
system between a co-culture of folate receptor positive and negative cells. Alternatively, it 
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would be interesting to track the particles in a mouse model. The nanoparticle systems will 
likely benefit from further characterisation and optimisation in advance of any such studies. A 
further objective could also be the development of a variant of the Pt(IV)LipA agent bearing a 
folic acid motif, forming a novel Pt(IV) agent that itself comprises folate receptor targeting 






Figure 308 Fluorescence slices 
Slice 1 Slice 2 
Slice 3 Slice 4 
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Slice 5 Slice 6 




Blank A549s taken from zero folate RPMI media culture. Cells were seeded overnight onto 
MatTek dishes and subsequently treated with folate receptor alpha polyclonal antibody 
(2µg/mL in 2mL supplemented RPMI) for 45 minutes. Cultures were washed three times with 
PBS before being immersed in imaging media and immediately transferred to a live cell 
imaging chamber for confocal microscopy studies. Images 1 through 12 represent the gradual 
progression from the bottom of the cell culture to the top, through the collected z stack profile. 
The images show the peripheral localisation of the fluorescence signal, corresponding to 
surface bound antibody based fluorescence.  
 
Slice 9 Slice 10 
Slice 11 Slice 12 
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Pt(IV)LipA Data 
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